NOTCH signalling pathway inhibitors and their use in treatment of cancer

By developing a new inhibitor of Notch signaling pathway, the problem of insufficient inhibitor specificity and effectiveness in the prior art is solved, and efficient treatment and prevention of Notch-dependent cancers are achieved, especially with Notch receptors Treatment effects of mutated tumors.

CN118994001APending Publication Date: 2024-11-22CELLESTIA BIOTECH AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411128418.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-04-10
Filing Date
2020-04-09
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing Notch signaling pathway inhibitors, such as gamma-secretase inhibitors, have broad additional targets and problems of ineffectiveness in certain tumors, especially those with Notch receptor mutations, which require development of more specific and Selective inhibitors for the treatment and prevention of cancer.

Method used

A novel compound, specifically a compound of formula (I), is provided for inhibiting Notch signaling pathways, through its pharmaceutically acceptable salt, hydrate, solvate or stereoisomer form for prevention or treatment Cancer, especially Notch-dependent cancer.

Benefits of technology

This compound significantly inhibits the Notch signaling pathway, demonstrates the efficient anti-proliferative effect on Notch-dependent cells and the efficacy of downregulating the Notch pathway. It has high biological characteristics and therapeutic efficacy, and is suitable for the prevention or treatment of various types of cancer. Includes tumors that are resistant to treatment with gamma-secretase inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994001A_ABST
    Figure CN118994001A_ABST
Patent Text Reader

Abstract

The present invention relates to novel Notch signaling pathway inhibitors and their use in the treatment and / or prevention of cancer. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese patent application No. 202080043231.4, filed on April 9, 2020, and entitled “NOTCH signaling pathway inhibitors and their use in cancer treatment.” Field of the Invention

[0002] The present invention relates to novel inhibitors of the Notch signaling pathway and their use in treating and / or preventing cancer. Background of the Invention

[0004] The Notch signaling pathway represents a key component in the molecular circuit that controls cell fate during development, cell survival, and cell proliferation (Shih IeM, Wang TL in Cancer Res 2007; 67(5): 1879-82). Abnormal activation of this pathway contributes to tumor formation. Notch family members have been found to be oncogenes in an increasing number of cancers. The role of Notch in human cancer has recently been emphasized by the presence of activating mutations and amplifications of the Notch gene in human cancers, and by the demonstration that genes / proteins in the Notch signaling pathway may be potential therapeutic targets. It is now clear that one of the main therapeutic targets in the NOTCH pathway is the Notch receptor, where γ-secretase inhibitors prevent the production of the oncogenic (intracellular) domain of the Notch molecule and inhibit Notch activity.

[0005] Despite significant progress in dissecting the complexities of this signaling pathway, options for developing novel Notch inhibitors are limited. However, a pioneering class of Notch inhibitors, such as Ayala Pharma's γ-secretase inhibitor AL101 (formerly BMS 906024), Eli Lilly's LY3039478, and Springworks Therapeutics' Nirogacestat (a synthetic small molecule), have entered clinical trials against several cancer types. These inhibitors inhibit the Notch signaling pathway, potentially leading to growth arrest in tumor cells in which the Notch signaling pathway is overactivated.

[0006] One of the drawbacks of the use of γ-secretase inhibitors currently under investigation to block Notch signaling is their wide range of additional targets, such as the precursor protein of amylin. Because they are able to block Notch signaling through all four receptors, γ-secretase inhibitors are known to cause goblet cell metaplasia in the intestine. In addition, some hematological malignancies and solid tumors have mutations in the Notch receptor (e.g., chromosomal translocations), resulting in constitutive expression of a dominant active form of the Notch intracellular domain (NICD) that is independent of the cleavage of the γ-secretase complex. Therefore, treatment with γ-secretase inhibitors will be ineffective for these tumors.

[0007] WO2013 / 093885 discloses several Notch inhibitory compounds, of which 6-(4-tert-butylphenoxy)pyridin-3-amine is a particularly preferred compound. The Notch inhibitory effects measured in these disclosed compounds vary significantly. Therefore, there remains a need to identify and develop inhibitors with further specificity and selectivity for the Notch signaling pathway, with improved properties that can be used to treat and / or prevent cancer. Summary of the Invention

[0009] The present invention provides a compound of formula (I)

[0010]

[0011] Its pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer,

[0012] wherein X is selected from the group consisting of CH2, CF2, CHF, CO, CHOH, CHO(C1-C3)alkyl, NH, N(C1-C3alkyl), S, SO and O;

[0013] where Y 1 、Y 2 and Y 3 are each independently selected from N and C;

[0014] Where Z is NR 10 R 11 , where R 10 With R 11 Each independently selected from H and C1-C6 alkyl;

[0015] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0016] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0017] where R 3 Selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl and C1-C6 alkoxy;

[0018] where R 4 、R 5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkoxy, C1-C6-S-alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl and C3-C 12 heterocyclic group;

[0019] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl and C1-C6 alkoxy;

[0020] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8Selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl and C1-C6 alkoxy;

[0021] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0022] where R 12 Selected from H, NH2, NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 12 Cycloalkyl and C3-C 12 heterocyclic group;

[0023] The proviso is that the compound of formula (I) is not 6-([1,1'-biphenyl]-4-yloxy)-pyridin-3-amine, 4-([1,1'-biphenyl]-4-yloxy)-aniline, 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine and 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin-3-amine.

[0024] The present invention also provides a compound of formula (I),

[0025]

[0026] Its pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer,

[0027] wherein X is selected from the group consisting of CH2, CF2, CHF, CO, CHOH, CHO(C1-C3)alkyl, NH, N(C1-C3alkyl), S, SO and O;

[0028] where Y 1 、Y 2 and Y 3 are each independently selected from N and C;

[0029] Where Z is NR 10 R 11 , where R 10 With R 11 Each independently selected from H and C1-C6 alkyl;

[0030] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0031] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0032] where R 3 Selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12Cycloalkyl, C3-C 12 Heterocyclyl and C1-C6 alkoxy;

[0033] where R 4 、R 5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkoxy, C1-C6-S-alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl and C3-C 12 heterocyclic group;

[0034] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl and C1-C6 alkoxy;

[0035] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl and C1-C6 alkoxy;

[0036] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0037] where R 12 Selected from H, NH2, NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 12 Cycloalkyl and C3-C 12 Heterocyclic group, for use in a method for preventing or treating cancer, preferably for use in a method for preventing or treating Notch-dependent cancer. The present invention also provides a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier, and a kit comprising a compound of formula (I), optionally with reagents and / or instructions. The present invention also provides the use of a compound of formula (I) in inhibiting the Notch signaling pathway in cells in vitro or in vivo.

[0038] The inventors of the present application have unexpectedly discovered that compounds that are substantially different in chemical structure from the compounds specifically disclosed in WO2013 / 093885 exhibit unparalleled biological properties in Notch inhibition, such as high efficacy against NOTCH-driven human cancers and high efficacy in downregulating NOTCH target genes. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 The anti-proliferative effects of compounds on NOTCH-positive and NOTCH-dependent human leukemia cell lines (RPMI8402) were demonstrated. Cells were treated with compounds for 72 hours, and the effects on proliferation were quantified using Alamar blue assay.

[0040] Figure 2 Shown are the effects of 6-([1,1'-biphenyl]-4-yloxy)-N-methylpyridin-3-amine on N1-ICD and cMYC (NOTCH target genes) in human leukemia cells. NOTCH-positive human leukemia RPMI8402 cells were treated with 1 μM of 6-(4-tert-butylphenoxy)pyridin-3-amine and 6-([1,1'-biphenyl]-4-yloxy)-N-methylpyridin-3-amine for 24 hours. After treatment, total protein lysates were extracted, and protein expression was analyzed by western blot. Data showed that 6-([1,1'-biphenyl]-4-yloxy)-N-methylpyridin-3-amine had enhanced efficacy in downregulating the NOTCH pathway in human cancer cells compared to 6-(4-tert-butylphenoxy)pyridin-3-amine.

[0041] Figure 3Shown are the effects of 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine, 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine, and N-methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine on N1-ICD and cMYC (NOTCH target genes) in human leukemia cells. NOTCH-positive human leukemia RPMI8402 cells were treated with 1 μM of 6-(4-tert-butylphenoxy)pyridin-3-amine, 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine, 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine, and N-methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine for 24 hours. Total protein lysates were extracted and protein expression was analyzed by Western blotting. The data showed that 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy]pyridin-3-amine, 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine, and N-methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine had enhanced efficacy in downregulating the NOTCH pathway in human cancer cells compared to 6-(4-tert-butylphenoxy)pyridin-3-amine. Detailed Description of the Invention

[0043] All publications, patent applications, patents, and other references mentioned herein are incorporated herein by reference in their entirety. The publications and applications discussed herein are provided solely for their disclosure prior to the filing date of the present application. In addition, the materials, methods, and examples are provided for illustrative purposes only and are not intended to be limiting.

[0044] In the event of a conflict, the present specification, including definitions, will control. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the subject matter herein belongs. As used herein, the following definitions are provided to facilitate understanding of the present invention.

[0045] As used herein, the term "comprise (verb) / includes (gerund)" is generally used in the sense of comprising (verb) / including (gerund), that is, allowing for the presence of one or more features or components. The terms "comprise" and "including" also encompass the more restrictive terms "consisting of..." (verb) and "consisting of..." (gerund).

[0046] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0047] As used herein, the term "subject" is well known in the art and refers to mammals, including dogs, cats, rats, mice, monkeys, cows, horses, goats, sheep, pigs, camels, and most preferably humans. In some embodiments, the subject is a subject in need of treatment or a subject suffering from a disease or condition such as cancer. However, in other embodiments, the subject may be a normal subject or a subject that has received anti-cancer treatment. The term does not denote a specific age or sex. Thus, it is intended to encompass adult, pediatric, and neonatal subjects, whether male or female.

[0048] As used herein, the terms "cancer", "cancer cell", "cell proliferative disease" and "cell proliferative disorder" refer to or describe the physiological condition in mammals that is typically characterized by uncontrolled cell growth. According to the present invention, cancer preferably refers to solid tumors, such as saliva, liver, brain, breast, prostate, colorectal, kidney, lung, sarcoma, or melanoma and liquid tumors affecting the blood, such as leukemia. According to the present invention, more preferably, the cancer is a Notch-dependent cancer selected from the group consisting of adenoid cystic carcinoma (ACC), T cell-Acutelymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), breast cancer, pancreatic cancer, prostate cancer, melanoma, brain tumor, tumor angiogenesis, liver cancer and colorectal cancer. Even more preferably, the Notch-dependent cancer is resistant to treatment with a gamma-secretase inhibitor. Examples of γ-secretase inhibitor therapies include 1) the γ-secretase inhibitor RO4929097 and cediranib maleate in patients with advanced solid tumors (NCT01131234), 2) the γ-secretase inhibitor RO4929097 in young patients with relapsed or refractory solid tumors, central nervous system tumors, lymphomas, or T-cell leukemias (NCT01088763), 3) a study of MK-0752 in combination with tamoxifen or letrozole in the treatment of early breast cancer (NCT00756717), 4) GDC-0449 and RO4929097 in patients with advanced or metastatic sarcomas (NCT01154452), and 5) RO4929097 and erlotinib hydrochloride in patients with advanced or metastatic sarcomas (NCT01154452). Hydrochloride) for the treatment of stage IV or recurrent non-small cell lung cancer (NCT01193881), 6) Bicalutamide plus RO4929097 in the treatment of patients with previously treated prostate cancer (NCT01200810), 7) RO4929097 in the treatment of patients with recurrent infiltrating glioma (NCT01269411), 8) Notch signaling pathway inhibitors for T-cell acute lymphoblastic leukemia / lymphoma (ALL) (NCT00100152), and 9) RO4929097 in the treatment of patients with metastatic colorectal cancer (NCT01116687).

[0049] The term "alkyl" as used herein refers to a saturated straight or branched chain group derived from a carbon atom of an alkane by removing a hydrogen atom. C1-C3 alkyl includes, for example, methyl, ethyl, n-propyl, isopropyl, and preferably includes unbranched C1-C3 alkyl. C1-C4 alkyl includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl, and preferably includes unbranched C1-C4 alkyl. C1-C6 alkyl includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl, and preferably includes unbranched C1-C6 alkyl. C1-C 10 Alkyl groups include, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl or n-decyl, preferably comprising an unbranched C1-C 10 As used herein, the term "C0 alkyl" refers to a covalent bond. Thus, for example, the term "C0 alkyl OCO alkylaryl" refers to an O aryl group.

[0050] As used herein, the term "C0-C3 alkyl, OCO-C3 alkylaryl" refers to Oaryl, as defined herein, when both C0-C3 alkyl groups are C0 alkyl. When the first C0-C3 alkyl group is C0 alkyl, the term refers to OCO-C3 alkylaryl. When the second C0-C3 alkyl group is C0 alkyl, the term refers to C0-C3 alkylOaryl. Preferably, the C0-C3 alkyl, OCO-C3 alkylaryl is C0-C3 alkylOaryl, more preferably Oaryl or C1-C3 alkylOaryl. As used herein, the term "C0-C3 alkyl, OCO-C3 alkylheteroaryl" refers to Oheteroaryl, as defined herein, when both C0-C3 alkyl groups are C0 alkyl. When the first C0-C3 alkyl group is C0 alkyl, the term refers to OCO-C3 alkylheteroaryl. When the second C0-C3 alkyl group is a C0 alkyl group, the term refers to a C0-C3 alkylOheteroaryl group. Preferably, the C0-C3 alkylOC0-C3 alkylheteroaryl group is a C0-C3 alkylOheteroaryl group, more preferably an Oheteroaryl group or a C1-C3 alkylOheteroaryl group, and most preferably an Oheteroaryl group. The aryl and heteroaryl groups of the C0-C3 alkylOC0-C3 alkylaryl group and the C0-C3 alkylOC0-C3 alkylheteroaryl group are optionally substituted with NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 The heterocyclyl is substituted, preferably optionally substituted with NH2.

[0051] The term "heteroalkyl" as used herein refers to an alkyl group as defined herein in which one, two, three or four hydrogen atoms are independently selected from OR a 、C(O)OR aNR b R c 、C(O)NR b R c 、S(O) n R d (wherein n is an integer from 0 to 2) and halogen substituents, while understanding that the point of attachment of the heteroalkyl group is through a carbon atom, wherein R a is H, C1-C3 alkylcarbonyl, C1-C3 alkyl, or C 3-7 Cycloalkyl; R b With R c Each independently represents H, C1-C3 alkylcarbonyl, C1-C3 alkyl, C 3-7 Cycloalkyl or NR b R c is guanidine; and when n is 0, R d is H, C1-C3 alkyl or C 3-7 Cycloalkyl, and when n is 1 or 2, R d is C1-C3 alkyl or C 3-7 Cycloalkyl. Most preferably, the term "heteroalkyl" or "heteroalkanediyl" as used herein refers to an alkyl or alkanediyl group as defined herein, wherein one, two, three or four hydrogen atoms are substituted by a substituent independently selected from OH, NH2, guanidine and halogen, more preferably one or two hydrogen atoms are substituted by a substituent independently selected from OH, NH2 and halogen. Representative examples include, but are not limited to, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 2-hydroxy-1-hydroxymethylethyl, 2-hydroxy-1-methylethyl, 2,3-dihydroxypropyl, 1-hydroxymethylethyl, 3-hydroxybutyl, 2,3-dihydroxybutyl, 1-hydroxy-2-methylpropyl, 3-hydroxy-1-(2-hydroxyethyl)-propyl, 2-hydroxy-1-methylpropyl, 1,1,1-trifluoroethyl, 1,1,1-trifluoromethyl, 2,2,3,3-tetrafluoropropyl.

[0052] The term "C 3-12 Cycloalkyl" and "C 3-7 "Cycloalkyl" refers to a monovalent saturated monocyclic or bicyclic hydrocarbon radical of 3-12 or 3-7 carbon atoms, preferably a monovalent saturated monocyclic radical, derived from a cycloalkane by removing a single hydrogen atom. 3-7 "Cycloalkyl" includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. The term "Cycloalkyl" as used herein includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. 3-12 Cycloalkyl" and "C 3-7 "Cycloalkyl" also includes C 1-3 Alkyl cycloalkyl. This type of "C 3-7Examples of "cycloalkyl" include cyclopropylmethyl, 2-cyclopropylethyl, cyclobutylmethyl, 2-cyclobutylethyl, cyclopentylmethyl, 2-cyclopentylethyl. The cycloalkyl groups of the present invention may be optionally substituted.

[0053] The terms "aryloxy" or "Oaryl," as used interchangeably herein, refer to the group -OR, where R is aryl as defined herein, for example, phenoxy.

[0054] The terms "C1-C6 alkoxy" or "OC1-C6 alkyl" used interchangeably herein refer to a group -OR, wherein R is a C1-C6 alkyl group as defined herein. Examples are methoxy, ethoxy, propoxy, butoxy.

[0055] As used herein, the term "aryl" refers to a monocyclic or bicyclic carbocyclic ring system having one or two aromatic rings, and is preferably a monocyclic carbocyclic ring system. The aryl group may also be fused to a cyclohexane, cyclohexene, cyclopentane, or cyclopentene ring, or to a cyclohexane, cyclohexene, cyclopentane, or cyclopentene ring containing a carbonyl group. The aryl groups of the present invention may be optionally substituted, as further described below. Preferred aryl and optionally substituted aryl groups of the present invention are phenyl or substituted phenyl, respectively. The substituents may be, for example, NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C6 alkyl, C1-C6 heteroalkyl, alkyl halogen ... 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 .

[0056] The term "heteroaryl" as used herein refers to substituted and unsubstituted aromatic 5 or 6-membered monocyclic groups and 9 or 10-membered bicyclic groups, preferably substituted and unsubstituted aromatic 5 or 6-membered monocyclic groups, having at least one heteroatom (O, S or N) in at least one or more rings. Each ring of the heteroaryl group containing heteroatoms may contain one or two oxygen or sulfur atoms and / or 1-4 nitrogen atoms, provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom. The fused rings completing the bicyclic group may contain only carbon atoms and may be saturated, partially saturated, or unsaturated. The heteroaryl group must include at least one fully aromatic ring, but the other fused ring may be aromatic or non-aromatic. The heteroaryl group may be attached to any available nitrogen or carbon atom of any ring. The heteroaryl groups of the present invention may be optionally substituted as further described below. Typically, the heteroaryl and optionally substituted heteroaryl groups of the present invention are each selected from the group consisting of substituted and / or unsubstituted aromatic 5- or 6-membered monocyclic groups having at least one heteroatom (O, S, or N), preferably one or two heteroatoms selected from S and N in the ring, more preferably one S and one N in the ring, or one or two N in the ring. Preferred heteroaryl groups are optionally substituted heteroaryl groups selected from the group consisting of optionally substituted pyridyl, optionally substituted pyrimidinyl, optionally substituted di- or triazinyl, optionally substituted thiazolyl, optionally substituted oxazolyl, and optionally substituted imidazolyl. Even more preferred heteroaryl groups are optionally substituted pyridyl, optionally substituted pyrimidinyl, optionally substituted imidazolyl, or optionally substituted thiazolyl. Most preferably, optionally substituted pyridyl, optionally substituted imidazolyl, or optionally substituted thiazolyl groups are used as heteroaryl groups in the present invention. The optional substituents may be, for example, NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 , or NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group.

[0057] As used herein, the term "heterocyclyl" refers to a saturated monocyclic ring having 3 to 12, preferably 3 to 7, more preferably 5 to 6 ring atoms, containing up to 3, preferably 1 or 2 heteroatoms independently selected from nitrogen, oxygen or sulfur, wherein the remaining ring atoms are carbon atoms. Examples of such saturated heterocyclic rings include [1,3]dioxanyl, [1,3]dioxolanyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, oxazolidinyl, thiazolidinyl, azepanyl, and the like. Preferably, such heterocyclyl groups are unsubstituted.

[0058] The term "halogen" used herein refers to F, Cl, Br or I, and is preferably F, Cl or Br, and more preferably F.

[0059] The term "optionally substituted" or "substituted" means that the group mentioned is substituted by one or more additional groups, preferably by one additional group, which are individually and independently selected from the listed groups.

[0060] In some aspects or embodiments of the present invention, the compound 6-(([1,1′-biphenyl]-4-yloxy)-pyridin-3-amine, which is excluded from the compounds of formula (I), has the following chemical structure:

[0061]

[0062] In some aspects or embodiments of the present invention, the compound 4-([1,1'-biphenyl]-4-yloxy)-aniline, which is excluded from the compounds of formula (I), has the following chemical structure:

[0063]

[0064] In some aspects or embodiments of the present invention, the compound 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine, which is excluded from the compounds of formula (I), has the following chemical structure:

[0065]

[0066] In some aspects or embodiments of the present invention, the compound 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin-3-amine, which is excluded from the compounds of formula (I), has the following chemical structure:

[0067]

[0068] In some aspects or embodiments of the present invention, the compound 4-(4'-methoxy-biphenyl-4-yloxy)aniline, which is excluded from the compounds of formula (I), has the following chemical structure:

[0069]

[0070] In some aspects or embodiments of the present invention, the compound excluded from the compounds of formula (I), 4-(4'-chlorobiphenyl-4-yloxy)aniline, has the following chemical structure:

[0071]

[0072] In some aspects or embodiments of the present invention, the compound excluded from the compounds of formula (I) is 4-(4'-tert-butyl-biphenyl-4-yloxy)aniline having the following chemical structure:

[0073]

[0074] In some aspects or embodiments of the invention, the compound excluded from the compounds of formula (I), 4-(4-(thiazol-2-yl)phenoxy)aniline, has the following chemical structure:

[0075]

[0076] In some aspects or embodiments of the invention, the compound 4-(4-(1H-imidazol-2-yl)phenoxy)aniline, which is excluded from the compounds of formula (I), has the following chemical structure:

[0077]

[0078] In some aspects or embodiments of the invention, the compound 4-(4-(oxazol-2-yl)phenoxy)aniline, which is excluded from the compounds of formula (I), has the following chemical structure:

[0079]

[0080] In some aspects or embodiments of the present invention, the compound 4-(4-(1H-pyrrol-1-yl)phenoxy)aniline, which is excluded from the compounds of formula (I), has the following chemical structure:

[0081]

[0082] Therefore, in a first aspect, the present invention provides a compound of formula (I)

[0083]

[0084] Its pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer,

[0085] wherein X is selected from the group consisting of CH2, CF2, CHF, CO, CHOH, CHO(C1-C3)alkyl, NH, N(C1-C3alkyl), S, SO and O;

[0086] where Y 1 、Y 2 and Y 3 are each independently selected from N and C;

[0087] Where Z is NR 10 R 11 , where R 10 With R 11Each independently selected from H and C1-C6 alkyl;

[0088] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0089] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0090] where R 3 Selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl and C1-C6 alkoxy;

[0091] where R 4 、R 5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkoxy, C1-C6-S-alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl and C3-C 12 heterocyclic group;

[0092] When Y 1 When N is R 7 does not exist, or when Y1 When R is C 7 Selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl and C1-C6 alkoxy;

[0093] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl and C1-C6 alkoxy;

[0094] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0095] where R 12 Selected from H, NH2, NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 12 Cycloalkyl and C3-C 12 heterocyclic group;

[0096] The condition is that the compound of formula (I) is not 6-([1,1'-biphenyl]-4-yloxy)-pyridin-3-amine, 4-([1,1'-biphenyl]-4-yloxy)-aniline, 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine and 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin-3-amine, and the preferred condition is that the compound of formula (I) is not 6-(([ 1,1'-biphenyl]-4-yloxy)-pyridin-3-amine, 4-([1,1'-biphenyl]-4-yloxy)-aniline, 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine, 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 4-(4'-methoxy-biphenyl-4-yloxy)aniline, 4-(4'-chlorobiphenyl-4-yloxy)aniline and 4-(4'-tert-butyl-biphenyl-4-yloxy)aniline, wherein the more preferred condition is that the compound of formula (I) is not 6-(([1,1'-biphenyl]-4-yloxy)-pyridin-3-amine, 4-([1,1'-biphenyl]-4-yloxy)-aniline, 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine, 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin- 3-amine, 4-(4'-methoxy-biphenyl-4-yloxy)aniline, 4-(4'-chlorobiphenyl-4-yloxy)aniline, 4-(4'-tert-butyl-biphenyl-4-yloxy)aniline, 4-(4-(thiazol-2-yl)phenoxy)aniline, 4-(4-(1H-imidazol-2-yl)phenoxy)aniline, 4-(4-(oxazol-2-yl)phenoxy)aniline and 4-(4-(1H-pyrrol-1-yl)phenoxy)aniline.

[0097] The Notch signaling pathway is evolutionarily conserved, and the basic molecules in this pathway are ligands (Delta and Jagged), Notch receptors, and transcription factors (Shih IeM, Wang TL in Cancer Res 2007; 67(5): 1879-82). Notch is a transmembrane heterodimeric receptor with four different members in humans and rodents (Notch1, Notch2, Notch3, and Notch4). Under physiological conditions, the binding of Notch ligands to their receptors initiates Notch signaling, which is initiated by a cascade reaction of proteolytic cleavage by α-secretase (also known as tumor necrosis factor-α-converting enzyme) and γ-secretase, which releases the intracellular domain (Notch-ICD) of the Notch receptor to initiate Notch signaling. The released intracellular Notch-ICD then translocates to the cell nucleus, where it regulates gene expression mainly by binding to the ubiquitous transcription factor CBF1 (suppressor of hairless Lag-1 (CSL)). This binding recruits transcriptional activators to the CSL complex and converts it from a transcriptional repressor to an activator, which in turn activates several downstream effectors. The physiological functions of Notch signaling are multifaceted and include maintenance of stem cells, specification of cell fate, and regulation of differentiation in development and tumorigenesis.

[0098] In cancer, molecular genetic alterations such as chromosomal translocations, point mutations, and chromosomal amplifications at the Notch receptor locus are known mechanisms for constitutive activation of the Notch pathway. Although the mechanisms differ, they all lead to elevated intracellular Notch-IC levels. The oncogenic potential of Notch was first discovered in human T-cell acute lymphoblastic leukemia (T-ALL), adenoid cystic carcinoma (ACC), breast cancer, and chronic lymphocytic leukemia (CLL). Although Notch1 signaling is essential for the normal development of T-cell progenitors, constitutive activation of Notch1 signaling due to molecular genetic alterations is associated with T-ALL. For example, interstitial deletions of the extracellular portion of human Notch1 due to chromosomal translocations are associated with approximately 1% of T-ALL cases, while activating point mutations in Notch1 are present in approximately 50% of T-ALL cases. The development of T-cell leukemia / lymphomas has been observed in Notch-ICD transgenic mouse models, suggesting that Notch activation plays a causal role in the development of T-ALL. In non-small cell lung cancer, chromosomal translocations have been found in a portion of tumors, and this translocation is thought to increase the transcriptional effect of Notch3 in tumors. In ovarian cancer, Notch3 gene amplification was found in approximately 19% of tumors, and overexpression of Notch3 was found in more than half of ovarian serous carcinomas. Similarly, activation of Notch signaling has been shown in the development of breast cancer. In animal models, constitutively activated Notch4 expression causes mouse mammary tumors, and activating mutations in Notch1 contribute to the development of T-ALL. Recent studies have further shown that overexpression of activated Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mouse mammary tumors. Activation of Notch signaling is also associated with lung and bone metastasis of breast cancer cells. Overexpression of Notch3 is sufficient to induce the formation of choroid plexus tumors in mouse models, indicating that Notch3 plays an important role in the occurrence of certain types of brain tumors.

[0099] The present invention also includes chemical modifications of the compounds of the present invention to extend their circulation life. Non-limiting examples of methods for transient or reversibly pegylated drugs, including polypeptide-based drugs, are provided in U.S. Patent Nos. 4,935,465 (issued June 19, 1990) and 6,342,244 (issued January 29, 2002) and in published U.S. patent application No. US2006 / 0074024. Those skilled in the art will typically learn about methods for transient or reversibly pegylated drugs, including polypeptide-based drugs, in, for example, published patent applications Nos. WO2005047366, US2005171328, and in NEKTAR PEG Reagent. More detailed information on PEG-based agents can be found in those listed in Pharmacol. Biotech 2005-2006 (Nektar Therapeutics, Inc., San Carlos, CA).

[0100] The present invention also relates to salts, hydrates, or solvates of the compounds of formula (I). Preferably, these salts, hydrates, and / or solvates are pharmaceutically acceptable. According to the present invention, pharmaceutically acceptable salts are prepared from acidic inorganic or organic compounds or basic inorganic or organic compounds. As used herein, the term "pharmaceutically acceptable salt" refers to salts that retain the biological effectiveness of the free acids and bases of the specified compound and are not biologically or otherwise undesirable.

[0101] The present invention also relates to stereoisomers of compounds of formula (I). "Stereoisomer (singular)" or "stereoisomers (plural)" refers to compounds that differ in the chirality of one or more stereocenters. Stereoisomers include enantiomers and diastereomers. If a compound of formula (I) has one or more asymmetric centers or has an asymmetrically substituted double bond, it can exist as stereoisomers and can therefore be produced as a single stereoisomer or a mixture. Unless otherwise indicated, this description is intended to include both single stereoisomers and mixtures. Methods for determining stereochemistry and separating stereoisomers are well known in the art (see discussion in: Advanced Organic Chemistry, Chapter 4, 4th Edition, J. March, John Wiley and Sons, New York, 1992).

[0102] Those skilled in the art will appreciate that if the compounds of the invention comprise a charged group, suitable counterions will be derived from organic or inorganic acids. These counterions include halides (e.g., chloride, bromide, fluoride, iodide), sulfate, phosphate, acetate, succinate, citrate, lactate, maleate, fumarate, palmitate, cholate, glutamate, glutarate, tartrate, stearates, salicylate, methanesulfonate, benzenesulfonate, sorbate, picrate, benzoate, cinnamate, etc. If the polar moiety is a negatively charged group, suitable counterions will be selected from sodium, ammonium, barium, calcium, copper, iron, lithium, potassium, and zinc, etc.

[0103] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention, a pharmaceutically acceptable salt, hydrate or stereoisomer thereof and a pharmaceutically acceptable carrier.

[0104] Therefore, in another aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I)

[0105]

[0106] Its pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer,

[0107] wherein X is selected from the group consisting of CH2, CF2, CHF, CO, CHOH, CHO(C1-C3)alkyl, NH, N(C1-C3alkyl), S, SO and O;

[0108] where Y 1 、Y 2 and Y 3 are each independently selected from N and C;

[0109] Where Z is NR 10 R 11 , where R 10 With R 11 Each independently selected from H and C1-C6 alkyl;

[0110] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0111] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0112] where R 3Selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl and C1-C6 alkoxy;

[0113] where R 4 、R 5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkoxy, C1-C6-S-alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl and C3-C 12 heterocyclic group;

[0114] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl and C1-C6 alkoxy;

[0115] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl and C1-C6 alkoxy;

[0116] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0117] where R 12 Selected from H, NH2, NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 12 Cycloalkyl and C3-C 12 Heterocyclic group;And a pharmaceutically acceptable carrier. Preferably, the compound of formula (I) contained in the pharmaceutical composition is not 4-([1,1'-biphenyl]-4-yloxy)-aniline, more preferably not 6-([1,1'-biphenyl]-4-yloxy)-pyridin-3-amine, 4-([1,1'-biphenyl]-4-yloxy)-aniline, 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine and 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin-3-amine. Even more preferably, the compound of formula (I) contained in the pharmaceutical composition is not 6-(([1,1'-biphenyl]-4-yloxy)-pyridin-3-amine, 4-([1,1'-biphenyl]-4-yloxy)-aniline, 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine, 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 4-(4'-methoxy-biphenyl-4-yloxy)aniline, 4-(4'-chlorobiphenyl-4-yloxy)aniline and 4-(4'-tert-butyl-biphenyl-4-yloxy)aniline. In particular, the compound of formula (I) contained in the pharmaceutical composition is not 6-(([1,1'-biphenyl]-4-yloxy)-pyridin-3-amine, 1H-Imidazol-2-yl)phenoxy)aniline, 4-(4-(1H-imidazol-2-yl)phenoxy)aniline, 4-(4-(1H-oxazol-2-yl)phenoxy)aniline and 4-(4-(1H-pyrrol-1-yl)phenoxy)aniline.

[0118] In another aspect, the present invention provides a compound of formula (I)

[0119]

[0120] Its pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer,

[0121] wherein X is selected from the group consisting of CH2, CF2, CHF, CO, CHOH, CHO(C1-C3)alkyl, NH, N(C1-C3alkyl), S, SO and O;

[0122] where Y 1 、Y 2 and Y 3 are each independently selected from N and C;

[0123] Where Z is NR 10 R 11 , where R 10 With R 11 Each independently selected from H and C1-C6 alkyl;

[0124] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0125] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0126] where R 3 Selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl and C1-C6 alkoxy;

[0127] where R 4 、R 5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkoxy, C1-C6-S-alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl and C3-C 12 heterocyclic group;

[0128] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl and C1-C6 alkoxy;

[0129] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl and C1-C6 alkoxy;

[0130] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0131] where R 12 Selected from H, NH2, NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 12 Cycloalkyl and C3-C 12 A heterocyclic group, for use in a method for preventing or treating cancer. Preferably, the compound of formula (I) in the method for preventing or treating cancer is not 4-([1,1'-biphenyl]-4-yloxy)-aniline, more preferably not 6-([1,1'-biphenyl]-4-yloxy)-pyridin-3-amine, 4-([1,1'-biphenyl]-4-yloxy)-aniline, 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine and 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin-3-amine. Even more preferably, the compound of formula (I) in the method for preventing or treating cancer is not 6-(([1,1'-biphenyl]-4-yloxy)-pyridin-3-amine, 4-([1,1'-biphenyl]-4-yloxy)-aniline, 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine, 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 4-(4'-methoxy-biphenyl-4-yloxy)aniline, 4-(4'-chlorobiphenyl-4-yloxy)aniline and 4-(4'-tert-butyl-biphenyl-4-yloxy)aniline. In particular, the compound of formula (I) in the method for preventing or treating cancer is not 6-(([1,1'-biphenyl]- 1H-Imidazol-2-yl)phenoxy)aniline, 4-(4-(1H-imidazol-2-yl)phenoxy)aniline, 4-(4-(1H-imidazol-2-yl)phenoxy)aniline, 4-(4-(1H-oxazol-2-yl)phenoxy)aniline and 4-(4-(1H-pyrrol-1-yl)phenoxy)aniline.

[0132] When R 1When it is C0-C3 alkyl, OC0-C3 alkylaryl or C0-C3 alkyl, OC0-C3 alkylheteroaryl, the optional substitution of the aryl and the heteroaryl is preferably in the para position.

[0133] When R 2 When aryl or heteroaryl, the optional substitution is preferably in the ortho or meta position, provided that the substituent is not halogen, OC1-C6 alkyl or methyl, and when the substituent is halogen, OC1-C6 alkyl or methyl, the optional substitution is preferably in the para position.

[0134] When R 9 When it is C0-C3 alkyl, OC0-C3 alkylaryl or C0-C3 alkyl, OC0-C3 alkylheteroaryl, the optional substitution of the aryl and the heteroaryl is preferably in the para position.

[0135] In one embodiment, X is selected from the group consisting of CH2, CF2, CHF, NH, N(C1-C3 alkyl), S, SO and O. In another embodiment, X is selected from the group consisting of CO, CHOH, CHO(C1-C3)alkyl, S, SO and O. In a preferred embodiment, X is selected from the group consisting of CH2, NH and O. In a more preferred embodiment, X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O. In an even more preferred embodiment, X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl and O. In a particularly preferred embodiment, X is selected from the group consisting of CH2, CO, CHOH, CHOCH3 and O. In a more particularly preferred embodiment, X is selected from the group consisting of CH2 and O. In an even more particularly preferred embodiment, X is O.

[0136] In one embodiment, R 1 is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted with NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, preferably optionally substituted with NH2; and C0-C3 alkylOC0-C3 alkylheteroaryl, wherein the heteroaryl is optionally substituted with NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 In another embodiment, R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 In a preferred embodiment, R 1is selected from H, halogen and C1-C4 alkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, preferably optionally substituted by NH2; and C0-C3 alkylOC0-C3 alkylheteroaryl, wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 In another preferred embodiment, R 1 is selected from H, halogen, C1-C6 alkyl and C1-C6 heteroalkyl. In a more preferred embodiment, R 1 is selected from H, C1-C6 alkyl, C0-C3 alkyl, OC0-C3 alkylaryl, wherein the aryl is optionally substituted with NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, preferably optionally substituted with NH2; C0-C3 alkyl, OC0-C3 alkylheteroaryl, wherein the heteroaryl is optionally substituted with NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, preferably optionally substituted with NH2. In an even more preferred embodiment, R 1 is selected from H, C1-C4 alkyl and C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted with NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, preferably optionally substituted with NH2; C0-C3 alkylOC0-C3 alkylheteroaryl, wherein the heteroaryl is optionally substituted with NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 In another more preferred embodiment, R 1 is selected from H, halogen and C1-C4 alkyl. In an even more preferred embodiment, R 1 is selected from H, methyl, C0-C3 alkyl, OC0-C3 alkylaryl, wherein the aryl is optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, preferably optionally substituted by NH2; and C0-C3 alkyl, OC0-C3 alkylheteroaryl, wherein the heteroaryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 In another even more preferred embodiment, R 1Selected from C0-C3 alkyl OC0-C3 alkylaryl, wherein the aryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl is substituted, preferably optionally substituted with NH2; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally substituted with NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl is substituted, preferably optionally substituted with NH2; and C1-C6 alkyl is substituted with aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 In another even more preferred embodiment, R 1 Selected from C0-C3 alkyl OC0-C3 alkylaryl, wherein the aryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic radical, preferably optionally substituted with NH2; and C0-C3 alkylOC0-C3 alkylheteroaryl, wherein the heteroaryl is optionally substituted with NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 In another even more preferred embodiment, R 1 Selected from H and methyl.

[0137] In one embodiment, R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are selected from NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 and C1-C6 alkyl C(O)R 12 In another embodiment, R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C(O)R 12 、C1-C6 alkyl C(O)R 12replace.

[0138] In a preferred embodiment, R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 and C1-C6 alkyl C(O)R 12 In a more preferred embodiment, R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C(O)R 12 、C1-C6 alkyl C(O)R 12 In another more preferred embodiment, R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 In a particularly preferred embodiment, R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by C1-C6 alkyl, halogen, C1-C6 heteroalkyl, C(O)R 12 、C1-C6 alkyl C(O)R 12 In another particularly preferred embodiment, R 2 is selected from aryl and heteroaryl, wherein the aryl and heteroaryl are optionally substituted by C1-C6 alkyl, halogen. In another particularly preferred embodiment, R 2 is selected from aryl and heteroaryl, wherein the aryl and heteroaryl are optionally substituted by NH2, halogen, CN. In another particularly preferred embodiment, R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally replaced by C(O)R 12 、C1-C6 alkyl C(O)R 12 Among these particularly preferred embodiments, preferred are embodiments wherein R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by C1-C6 alkyl, halogen, C1-C6 heteroalkyl, C(O)R 12 、C1-C6 alkyl C(O)R 12 In an even more particularly preferred embodiment, R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C (O) R12 replace.

[0139] In an even more particularly preferred embodiment, R 2 selected from phenyl, pyridine, imidazole and thiazole, each optionally substituted with NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C(O)R 12 、C1-C6 alkyl C(O)R 12 In another even more particularly preferred embodiment, R 2 selected from phenyl, thiazole, pyridine, imidazole and thiazole, each optionally substituted with NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 In another even more particularly preferred embodiment, R 2 selected from phenyl, pyridine, imidazole and thiazole, each optionally substituted with NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C(O)R 12 、C1-C6 alkyl C(O)R 12 In another even more particularly preferred embodiment, R 2 selected from phenyl, pyridine, imidazole and thiazole, each optionally substituted with C1-C6 alkyl, halogen, C1-C6 heteroalkyl, C(O)R 12 、C1-C6 alkyl C(O)R 12 In another even more particularly preferred embodiment, R 2 is selected from phenyl, pyridine, imidazole and thiazole, each optionally substituted by C1-C6 alkyl, halogen. In another even more particularly preferred embodiment, R 2 is selected from phenyl, pyridine, imidazole and thiazole, each optionally substituted by NH2, halogen, CN. In another even more particularly preferred embodiment, R 2 selected from phenyl, pyridine, imidazole and thiazole, each optionally substituted with C(O)R 12 、C1-C6 alkyl C(O)R 12 Among these even more particularly preferred embodiments, the embodiment in which R 2 selected from phenyl, pyridine, imidazole and thiazole, each optionally substituted with C1-C6 alkyl, halogen, C1-C6 heteroalkyl, C(O)R 12 、C1-C6 alkyl C(O)R 12 In another even more particularly preferred embodiment, R 2is selected from phenyl, pyridine, imidazole and thiazole, each optionally substituted by C1-C6 alkyl, halogen. In another even more particularly preferred embodiment, R 2 selected from phenyl, pyridine, imidazole and thiazole, each optionally substituted with C(O)R 12 、C1-C6 alkyl C(O)R 12 In a most particularly preferred embodiment, R 2 selected from phenyl, pyridine, imidazole and thiazole, each optionally substituted with OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C(O)R 12 replace.

[0140] In a preferred embodiment, R 2 is selected from aryl and heteroaryl, wherein the heteroaryl is an optionally substituted aromatic 5- or 6-membered monocyclic group.

[0141] In another preferred embodiment, R 2 is selected from aryl and heteroaryl, provided that the heteroaryl is not unsubstituted thiazole, oxazole, imidazole and pyrrole.

[0142] In another preferred embodiment, R 2 is selected from aryl and heteroaryl, with the proviso that the heteroaryl is not thiazole, oxazole, imidazole and pyrrole.

[0143] In one embodiment, R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 In a preferred embodiment, R 3 is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl. In a more preferred embodiment, R 3 is selected from H, halogen and C1-C4 alkyl. In an even more preferred embodiment, R 3 For H.

[0144] In one embodiment, R 4 、R 5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl. 4 、R 5 and R 6 are each independently selected from H, halogen, CN, C1-C4 alkyl and C1-C4 heteroalkyl. In an even more preferred embodiment, R 4 、R 5 and R 6 are each independently selected from H, halogen and C1-C4 alkyl. In a particularly preferred embodiment, R 4 、R5 and R 6 are each independently selected from H, halogen and methyl. In a more particularly preferred embodiment, R 4 Selected from H and halogen and / or R 5 and / or R 6 is selected from H and C1-C6 alkyl, in particular from H and C1-C4 alkyl, more particularly from H and methyl.

[0145] In one embodiment, when Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl and C3-C 12 In a preferred embodiment, when Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl. In a more preferred embodiment, when Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H, halogen and C1-C4 alkyl, preferably Y 1 When R is C 7 In an even more preferred embodiment, when Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H, halogen and methyl. In a particularly preferred embodiment, when Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H and halogen. In a particularly preferred embodiment, R 7 Does not exist.

[0146] In one embodiment, when Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 In a preferred embodiment, when Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl. In a more preferred embodiment, when Y3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H, halogen and C1-C4 alkyl, preferably when Y 3 When R is C 8 In an even more preferred embodiment, when Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H, halogen and methyl. In a particularly preferred embodiment, when Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H and halogen. In a particularly preferred embodiment, R 8 For H.

[0147] In one embodiment, when Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 In a preferred embodiment, when Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl. In a more preferred embodiment, when Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H and C1-C4 alkyl, preferably when Y 2 When R is C 9 In an even more preferred embodiment, when Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is selected from H, halogen and methyl. In a particularly preferred embodiment, when Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is selected from H and halogen, preferably H.

[0148] In one embodiment, when Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl, preferably when Y 1 When R is C 7 is selected from H, halogen and methyl, when Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl, preferably when Y 3 When R is C 8 is selected from H, halogen and methyl, and when Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl is preferably selected from H, halogen and methyl.

[0149] In a preferred embodiment, when Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H and halogen, when Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is H, and when Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H and methyl.

[0150] In one embodiment, R 10 and R 11 At least one of them is C1-C6 alkyl, preferably C1-C4 alkyl, preferably methyl. 10 and R 11 In a more preferred embodiment, R 10 H and R 11 is selected from H and C1-C4 alkyl. In an even more preferred embodiment, R 10 H and R 11 In a particularly preferred embodiment, R 10 H and R 11 In a more particularly preferred embodiment, R 10 H and R 11 In an even more particularly preferred embodiment, R 10 H and R11 It is a methyl group.

[0151] In one embodiment, R 12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl. In a preferred embodiment, R 12 is selected from NH2, C1-C6 alkyl and C1-C6 heteroalkyl. In a more preferred embodiment, R 12 is NH2.

[0152] In one embodiment, Y 1 is N. In a preferred embodiment, Y 1 and Y 2 are each independently selected from N and C, and Y 3 In a more preferred embodiment, Y 1 is selected from N and C, and Y 2 and Y 3 Selected from N and C, with the condition that Y 2 and Y 3 One of them is C. In a particularly preferred embodiment, Y 1 N and R 7 Does not exist, Y 2 is selected from N and C, and Y 3 In a particularly preferred embodiment, Y 1 N and R 7 Does not exist.

[0153] In one embodiment, at least one selected from R 1 、R 3 、R 4 、R 5 、R 6 、R 7 、R 8 and R 9 The substituents are not H. In another embodiment, at least one selected from R 1 、R 3 、R 8 and R 9 The substituent is not H.

[0154] Preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0155] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O, preferably selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl and O;

[0156] where Y 1 、Y 2 and Y3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C, and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0157] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0158] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic group, C1-C6 alkoxy group; C1-C6 heteroalkyl group, C0-C3 alkyl group OC0-C3 alkylaryl group, wherein the aryl group is optionally NH2, OC1-C6 alkyl group, C1-C6 alkyl group, C1-C6 heteroalkyl group, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0159] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0160] where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0161] where R 4 、R 5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;

[0162] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0163] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0164] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0165] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0166] Further preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates, or stereoisomers are those,

[0167] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O, preferably selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl and O;

[0168] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C, and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 is selected from N and C, and Y 3 is C;

[0169] Where Z is NR 10 R11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0170] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic group, C1-C6 alkoxy group; C1-C6 heteroalkyl group, C0-C3 alkyl group OC0-C3 alkylaryl group, wherein the aryl group is optionally NH2, OC1-C6 alkyl group, C1-C6 alkyl group, C1-C6 heteroalkyl group, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0171] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0172] where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0173] where R 4 、R 5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;

[0174] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl and C3-C12 Cycloalkyl;

[0175] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0176] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0177] where R 12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl; with the condition that when R 1 Selected from C0-C3 alkyl OC0-C3 alkylaryl, wherein the aryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic substitution, R 2 is selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with NH2, halogen, CN, preferably wherein the aryl and the heteroaryl are unsubstituted.

[0178] More preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates, or stereoisomers are those,

[0179] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O, preferably selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl and O;

[0180] where Y 1 、Y 2 and Y3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C, and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0181] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0182] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl;

[0183] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0184] where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0185] where R 4 、R 5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;

[0186] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0187] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0188] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0189] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0190] Further more preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates, or stereoisomers are those,

[0191] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O, preferably selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl and O;

[0192] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C, and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0193] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0194] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl;

[0195] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R12 、C1-C6 alkyl C(O)R 12 replace;

[0196] where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0197] where R 4 、R 5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;

[0198] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0199] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0200] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0201] where R 12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl, with the condition that when R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are replaced by C1-C6 alkyl, halogen, C1-C6 heteroalkyl, C(O)R 12 、C1-C6 alkyl C(O)R 12 Replacement, R 1 is selected from H, halogen, C1-C6 alkyl and C1-C6 heteroalkyl, preferably H or methyl.

[0202] Further more preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates, or stereoisomers are those,

[0203] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O, preferably selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl and O;

[0204] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C, and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0205] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0206] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl;

[0207] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0208] where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0209] where R 4 、R 5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;

[0210] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0211] When Y3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0212] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0213] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0214] Further more preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0215] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O, preferably selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl and O;

[0216] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0217] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0218] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic group, C1-C6 alkoxy group; C1-C6 heteroalkyl group, C0-C3 alkyl group OC0-C3 alkylaryl group, wherein the aryl group is optionally NH2, OC1-C6 alkyl group, C1-C6 alkyl group, C1-C6 heteroalkyl group, halogen, CN, C3-C 12Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic substitution, preferably wherein R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic group, C1-C6 alkoxy group; C1-C6 heteroalkyl group, C0-C3 alkyl group OC0-C3 alkylaryl group, wherein the aryl group is optionally NH2, OC1-C6 alkyl group, C1-C6 alkyl group, C1-C6 heteroalkyl group, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C0-C3 alkylOC0-C3 alkylheteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0219] where R 2 is selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with NH2, halogen, CN;

[0220] where R 3 is selected from H, halogen and C1-C4 alkyl;

[0221] where R 4 、R 5 and R 6 Each independently selected from H, halogen and C1-C4 alkyl;

[0222] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H, halogen and C1-C4 alkyl;

[0223] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8is selected from H, halogen and C1-C4 alkyl; and

[0224] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen and C1-C4 alkyl.

[0225] Even more preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0226] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O, preferably selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl and O;

[0227] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0228] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0229] where R 1 is selected from H, halogen, C1-C4 alkyl and C1-C4 heteroalkyl;

[0230] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0231] where R 3 is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl;

[0232] where R 4 、R 5 and R 6 are each independently selected from H, halogen, CN, C1-C4 alkyl and C1-C4 heteroalkyl;

[0233] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl;

[0234] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl;

[0235] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl; and

[0236] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0237] Particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0238] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O, preferably selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl and O;

[0239] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0240] Where Z is NR 10 R 11 , where R 10 and R 11 are each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, more preferably R 10 H and R 11 is H or methyl;

[0241] where R1 is selected from H, halogen and C1-C4 alkyl;

[0242] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0243] where R 3 is selected from H, halogen and C1-C4 alkyl;

[0244] where R 4 、R 5 and R 6 Each independently selected from H, halogen and C1-C4 alkyl;

[0245] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H, halogen and C1-C4 alkyl;

[0246] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H, halogen and C1-C4 alkyl;

[0247] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is selected from H, halogen and C1-C4 alkyl; and

[0248] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0249] Further particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0250] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O, preferably selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl and O;

[0251] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0252] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, preferably R 10 H and R 11 is H or methyl;

[0253] where R 1 is selected from H, halogen and C1-C4 alkyl;

[0254] where R 2 is selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with C1-C6 heteroalkyl;

[0255] where R 3 is selected from H, halogen and C1-C4 alkyl;

[0256] where R 4 、R 5 and R 6 Each independently selected from H, halogen and C1-C4 alkyl;

[0257] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H, halogen and C1-C4 alkyl;

[0258] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H, halogen and C1-C4 alkyl;

[0259] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is selected from H, halogen and C1-C4 alkyl; and

[0260] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0261] Further particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0262] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O, preferably selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl and O;

[0263] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0264] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, preferably R 10 H and R 11 is H or methyl;

[0265] where R 1 is selected from H, halogen and C1-C4 alkyl;

[0266] where R 2 is selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by C1-C6 alkyl, halogen;

[0267] where R 3 is selected from H, halogen and C1-C4 alkyl;

[0268] where R 4 、R 5 and R 6 Each independently selected from H, halogen and C1-C4 alkyl;

[0269] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H, halogen and C1-C4 alkyl;

[0270] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C8 is selected from H, halogen and C1-C4 alkyl;

[0271] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is selected from H, halogen and C1-C4 alkyl; and

[0272] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0273] Further particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0274] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O, preferably selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl and O;

[0275] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0276] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, preferably R 10 H and R 11 is H or methyl;

[0277] where R 1 is selected from H, halogen and C1-C4 alkyl;

[0278] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally replaced by C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0279] where R 3 is selected from H, halogen and C1-C4 alkyl;

[0280] where R 4 、R 5 and R 6 Each independently selected from H, halogen and C1-C4 alkyl;

[0281] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H, halogen and C1-C4 alkyl;

[0282] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H, halogen and C1-C4 alkyl;

[0283] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is selected from H, halogen and C1-C4 alkyl; and

[0284] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0285] Further particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0286] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O, preferably selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl and O;

[0287] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0288] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, preferably R10 H and R 11 is H or methyl;

[0289] where R 1 Selected from C0-C3 alkyl OC0-C3 alkylaryl, wherein the aryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl is substituted, preferably optionally substituted with NH2; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally substituted with NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl is substituted, preferably optionally substituted with NH2; and C1-C6 alkyl is substituted with aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl is substituted, preferably optionally substituted with NH2, wherein R 1 Preferably selected from C0-C3 alkyl OC0-C3 alkylaryl, wherein the aryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic radical, preferably optionally substituted with NH2; and C0-C3 alkylOC0-C3 alkylheteroaryl, wherein the heteroaryl is optionally substituted with NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted, preferably optionally substituted with NH2;

[0290] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, halogen, C1-C6 alkyl, CN, preferably optionally substituted by halogen, C1-C6 alkyl;

[0291] where R 3 is selected from H, halogen and C1-C4 alkyl;

[0292] where R 4 、R 5 and R 6 Each independently selected from H, halogen and C1-C4 alkyl;

[0293] When Y 1When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H, halogen and C1-C4 alkyl;

[0294] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H, halogen and C1-C4 alkyl; and

[0295] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen and C1-C4 alkyl.

[0296] Preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0297] wherein X is selected from CH2, NH and O;

[0298] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0299] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0300] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic group, C1-C6 alkoxy group; C1-C6 heteroalkyl group, C0-C3 alkyl group OC0-C3 alkylaryl group, wherein the aryl group is optionally NH2, OC1-C6 alkyl group, C1-C6 alkyl group, C1-C6 heteroalkyl group, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0301] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0302] where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0303] where R 4 、R 5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;

[0304] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0305] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0306] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0307] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0308] Further preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0309] wherein X is selected from CH2, NH and O;

[0310] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0311] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0312] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic group, C1-C6 alkoxy group; C1-C6 heteroalkyl group, C0-C3 alkyl group OC0-C3 alkylaryl group, wherein the aryl group is optionally NH2, OC1-C6 alkyl group, C1-C6 alkyl group, C1-C6 heteroalkyl group, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0313] where R 2Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0314] where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0315] where R 4 、R 5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;

[0316] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0317] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0318] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0319] where R 12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl; with the condition that when R 1 Selected from C0-C3 alkyl OC0-C3 alkylaryl, wherein the aryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic substitution, R 2 is selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with NH2, halogen, CN, preferably wherein the aryl and the heteroaryl are unsubstituted.

[0320] More preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0321] wherein X is selected from CH2, NH and O;

[0322] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0323] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0324] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl;

[0325] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R12 、C1-C6 alkyl C(O)R 12 replace;

[0326] where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0327] where R 4 、R 5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;

[0328] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0329] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0330] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0331] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0332] Further more preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0333] wherein X is selected from CH2, NH and O;

[0334] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2Selected from N and C and Y 3 is C;

[0335] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0336] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl;

[0337] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0338] where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0339] where R 4 、R 5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;

[0340] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0341] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0342] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0343] where R 12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl, with the condition that when R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are replaced by C1-C6 alkyl, halogen, C1-C6 heteroalkyl, C(O)R 12 、C1-C6 alkyl C(O)R 12 Replacement, R 1 is selected from H, halogen, C1-C6 alkyl and C1-C6 heteroalkyl, preferably H or methyl.

[0344] Further more preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0345] wherein X is selected from CH2, NH and O;

[0346] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0347] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0348] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl;

[0349] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0350] where R 3Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0351] where R 4 、R 5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;

[0352] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0353] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0354] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0355] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0356] Further more preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0357] wherein X is selected from CH2, NH and O;

[0358] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0359] Where Z is NR 10 R 11, where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0360] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic group, C1-C6 alkoxy group; C1-C6 heteroalkyl group, C0-C3 alkyl group OC0-C3 alkylaryl group, wherein the aryl group is optionally NH2, OC1-C6 alkyl group, C1-C6 alkyl group, C1-C6 heteroalkyl group, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic substitution, preferably wherein R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic group, C1-C6 alkoxy group; C1-C6 heteroalkyl group, C0-C3 alkyl group OC0-C3 alkylaryl group, wherein the aryl group is optionally NH2, OC1-C6 alkyl group, C1-C6 alkyl group, C1-C6 heteroalkyl group, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C0-C3 alkylOC0-C3 alkylheteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0361] where R 2 is selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with NH2, halogen, CN;

[0362] where R 3 is selected from H, halogen and C1-C4 alkyl;

[0363] where R 4 、R 5 and R6 Each independently selected from H, halogen and C1-C4 alkyl;

[0364] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H, halogen and C1-C4 alkyl;

[0365] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H, halogen and C1-C4 alkyl; and

[0366] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen and C1-C4 alkyl.

[0367] Even more preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0368] wherein X is selected from CH2, NH and O, and is preferably O;

[0369] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0370] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0371] where R 1 is selected from H, halogen, C1-C4 alkyl and C1-C4 heteroalkyl;

[0372] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C(O)R 12 、C1-C6 alkyl C(O)R12 replace;

[0373] where R 3 is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl;

[0374] where R 4 、R 5 and R 6 are each independently selected from H, halogen, CN, C1-C4 alkyl and C1-C4 heteroalkyl;

[0375] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl;

[0376] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl;

[0377] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is selected from H, halogen, C1-C4 alkyl and C3-C7 cycloalkyl; and

[0378] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0379] Particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0380] wherein X is selected from CH2, NH and O, and is preferably O;

[0381] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0382] Where Z is NR 10 R11 , where R 10 and R 11 are each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, more preferably R 10 H and R 11 is H or methyl;

[0383] where R 1 is selected from H, halogen and C1-C4 alkyl;

[0384] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0385] where R 3 is selected from H, halogen and C1-C4 alkyl;

[0386] where R 4 、R 5 and R 6 Each independently selected from H, halogen and C1-C4 alkyl;

[0387] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 When Y is selected from H, halogen and C1-C4 alkyl 1 is C;

[0388] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H, halogen and C1-C4 alkyl;

[0389] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is selected from H, halogen and C1-C4 alkyl; and

[0390] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0391] Further particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0392] wherein X is selected from CH2, NH and O, and is preferably O;

[0393] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0394] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, preferably R 10 H and R 11 is H or methyl;

[0395] where R 1 is selected from H, halogen and C1-C4 alkyl;

[0396] where R 2 is selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with C1-C6 heteroalkyl;

[0397] where R 3 is selected from H, halogen and C1-C4 alkyl;

[0398] where R 4 、R 5 and R 6 Each independently selected from H, halogen and C1-C4 alkyl;

[0399] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H, halogen and C1-C4 alkyl;

[0400] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H, halogen and C1-C4 alkyl;

[0401] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is selected from H, halogen and C1-C4 alkyl; and

[0402] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0403] Further particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0404] wherein X is selected from CH2, NH and O, and is preferably O;

[0405] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0406] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, preferably R 10 H and R 11 is H or methyl;

[0407] where R 1 is selected from H, halogen and C1-C4 alkyl;

[0408] where R 2 is selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by C1-C6 alkyl, halogen;

[0409] where R 3 is selected from H, halogen and C1-C4 alkyl;

[0410] where R 4 、R 5 and R 6 Each independently selected from H, halogen and C1-C4 alkyl;

[0411] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H, halogen and C1-C4 alkyl;

[0412] When Y3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H, halogen and C1-C4 alkyl;

[0413] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is selected from H, halogen and C1-C4 alkyl; and

[0414] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0415] Further particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0416] wherein X is selected from CH2, NH and O, and is preferably O;

[0417] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0418] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, preferably R 10 H and R 11 is H or methyl;

[0419] where R 1 is selected from H, halogen and C1-C4 alkyl;

[0420] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally replaced by C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0421] where R 3 is selected from H, halogen and C1-C4 alkyl;

[0422] where R 4 、R 5 and R 6 Each independently selected from H, halogen and C1-C4 alkyl;

[0423] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H, halogen and C1-C4 alkyl;

[0424] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H, halogen and C1-C4 alkyl;

[0425] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is selected from H, halogen and C1-C4 alkyl; and

[0426] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0427] Further particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0428] wherein X is selected from CH2, NH and O, and is preferably O;

[0429] where Y 1 、Y 2 and Y 3 Each independently selected from N and C, preferably Y 1 and Y 2 are each independently selected from N and C and Y 3 C, more preferably Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0430] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl, preferably independently selected from H and methyl, preferably R 10 H and R 11 is H or methyl;

[0431] where R 1 Selected from C0-C3 alkyl OC0-C3 alkylaryl, wherein the aryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl is substituted, preferably optionally substituted with NH2; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally substituted with NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl is substituted, preferably optionally substituted with NH2; and C1-C6 alkyl is substituted with aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl is substituted, preferably optionally substituted with NH2, wherein R 1 Preferably selected from C0-C3 alkyl OC0-C3 alkylaryl, wherein the aryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic radical, preferably optionally substituted with NH2; and C0-C3 alkylOC0-C3 alkylheteroaryl, wherein the heteroaryl is optionally substituted with NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted, preferably optionally substituted with NH2;

[0432] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with NH2, halogen, C1-C6 alkyl, CN; preferably optionally substituted with halogen, C1-C6 alkyl;

[0433] where R 3 is selected from H, halogen and C1-C4 alkyl;

[0434] where R 4 、R 5 and R 6 Each independently selected from H, halogen and C1-C4 alkyl;

[0435] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C7 is selected from H, halogen and C1-C4 alkyl;

[0436] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H, halogen and C1-C4 alkyl; and

[0437] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen and C1-C4 alkyl.

[0438] Further particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0439] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O;

[0440] where Y 1 、Y 2 and Y 3 are each independently selected from N and C;

[0441] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0442] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl;

[0443] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0444] where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0445] where R 4 、R5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;

[0446] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0447] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0448] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0449] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0450] More particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0451] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O;

[0452] where Y 1 、Y 2 and Y 3 are each independently selected from N and C;

[0453] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0454] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0455] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0456] where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0457] where R 4 、R 5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;

[0458] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0459] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0460] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0461] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0462] Further more particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0463] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O;

[0464] where Y 1 N and R 7 Does not exist, Y 2 is selected from N and C, and Y 3 is C;

[0465] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0466] where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted by aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0467] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace;

[0468] where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0469] where R 4 、R 5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl;

[0470] where R 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl;

[0471] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and

[0472] where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

[0473] Further more particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0474] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O;

[0475] where Y 1 、Y 2 and Y 3 are each independently selected from N and C;

[0476] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0477] where R1 Selected from H, C1-C6 alkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted with NH2; C0-C3 alkylOC0-C3 alkylheteroaryl, wherein the heteroaryl is optionally substituted with NH2;

[0478] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C (O) R 12 replace;

[0479] where R 3 is H;

[0480] where R 4 is selected from H and halogen;

[0481] where R 5 and R 6 Each independently selected from H and C1-C6 alkyl;

[0482] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is H;

[0483] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is H;

[0484] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is H; and

[0485] where R 12 is NH2.

[0486] Further more particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0487] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O;

[0488] where Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C;

[0489] Where Z is NR10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0490] where R 1 Selected from H, C1-C6 alkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted with NH2; C0-C3 alkylOC0-C3 alkylheteroaryl, wherein the heteroaryl is optionally substituted with NH2;

[0491] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C (O) R 12 replace;

[0492] where R 3 is H;

[0493] where R 4 is selected from H and halogen;

[0494] where R 5 and R 6 Each independently selected from H and C1-C6 alkyl;

[0495] where R 8 is H;

[0496] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is H; and

[0497] where R 12 is NH2.

[0498] Further more particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0499] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O;

[0500] where Y 1 、Y 2 and Y 3 are each independently selected from N and C;

[0501] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0502] where R 1 Selected from H and C1-C6 alkyl;

[0503] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C (O) R 12 replace;

[0504] where R 3 is H;

[0505] where R 4 is selected from H and halogen;

[0506] where R 5 and R 6 Each independently selected from H and C1-C6 alkyl;

[0507] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is H;

[0508] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is H;

[0509] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is H; and

[0510] where R 12 is NH2.

[0511] Further more particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers are those,

[0512] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O;

[0513] where Y 1 N and R 7 Does not exist, Y 2 is selected from N and C, and Y 3 is C;

[0514] Where Z is NR 10 R 11 , where R 10 and R11 Each independently selected from H and C1-C6 alkyl;

[0515] where R 1 Selected from H and C1-C6 alkyl;

[0516] where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C (O) R 12 replace;

[0517] where R 3 is H;

[0518] where R 4 is selected from H and halogen;

[0519] where R 5 and R 6 Each independently selected from H and C1-C6 alkyl;

[0520] where R 8 is H;

[0521] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is H; and

[0522] where R 12 is NH2.

[0523] Further more particularly preferred pharmaceutically acceptable salts, hydrates, solvates, or stereoisomers of compounds of formula (I) are those,

[0524] wherein X is selected from the group consisting of CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O;

[0525] where Y 1 、Y 2 and Y 3 are each independently selected from N and C;

[0526] Where Z is NR 10 R 11 , where R 10 and R 11 Each independently selected from H and C1-C6 alkyl;

[0527] where R 1 Selected from C0-C3 alkyl OC0-C3 alkylaryl, wherein the aryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C12 Cycloalkyl, C3-C 12 and C0-C3 alkylOC0-C3 alkylheteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 heterocyclic substitution;

[0528] where R 2 is selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with NH2, halogen, C1-C6 alkyl, CN;

[0529] where R 3 is selected from H, halogen and C1-C4 alkyl;

[0530] where R 4 、R 5 and R 6 Each independently selected from H, halogen and C1-C4 alkyl;

[0531] When Y 1 When N is R 7 does not exist, or when Y 1 When R is C 7 is selected from H, halogen and C1-C4 alkyl;

[0532] When Y 3 When N is R 8 does not exist, or when Y 3 When R is C 8 is selected from H, halogen and C1-C4 alkyl; and

[0533] When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen and C1-C4 alkyl.

[0534] Even more particularly preferred compounds of formula (I) are selected from the group consisting of:

[0535]

[0536]

[0537]

[0538]

[0539]

[0540] Further even more particularly preferred compounds of the formula (I) are selected from the group consisting of:

[0541]

[0542]

[0543]

[0544]

[0545]

[0546] Further even more particularly preferred compounds of the formula (I) are selected from the group consisting of:

[0547]

[0548]

[0549]

[0550]

[0551]

[0552] Further even more particularly preferred compounds of the formula (I) are selected from the group consisting of:

[0553]

[0554]

[0555]

[0556]

[0557]

[0558] Further even more particularly preferred compounds of the formula (I) are selected from the group consisting of:

[0559]

[0560]

[0561]

[0562]

[0563]

[0564] Further even more particularly preferred compounds of the formula (I) are selected from the following group:

[0565]

[0566]

[0567] The most particularly preferred compounds among the compounds of formula (I) are selected from the following group:

[0568]

[0569] More particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof are selected from the following group:

[0570]

[0571]

[0572] Still further particularly preferred compounds of formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof are selected from the following group:

[0573]

[0574]

[0575] Further more particularly preferred compounds of the formula (I) used and the pharmaceutical compositions comprising the compounds of the formula (I) are selected from the following group:

[0576]

[0577]

[0578] Further more particularly preferred compounds of the formula (I) used and the pharmaceutical compositions comprising the compounds of the formula (I) are selected from the following group:

[0579]

[0580] Compound preparation

[0581] The compounds of the present invention can be prepared by the exemplary methods described in the following reaction schemes or the methods described in the examples. Exemplary reagents and methods for these reactions are presented below. The starting materials can be purchased or readily prepared by one of ordinary skill in the art.

[0582] Solution 1: X=NH, N(C1-C3-alkyl), S and O

[0583]

[0584] The synthesis of diarylamino, diarylether and diarylsulfide analogs is described in Scheme 1: a radical of formula ( II ) of each aminoaryl moiety (X = NH, ultimately monoalkylated) and the formula ( III ) is reacted with a halogenated nitroaryl precursor. Preferably, the solvent is a mixture of DMSO and an alcohol such as tBuOH. An alcoholate such as tBuOK can be used as a base. The reaction temperature is between room temperature and 150°C, preferably between 60 and 110°C. In the presence of a base, in a polar solvent, a compound of formula ( II ) of each hydroxyl- or mercapto-aryl moiety (X = O, S) and the formula ( III ) is reacted with a halogenated nitro-aryl precursor. The preferred reaction conditions are at room temperature, in DMF, with carbonate as the base. Finally, the compound of formula ( IV ) is reduced to the nitro functional group of formula ( V ) of the corresponding amine. Preferred Béchamp conditions are Fe powder in a mixture of EtOH, H2O and AcOH under ultrasonic treatment. Catalytic hydrogenation can be carried out in the presence of Pd / C in a polar solvent such as alcohol. Alternatively, by using the formula ( VI ) is substituted with halogen to form ( VII ) containing an X-aryl moiety, the formula ( VIII ) of the target compound (Y 3 =N), and finally a protecting group (PG) is present. Preferred conditions are using phosphate as a base, in a non-polar aromatic solvent, under ferrocenyl catalysis, at 100 to 150°C [see Advanced Synthesis & Catalysis 353 (2011), 3403].

[0585] Option 2:

[0586]

[0587] Scheme 2 description formula ( V) of amino derivatives: The preferred method is to stir the amine of formula (V) and the corresponding aldehyde in a polar solvent such as an alcohol in the presence of a weak acid such as acetic acid. Then add a reducing agent such as NaBH3CN. Perform basic workup to ultimately obtain the compound of formula (IX). Alternatively, the amine of formula (V) and the aldehyde are mixed in a non-polar solvent such as dichloromethane in the presence of a base such as triethylamine. Then add a reducing agent such as NaBH(OAc)3. Aqueous workup ultimately produces the compound of formula (IX). Formula ( IX ; R=H) is represented by the formula ( V ) with paraformaldehyde in MeOH with MeONa as base, followed by reduction with NaBH4 and aqueous workup.

[0588] Option 3: X=CH2, CF2, CHF, CHOH, CHOAlk, CO

[0589]

[0590] Scheme 3 illustrates the synthesis of carbon-bridged analogs (X = CH2, CF2, CHF, CHOH, CHOAlk, CO): X ) is catalyzed by a transition metal complex and reacts with the halogen-aryl moiety of formula ( XI ) is coupled with an aryl acetate of formula ( XII ) nitro derivatives. Preferred conditions are in a non-polar solvent, at elevated temperature, with XPhos / Pd2(allyl)2Cl2 as a catalyst. Formula ( XII ) can be oxidized to the methylene bridge (X=CH2) of formula ( XIV ) of the corresponding diaryl ketone. The preferred conditions are oxygen as a reagent, in a mixture of acetic acid and DMSO at elevated temperature, catalyzed by FeCl2·(H2O)4 [similar to Angew.Chem.Int.Ed.51 (2012), 2745]. Formula ( XIV ) is reduced to give the formula ( XVII ) benzyl alcohol. The preferred reducing agent may be sodium borohydride. Alternatively, the borate ester of formula (XV) may be reacted with a borate ester of formula ( XVI ) is subjected to aryl-aldehyde cross-coupling to obtain ( XVII ) benzyl alcohol. In an aprotic polar solvent, in the presence of a strong base (such as NaH), XVII ) is alkylated with an alkyl iodide to give a compound of formula ( XVIII ) [similar to Example 2 in US5965740]. Formula ( XIX ) can be obtained by the formula ( XII ) or oxidative fluorination of a compound of formula ( XVII ) compounds. Oxidative fluorination can be carried out at elevated temperatures in polar solvents in the presence of the Jacobsen salene complex, iodobenzene, a base, and tris(hydrogen fluoride) [J. Am. Chem. Soc. 136 (2014), 6842]. Fluorine substitution of the benzyl hydroxyl group can be achieved by applying the following conditions: for example, in dichloromethane, in the presence of bis(1,5-cyclooctadiene)rhodium(I) tetrafluoroborate, activation with trichloroacetimide and 1,8-diazabicyclo[5.4.0]undec-7-ene, followed by triethylamine tris(hydrogen fluoride) in a mixture of F3C-C6H5 and tetrahydrofuran at slightly elevated temperatures [Tetrahedron 71 (2015), 5932]. The formula ( XIV ) is converted into a ketone derivative of formula ( XX ) [similar to the preparation of compound 76 in step 2 of US2015246938; page 55]. Finally, as described in Scheme 1, the formula ( XII )、( XIV )and( XVII )-( XX ) are reduced to their respective amino derivatives.

[0591] Stereoisomers

[0592] The compounds of the present invention may exist as stereoisomers in which asymmetric or chiral centers are present. These compounds are represented by the symbols "R" or "S," depending on the configuration of substituents around the chiral carbon atom. The present invention encompasses various stereoisomers and mixtures thereof. Stereoisomers include enantiomers and diastereomers and mixtures of enantiomers or diastereomers. Individual stereoisomers of the compounds of the present invention may be synthesized from commercially available starting materials containing asymmetric or chiral centers, or by preparing a racemic mixture followed by resolution by methods well known to those skilled in the art. Examples of such resolution methods include: (1) attaching the enantiomeric mixture to a chiral auxiliary, separating the resulting diastereomeric mixture by recrystallization or chromatography, and liberating the optically pure product from the auxiliary, (2) forming salts using an optically active resolving agent, or (3) directly separating the enantiomer mixture on a chiral chromatographic column.

[0593] Geometric isomers may also exist in the compounds of the present invention. The present invention contemplates various geometric isomers and mixtures thereof arising from the arrangement of substituents around a carbon-carbon double bond or around a carbocyclic ring.

[0594] The compounds of the present invention may also exist in racemic form, which is designated by the descriptor "rac". As used herein, the term racemate refers to an equimolar mixture of a pair of enantiomers. Racemates are typically formed when synthesis results in the formation of a stereogenic center. As used herein, the term racemic mixture refers to racemates. The compounds of the present invention may also exist in diastereomeric meso forms, which are designated by the descriptor "rel". As used herein, the term diastereomeric meso forms refers to achiral forms having a pseudostereomeric C atom, which are designated by the descriptors "r" or "s", respectively.

[0595] salts

[0596] The compounds of the present invention may be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids. "Pharmaceutically acceptable salts" refers to salts that, within the scope of sound medical judgment, are suitable for contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic reaction, etc., and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. These salts can be prepared in situ during the final isolation and purification of the compounds of the present invention, or separately by reacting the free base functional group with a suitable acid.

[0597] Representative acid addition salts include, but are not limited to, trifluoroacetic acid (TFA), acetate, adipic acid, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate, and undecanoate. In addition, basic nitrogen-containing groups can be quaternized with reagents such as lower alkyl halides, such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates; long-chain halides, such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; aralkyl halides, such as benzyl and phenethyl bromides, etc. Water-soluble or oil-soluble or dispersible products are thus obtained. Examples of acids that can be used to form pharmaceutically acceptable acid addition salts include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid and organic acids such as oxalic acid, maleic acid, succinic acid and citric acid.

[0598] Basic addition salts can be prepared in situ during the final isolation and purification of the compounds of the invention by reacting the carboxylic acid-containing moiety with a suitable base, such as a hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation, or with ammonia or an organic primary, secondary, or tertiary amine. Pharmaceutically acceptable basic addition salts include, but are not limited to, salts based on alkali or alkaline earth metal cations such as lithium, sodium, potassium, calcium, magnesium, and aluminum, and non-toxic quaternary ammonium and amine cations, including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, and the like. Other representative organic amines useful for forming basic addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine, and the like.

[0599] Solvates / hydrates

[0600] It should be understood that solvates and hydrates of compounds according to formula (I) are also within the scope of the present invention. Methods of solvation are well known in the art. Another embodiment of the present invention may also include compounds identical to compounds of formula (I) except that one or more atoms are replaced by atoms having an atomic mass number or mass different from that normally found in nature, such as those enriched in 2 H(D), 3 H. 13 C. 127 These isotopic analogs and their pharmaceutically acceptable salts and formulations are considered to be useful agents in therapy and / or diagnosis, for example, but not limited to, fine-tuning of in vivo half-life can lead to optimized dosage regimens.

[0601] Pharmaceutical composition

[0602] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) according to the present invention and a pharmaceutically acceptable diluent, excipient or carrier.

[0603] In one embodiment, the pharmaceutical composition further comprises another pharmaceutically active agent.

[0604] In one embodiment, the present invention provides a pharmaceutical composition comprising a compound of formula (I) according to the present invention and a pharmaceutically acceptable diluent, excipient or carrier, wherein the compound of formula (I) is present in a therapeutically effective amount.

[0605] Preparation and administration:

[0606] According to the present invention, the compounds of the present invention can be administered orally, parenterally, by inhalation, rectally or topically, in single or divided doses, including dermal, ocular, mucosal scalp, sublingual, buccal and intranasal administration routes; in addition, the compounds provided by the present invention can be formulated for in vitro and in vitro treatment of leukocyte populations.

[0607] When the compound of the present invention is administered, for example, by oral route, it can be administered as a drug in the form of a pharmaceutical composition comprising the compound and a pharmaceutically acceptable diluent, excipient or carrier material. Therefore, the present invention also provides a pharmaceutical composition comprising the compound according to the present invention as described above and one or more pharmaceutically acceptable diluents, excipients or carriers. The pharmaceutical composition can be prepared in a conventional manner, and the final dosage form can be a solid dosage form, such as tablets, dragees, capsules, etc., or a liquid dosage form, such as solutions, suspensions, emulsions, etc. Pharmaceutically acceptable diluents, excipients or carriers include sterile aqueous solutions or dispersions and sterile powders for the temporary preparation of sterile injection solutions or dispersions. The use of such media and reagents for pharmaceutically active substances is well known in the art. In one embodiment, the present invention provides a pharmaceutical composition comprising a compound of formula (I) according to the present invention and at least one pharmaceutically acceptable diluent, excipient or carrier, wherein the composition is a tablet or capsule, preferably a tablet.

[0608] Dosage regimen

[0609] Exemplary treatment regimens require administration once a day, twice a day, three times a day, every other day, twice a week, or once a week. The compositions of the present invention are typically administered on a variety of occasions. The intervals between single doses may be, for example, less than one day, daily, every other day, twice a week, or once a week. Administration of the compositions of the present invention may be continuous, uninterrupted treatment. In an exemplary treatment regimen, the compound of formula (I) of the present invention may be administered at a dose of 0.1-100 mg per day.

[0610] Therapeutic uses

[0611] The compounds according to the invention as described above have prophylactic and therapeutic use in human and veterinary diseases.

[0612] Therefore, in another aspect, the present invention provides the use of the compounds as described herein and the pharmaceutical compositions as described herein for prophylactic and / or therapeutic purposes. In one embodiment of the present invention, the compounds as described herein according to the invention or the pharmaceutical compositions as described herein can be used as a medicament, preferably for human and / or veterinary medicine. Therefore, the present invention provides the compounds as described herein according to the invention or the pharmaceutical compositions as described herein for use as a medicament.

[0613] In another aspect, the present invention also provides a compound of the present invention or a pharmaceutical composition of the present invention for use in a method for preventing or treating cancer. Also provided is a method for treating and / or preventing cancer, comprising administering a compound of the present invention or a pharmaceutical composition of the present invention to a subject in need thereof. Also provided is use of a compound of the present invention or a pharmaceutical composition of the present invention in the preparation of a medicament for treating and / or preventing cancer in a subject. Also provided is use of a compound of the present invention or a pharmaceutical composition of the present invention in treating and / or preventing cancer in a subject.

[0614] The cancer to be prevented or treated is preferably a Notch-dependent cancer, more preferably, the Notch-dependent cancer is selected from the group consisting of adenoid cystic carcinoma (ACC), T-cell acute lymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), breast cancer, pancreatic cancer, prostate cancer, melanoma, brain tumor, tumor angiogenesis, liver cancer, and colorectal cancer. Preferably, the compounds of the present invention can also be used to treat Notch-dependent cancers that are resistant to treatment with γ-secretase inhibitors. Notch signaling-dependent human tumors that are resistant to treatment with γ-secretase inhibitors can be determined by the level of the Notch intracellular domain (NICD), Notch target genes, Notch receptors, and mutation status of other components of the Notch pathway.

[0615] In another aspect, the present invention provides a method for treating a disease associated with upregulated Notch signaling pathway activity, comprising administering a compound or pharmaceutical composition of the present invention to a subject in need thereof.

[0616] The daily dosage of the compounds of the present invention will necessarily vary depending on the host being treated, the particular route of administration, and the severity and nature of the disease being treated. Thus, the optimal dosage can be determined by the physician treating any particular patient. Furthermore, it should be noted that the clinician or attending physician will know how and when to initiate, interrupt, adjust, or terminate treatment based on the individual patient's response. For any compound used in the methods of the present invention, a preliminary estimate of the therapeutically effective dosage can be made from cell culture assays, animal models, or microdosing in human subjects.

[0617] As used herein, "treat" refers to both therapeutic treatment and prophylactic or preventative measures. Subjects in need of treatment include those already suffering from the disease, such as cancer, and those in whom the disease, such as cancer, is to be prevented. Thus, the mammal to be treated herein, preferably a human, may have already been diagnosed with the disease, such as cancer, or may be susceptible to infection or development of the disease, such as cancer.

[0618] As used herein, "prevention" includes prophylactic treatment. In prophylactic applications, the pharmaceutical compositions of the present invention are administered to a subject suspected of having cancer or at risk of developing cancer. In therapeutic applications, the drug combination is administered to a subject, such as a patient already suffering from cancer, in an amount sufficient to cure or at least partially arrest the symptoms of the disease. An effective amount for this use will depend on the severity and course of the disease, previous treatments, the subject's health and response to the drugs, and the judgment of the attending physician.

[0619] The term "therapeutically effective amount" refers to an amount of a drug that is effective in treating a disease or condition in a mammal. In the case of cancer, a therapeutically effective amount of the drug can reduce the number of tumors or cancer cells, reduce the size of the tumor; inhibit (i.e., slow down and preferably stop to some extent) the infiltration of cancer cells into surrounding organs; inhibit (i.e., slow down and preferably stop to some extent) tumor metastasis; inhibit the growth of tumors to some extent; and / or alleviate to some extent one or more symptoms associated with cancer. To the extent that the compounds of the present invention can prevent cancer cell growth and / or kill existing cancer cells, they can have a cytostatic effect and / or be cytotoxic. The phrase "therapeutically effective amount" as used herein means sufficient to prevent or preferably reduce the growth or progression of target cell clusters, cancer cell populations, or clinically significant changes in mitotic activity or other pathological characteristics by at least about 30%, preferably by at least 50%, preferably by at least 70%, preferably by at least 80%, preferably by at least 90%.

[0620] In one embodiment, the compounds of the present invention can be used in combination with conventional treatments such as standard radiotherapy and / or standard chemotherapy (e.g., simultaneously or nearly simultaneously or one after the other) for anti-cell proliferative diseases. Standard radiotherapy and chemotherapy can also be concomitant chemo-radiotherapy. Standard radiotherapy and / or chemotherapy can be performed before, simultaneously with, or after administration of a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.

[0621] The term "concomitant chemoradiotherapy" is used when both treatments (chemotherapy and radiation therapy) are given at the same time or nearly the same time, such as one after the other or on the same day.

[0622] The term "standard radiotherapy" refers to the use of ionizing radiation as part of cancer treatment to control malignant cells. Preferably, the ionizing radiation is gamma radiation. It is also common to combine radiotherapy with surgery, chemotherapy, hormone therapy, or a combination thereof. The most common types of cancer are generally treatable with radiotherapy. The exact purpose of treatment (curative, adjuvant, neoadjuvant, or palliative) will depend on the type, location, and stage of the tumor and the overall health of the subject in need thereof.

[0623] The term "standard chemotherapy" generally refers to the use of specific chemotherapy / chemotherapeutic agents to treat cancer. Chemotherapeutic agents are agents that are commonly used to treat cancer. Chemotherapeutic agents used to treat cancer include, for example, altretamine, bleomycin, busulphan, capecitabine, carboplatin, carmustine, chlororambucil, cisplatin, cladribine, cristantaspase, cyclophosphamid, cytarabine, dacarbazine, daunorubicin, doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil, gemcitabine, idarubicin, ifosfamide, dapoxetine ... Ifosfamide, Irinotecan, Lomustine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin, Mitoxantrone, Oxaliplatin, Pentostatin, Procarbazine, Streptozocin, Taco, Temozolomide, Tioguanine / Thioguanine, Thiotepa, Topotecan, Treosulfan, Vinblastine, Vincristine, Vindesine, or Vinorelbine.

[0624] When a chemotherapeutic agent is used in combination with a compound according to the invention, it may be used in the form of a pharmaceutical comprising the combination of the two drugs for simultaneous administration, or it may be used in the form of separate dosage forms, each comprising the drug, in the latter case, separate dosage forms may be used, for example, a dosage form with the compound of the invention followed by a dosage form containing the chemotherapeutic agent (or vice versa). This embodiment in which the two separate dosage forms are provided in the form of a kit is conceivable.

[0625] Furthermore, the compounds of the present invention may optionally be used in conjunction with conventional tumor mass removal, for example by segmental resection (biopsy or excision), to combat cell proliferative diseases such as cancer.

[0626] The term "tumor mass removal" refers to any removal, ablation or resection of a tumor mass from a subject. Removal can be chemical, radiological or surgical. Preferably, the removal is a surgical procedure, such as ablation or resection. Resection can be a "segmentectomy" (or segmentectomy), a surgical procedure to remove part of an organ or gland from a subject. It can also be used to remove a tumor and the normal tissue surrounding it. A debulking agent can also be used to remove a tumor mass. The term "debulking agent" includes agents that kill cancer cells in a tumor mass (e.g., FL1 as described above). 0 and FL1 - cells) or any external / environmental factors (e.g., gamma-irradiation) or traditional surgery.

[0627] For suitable carriers, reference may be made to standard texts describing these, such as "Comprehensive Medicinal Chemistry", Volume 5, Chapter 25.2, Pergamon Publishing House, 1990, and "Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete", written by HP Fiedler, Editio Cantor Publishing House, 2002. The term "pharmaceutically acceptable carrier" refers to a carrier or excipient that can be used to prepare a pharmaceutical composition that is generally safe and has acceptable toxicity. Acceptable carriers include those that are acceptable for veterinary and human pharmaceuticals. "Pharmaceutically acceptable carrier" as used in the specification and claims includes one or more such carriers.

[0628] Optionally, the pharmaceutical composition of the present invention further comprises one or more other active agents selected from the group of non-restrictive chemotherapeutic agents for the treatment of cancer. Such chemotherapeutic agents can be selected from, for example: hexamethylmelamine, bleomycin, bupropion, capecitabine, carboplatin, carmustine, chlorobutyric acid, cisplatin, cladribine, clestatin, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, doxorubicin, epirubicin, etoposide (Etoposide), fludarabine, fluorouracil, gemcitabine, idarubicin, ifosfamide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, mitomycin, mitoxantrone, oxaliplatin, pentostatin, procarbazine, streptozotocin, taco, temozolomide, thioguanine / thioguanine, thiotepa, topotecan, endosulfan, vinblastine, vincristine, vindesine and vinorelbine.

[0629] The compounds of the present invention that can be used to treat and / or prevent cancer can be incorporated into a variety of preparations and drugs for therapeutic administration. More particularly, one or more compounds provided herein can be formulated as pharmaceutical compositions by combining with appropriate pharmaceutically acceptable carriers, and can be formulated into preparations in solid, semisolid, liquid or gaseous forms, such as tablets, capsules, pills, powders, granules, dragees, gels, slurries, ointments, solutions, suppositories, injections, inhalants and aerosols. In this regard, the administration of the compound can be achieved in a variety of ways, including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal, intracranial and / or intratracheal administration. Moreover, the compound can be administered in a local rather than systemic manner, in the form of a reservoir or sustained-release formulation. These compounds can be formulated with common excipients, diluents or carriers and compressed into tablets, or formulated into convenient oral elixirs or solutions, or administered by intramuscular or intravenous routes. The compound can be administered transdermally and can be formulated into sustained-release dosage forms, etc. These compounds can be administered alone, in combination with one another, or in combination with other known compounds. Suitable formulations for use in the present invention can be found in Remington's Pharmaceutical Sciences (Mack Publishing Company (1985), Philadelphia, PA, 17th ed.), which is incorporated herein by reference. In addition, for a brief review of drug delivery methods, see Langer, Science (1990) 249: 1527-1533, which is incorporated herein by reference.

[0630] The amount of the compound provided herein that can be combined with a carrier material to produce a single dosage form will vary depending on the disease being treated, the subject in need thereof, and the specific mode of administration. However, as a general guide, a unit dose suitable for the compounds of the present invention may preferably, for example, comprise 0.1 mg to about 1000 mg, 1 mg to about 500 mg, and 1 mg to about 300 mg of the active compound. In another embodiment, the unit dose is between 1 mg and about 100 mg. This unit dose can be administered more than once a day, for example, 2, 3, 4, 5, or 6 times a day, but preferably 1 or 2 times a day, so that the total dose for a 70 kg adult is in the range of 0.001 to about 15 mg per kg of body weight per administration. The preferred dose for each administration is 0.01 to about 1.5 mg per kg of subject body weight, and this treatment can be sustained for weeks or months, and in some cases for years. However, it should be understood that the specific dosage amount for any particular patient will depend on a variety of factors, including the activity of the specific compound employed; the age, weight, general health, sex, and diet of the subject being treated; the time and route of administration; the rate of excretion; other medications previously used; and the severity of the specific disease being treated, as is well known to those skilled in the art. Typical dosages may be a single 1 mg to about 100 mg tablet or 1 mg to about 300 mg, taken once daily, or multiple times daily, or a time-release capsule or tablet taken once daily containing proportionally higher amounts of the active ingredient. The time-release effect may be achieved by capsule materials that dissolve at different pH values, by capsules that release slowly by osmotic pressure, or by any other known controlled-release means. It will be apparent to those skilled in the art that dosages outside of these ranges may be necessary in some cases.

[0631] Another object of the present invention is a kit comprising a container and a package insert, wherein the container comprises at least one dose of a drug comprising a compound of formula (I) and optionally one or more pharmaceutically acceptable diluents, excipients, or carriers, and the package insert comprises instructions for using the drug to treat cancer in a subject. The kit may further comprise one or more doses of a chemotherapeutic agent. Optionally, the kit may further comprise the agent and / or instructions for use.

[0632] Typically, the kit includes a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, and the like. The container can be made of a variety of materials, such as glass or plastic. The container contains a pharmaceutical composition that is effective for treating the disease and may have a sterile access port (e.g., the container can be an intravenous fluid bag or a vial with a stopper pierceable by a hypodermic needle). The label or package insert indicates that the composition is used to treat a selected condition, such as cancer.

[0633] Another object of the present invention is to provide a use of the compound of the present invention for inhibiting the Notch signaling pathway in cells in vitro or in vivo. Typically, the cells are cancer cells.

[0634] Another object of the present invention is to provide a method for treating a subject with a Notch-dependent cancer, comprising i) determining whether the cancer is dependent on the Notch signaling pathway in cancer cells obtained from a biological sample of the subject,

[0635] ii) and based on whether the cancer is a Notch-dependent cancer, treating the subject by administering a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition of the present invention.

[0636] Typically, Notch signaling pathway dependency in cancer cells is determined by any method known in the art. For example, the method may include an in vitro γ-secretase complex activity assay as described herein.

[0637] The treatment method may further comprise administering at least one conventional cancer treatment. The conventional cancer treatment is administered before, simultaneously with, or after administering the therapeutically effective amount of the compound of the present invention or the pharmaceutical composition of the present invention.

[0638] Typically, conventional cancer treatment includes radiation therapy and / or chemotherapy.

[0639] Another object of the present invention is to provide use of the compound of the present invention in a method for causing cell apoptosis in vitro or in vivo by inducing G0 / G1 cell cycle arrest.

[0640] Another object of the present invention is to provide use of the compound of the present invention in diagnosing, predicting and / or monitoring Notch-dependent cancer in a subject.

[0641] Those skilled in the art will appreciate that the invention described herein is subject to change and modification in addition to that specifically described. It should be understood that the present invention includes all such changes and modifications without departing from its spirit or essential characteristics. The present invention also includes, individually or collectively, all steps, features, compositions and compounds mentioned or indicated in this specification, and any and all combinations of said steps or features or any two or more of said steps or features. Therefore, the present invention is considered to be illustrative in all respects, not restrictive, and the scope of the present invention is indicated by the appended claims, and is intended to include all changes within the meaning and scope of equivalents.

[0642] Throughout this specification, various references are cited, each of which is incorporated herein by reference in its entirety.

[0643] The foregoing description will be more fully understood with reference to the following examples. However, these examples are illustrative of the methods of the present invention and are not intended to limit the scope of the invention. Example

[0644] Chemical synthesis of compounds

[0645] abbreviation

[0646] AcOH(acetic acid)

[0647] Brine (saturated aqueous NaCl solution) CV (column volumes) column volume

[0648] DCM (dichloromethane)

[0649] DME (1,2-dimethoxyethane) DMF (dimethylformamide)

[0650] DMSO-d6 (deuterated dimethyl sulfoxide) Equiv(equivalent(s)) equivalent

[0651] EtOAc (ethyl acetate)

[0652] Et2O (diethyl ether)

[0653] EtOH (ethanol)

[0654] expl.(example)

[0655] Fe(iron)

[0656] h(hour(s)) hours

[0657] M (molar concentration)

[0658] MeOH (methanol)

[0659] MgSO4 (magnesium sulfate)

[0660] min(minute(s)) minutes

[0661] mL (milliliter(s)) milliliters

[0662] Mw (molecular weight) molecular weight

[0663] NaHCO3 (sodium bicarbonate)

[0664] Na2SO4 (sodium sulfate)

[0665] Pd / C (palladium on carbon)

[0666] pTSA (p-toluenesulfonic acid)

[0667] RT(room temperature) room temperature

[0668] tBuOH (tert.-butanol) tert-butyl alcohol

[0669] tBuOK (potassium tert.-butylate)

[0670] TEA (triethylamine)

[0671] THF (tetrahydrofurane)

[0672] TLC(thin layer chromatography(R f :retention factor))Thin layer chromatography (R f : Retention factor)

[0673] The following general methods were used for the synthesis of the reported compounds:

[0674] General Method A: Aromatic nucleophilic substitution with substituted phenols (see Scheme 1)

[0675]

[0676] To the desired aryl alcohol in dimethylformamide (DMF) A (1.1 equiv.) and the corresponding 4-halogen-nitroaryl B(1.0 equiv) (0.5 M) was added K2CO3 (1.2 equiv). The reaction was stirred at room temperature. Completion was typically observed after 14 hours (monitored by TLC using EtOAc / hexane or EtOAc / cyclohexane as eluent and stained with KMnO4), and the reaction mixture was poured into a mixture of Et2O and a saturated aqueous NaHCO3 solution. The layers were separated and the aqueous phase was extracted twice with Et2O. The combined organic layers were washed with a saturated aqueous NaHCO3 solution, dried over Na2SO4 or MgSO4, filtered off and concentrated under reduced pressure. The crude product was purified by rapid combined column chromatography using EtOAc / hexane or EtOAc / cyclohexane as eluent to give the corresponding nitro compound. C .

[0677] General Method B: Nitroaromatic Reduction (see Scheme 1)

[0678]

[0679] To the nitro compound C To the mixture of iron powder (5.0 eq.) and EtOH / H2O / AcOH 2:2:1 (0.1 M) was added 4-nitropropane-2-yl (4-nitropropane-2-yl)propane (1.0 eq.). The reaction was sonicated until completion (monitored by TLC with EtOAc / hexane or EtOAc / cyclohexane as eluent and stained with KMnO4). The obtained brown slurry was filtered through filter paper, rinsed with EtOAc, and the organic solvent was evaporated. EtOAc was added, followed by the careful addition of saturated aqueous NaHCO3 solution. The layers were separated and the aqueous layer was extracted three times with EtOAc. The combined organic layers were dried over MgSO4 or Na2SO4, filtered off, and the solvent was evaporated. The crude product was purified by flash combined column chromatography using EtOAc / hexane or EtOAc / cyclohexane as eluent to give the corresponding title compound. D .

[0680] General Method C: Aminoarylmethylation (see Scheme 2)

[0681]

[0682] To a freshly prepared sodium methoxide solution (5.0 equivalents of sodium, 0.1 M in MeOH) under an inert atmosphere, the aminoaryl derivative was added. D(1.0 equiv.). The reaction was stirred at room temperature (1 h). Paraformaldehyde (1.4 equiv.) was then added, followed by NaBH4 (2.0 equiv.) after 16 h. The mixture was stirred until completion (monitored by TLC). The MeOH was evaporated and EtOAc was added, followed by a saturated aqueous NaHCO3 solution. The layers were separated and the organic layer was washed with brine, dried over MgSO4 or Na2SO4, filtered and evaporated in vacuo. The crude residue was purified by column chromatography using EtOAc / hexane or EtOAc / cyclohexane as eluent to give the title compound. E General Method D: Suzuki coupling reaction

[0683]

[0684] To the desired boric acid F (1.2 equivalents), the desired aryl bromide G To a suspension of (1.0 equiv) and the exact base (2.0-2.5 equiv) in dioxane / H2O 4:1 (0.05-0.1 M) is added palladium catalyst (10% mol). The reaction mixture is stirred under reflux. After 16 hours, EtOAc and H2O are added. The layers are separated and the aqueous layer is extracted with EtOAc (2x). The combined organic layers are washed with brine, dried over MgSO4 or Na2SO4, filtered through a celite pad and concentrated under reduced pressure. The residue is purified by column chromatography using EtOAc / hexane or EtOAc / cyclohexane as eluent to give the title compound. C .

[0685] NB: This method is also applicable to bromoaryl derivatives F and as arylboronic acid / ester G Suzuki coupling reaction between .

[0686] General Method E: Suzuki Coupling Reaction

[0687]

[0688] To the desired boric acid F (1.2 equivalents), the desired aryl bromide GTo a suspension of tetrakis(triphenylphosphine)palladium(0) (1.0 equiv.) and K2CO3 (2.0-2.5 equiv.) in dioxane / H2O 4:1 (0.05-0.1 M) was added tetrakis(triphenylphosphine)palladium(0) (10% mol). The reaction mixture was stirred under reflux. After 16 hours, EtOAc and H2O were added. The layers were separated and the aqueous layer was extracted with EtOAc (2x). The combined organic layers were washed with brine, dried over MgSO4 or Na2SO4, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by column chromatography using EtOAc / hexane or EtOAc / cyclohexane as eluent to give the title compound. C .

[0689] General Method F: Nitroaromatic Reduction (see Scheme 1)

[0690]

[0691] At room temperature, to nitro compounds C To a solution of (1.0 equiv.) in a 3:1 mixture of acetone / H2O is added NH4Cl (5 equiv.). To this stirred solution is added zinc (5.0 equiv.) portionwise. The reaction mixture is stirred for 1 hour (monitored by TLC with EtOAc / hexane or EtOAc / cyclohexane as eluent and stained with KMnO4) and then concentrated under reduced pressure. The residue is suspended in EtOAc and filtered through a pad of celite, which is washed with EtOAc. The filtrate is washed with NaHCO3 (2x), dried over MgSO4 or Na2SO4, filtered off and the solvent evaporated to give the corresponding title compound. D .

[0692] General Method G: Aminoarylmethylation (see Scheme 2)

[0693]

[0694] At room temperature, to aminoaryl derivatives D To a solution (0.25 M) of (1.0 equiv) in dichloroethene (DCE) was added paraformaldehyde (1.1 equiv). The mixture was stirred for 5 minutes, then NaBH(OAc)3 (1.5 equiv) was added, followed by AcOH (1 equiv). The reaction was stirred at room temperature overnight. The reaction mixture was quenched by the addition of 1 M NaOH and diluted with H2O and CH2Cl2. The two layers were separated and the aqueous layer was extracted with CH2Cl2 (2x). The combined organic layers were washed with brine, dried over MgSO4 or Na2SO4, filtered and evaporated in vacuo. The crude residue was purified by column chromatography using EtOAc / hexane or EtOAc / cyclohexane as eluent to give the title compound. E .

[0695] Example 1: 6-([1,1'-biphenyl]-4-yloxy)pyridin-3-amine

[0696]

[0697] Following General Procedure B, 6-([1,1′-biphenyl]-4-yloxy)pyridin-3-amine (1.66 mmol, 434 mg) was obtained in 97% yield from 2-([1,1′-biphenyl]-4-yloxy)-5-nitropyridine (1.71 mmol, 500 mg). 17 H 14 N2O; molecular weight is 262.31 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.75 (dd, J = 3.0, 0.6Hz, 1H), 7.61-7.52 (m, 4H), 7.47-7. 39(m,2H),7.36-7.29(m,1H),7.17-7.06(m,3H),6.82(dd,J=8.6,0.6Hz,1H); 13 CNMR(101MHz,CDCl3)δ156.60,155.34,140.87,138.96,136.84,134.28,128 .85,128.45,127.11,127.09,127.01,120.20,112.77,77.48,77.16,76.84.

[0698] The starting material was prepared as follows:

[0699] Step 1: 2-([1,1'-biphenyl]-4-yloxy)-5-nitropyridine

[0700]

[0701] Following general procedure A, 2-([1,1′-biphenyl]-4-yloxy)-5-nitropyridine (4.65 mmol, 1.36 g) was obtained in 99% yield from [1,1′-biphenyl]-4-ol (4.70 mmol, 800 mg) and 2-chloro-5-nitropyridine (4.70 mmol, 745 mg) without purification.

[0702] C 17 H 12 N2O3; molecular weight is 292.29 g.mol -1 ; 1H NMR (400MHz, CDCl3) δ9.08(d,J=2.8Hz,1H),8.50(dd,J=9.1,2.8Hz,1H),7.67(d,J=8.8Hz,2H),7.60(dd,J=8. 3,1.2Hz,2H),7.46(dd,J=8.2,6.8Hz,2H),7.40-7.33(m,1H),7.26-7.20(m,2H),7.08(dd,J=9.1,0.5Hz,1H).

[0703] Example 2: 6-([1,1'-biphenyl]-4-yloxy)-N-methylpyridin-3-amine

[0704]

[0705] Following General Procedure C, 6-([1,1′-biphenyl]-4-yloxy)-N-methylpyridin-3-amine (3.98 mmol, 1.10 g) was obtained in 86% yield from 6-([1,1′-biphenyl]-4-yloxy)pyridin-3-amine (4.61 mmol, 1.21 g). 18 H 16 N2O; molecular weight is 276.34 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.69 (d, J = 3.0Hz, 1H), 7.59-7.53 (m, 4H), 7.42 (t, J = 7.6Hz, 2H), 7.35-7. 29(m,1H),7.15-7.09(m,2H),7.05(dd,J=8.7,3.1Hz,1H),6.86(d,J=8.7Hz,1H),2.86(s,3H).

[0706] Example 3: 6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine

[0707]

[0708] Following general procedure B, 6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine (2.43 mmol, 0.64 g) was obtained in 93% yield from 5-nitro-2-((6-phenylpyridin-3-yl)oxy)pyridine (2.63 mmol, 0.77 g).

[0709] C 16 H 13 N3O; molecular weight is 263.30 g.mol -1 ;solid; 1H NMR (400MHz, CDCl3) δ8.53(d,J=2.7Hz,1H),7.96(d,J=7.3Hz,2H),7.71(dd,J=7.9,5.9Hz,2H),7.51(dd,J=8.6,2.7H z, 1H), 7.46 (t, J = 7.5Hz, 2H), 7.39 (t, J = 7.3Hz, 1H), 7.13 (dd, J = 8.6, 2.9Hz, 1H), 6.86 (d, J = 8.6Hz, 1H), 3.63 (s, 2H).

[0710] The starting material was prepared as follows:

[0711] Step 1: 5-Nitro-2-((6-phenylpyridin-3-yl)oxy)pyridine

[0712]

[0713] Following general procedure A, 5-nitro-2-((6-phenylpyridin-3-yl)oxy)pyridine (2.63 mmol, 0.77 g) was obtained in 93% yield from 6-phenylpyridin-3-ol (2.92 mmol, 0.51 g) and 2-chloro-5-nitropyridine (2.84 mmol, 0.45 g).

[0714] C 16 H 11 N3O3; molecular weight is 293.28g.mol -1 ;solid; 1 H NMR (400MHz, CDCl3) δ9.04(d,J=2.7Hz,1H),8.59(d,J=2.6Hz,1H),8.54(dd,J=9.0,2.8Hz,1H),8.04-7.97(m,2H),7.8 3(d,J=8.6Hz,1H),7.62(dd,J=8.6,2.8Hz,1H),7.52-7.47(m,2H),7.45(dd,J=4.9,3.6Hz,1H),7.16(d,J=9.0Hz,1H).

[0715] Example 4: 3-Fluoro-4-(4-(pyridin-2-yl)phenoxy)aniline

[0716]

[0717] Following general procedure B, 3-fluoro-4-(4-(pyridin-2-yl)phenoxy)aniline (1.8 mmol, 0.51 g) was obtained in 42% yield from 2-(4-(2-fluoro-4-nitrophenoxy)phenyl)pyridine (4.38 mmol, 1.36 g).

[0718] C 17 H 13 FN2O; molecular weight 280.30 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.63(d,J=5.0Hz,1H),7.90(d,J=8.5Hz,2H),7.75(s,1H),7.66(d,J=8.0Hz,1H),7.28(m, 1H),7.02-6.94(m,2H),6.90(t,J=8.8Hz,1H),6.46(dd,J=12.0,2.7Hz,1H),6.39(ddd,J=8.6,2.7,1.3Hz,1H).

[0719] The starting material was prepared as follows:

[0720] Step 1: 2-(4-(2-fluoro-4-nitrophenoxy)phenyl)pyridine

[0721]

[0722] Following general procedure A, 2-(4-(2-fluoro-4-nitrophenoxy)phenyl)pyridine (4.38 mmol, 1.36 g) was obtained in 30% yield from 4-(pyridin-2-yl)phenol (14.6 mmol, 2.50 g) and 1,2-difluoro-4-nitrobenzene (14.3 mmol, 2.28 g).

[0723] C 17 H 11 FN2O3; molecular weight 310.28g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.71 (ddd, J=4.9, 1.8, 0.9Hz, 1H), 8.12 (dd, J=10.2, 2.6Hz, 1H), 8.10-8.04 (m, 2H), 8.01 (ddd, J=9 .0,2.6,1.5Hz,1H),7.84-7.76(m,1H),7.76-7.71(m,1H),7.29(s,1H),7.23-7.16(m,2H),7.06(dd,J=9.1,7.9Hz,1H).

[0724] Example 5: 3-Fluoro-4-(4-(pyridin-3-yl)phenoxy)aniline

[0725]

[0726] Following general procedure B, 3-fluoro-4-(4-(pyridin-3-yl)phenoxy)aniline (11.1 mmol, 3.1 g) was obtained in 63% yield from 3-(4-(2-fluoro-4-nitrophenoxy)phenyl)pyridine (17.7 mmol, 5.48 g).

[0727] C 17 H 13 FN2O; molecular weight 280.30 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.82(d,J=2.4Hz,1H),8.57(dd,J=5.0,1.5Hz,1H),7.95(s,1H),7.52-7.47(m,2H),7.45(s ,1H),7.06-7.00(m,2H),6.97(t,J=8.7Hz,1H),6.54(dd,J=12.0,2.7Hz,1H),6.46(ddd,J=8.6,2.7,1.2Hz,1H).

[0728] The starting material was prepared as follows:

[0729] Step 1: 3-(4-(2-fluoro-4-nitrophenoxy)phenyl)pyridine

[0730]

[0731] Following general procedure A, 3-(4-(2-fluoro-4-nitrophenoxy)phenyl)pyridine (17.7 mmol, 5.48 g) was obtained in 79% yield from 4-(pyridin-3-yl)phenol (22.4 mmol, 3.84 g) and 1,2-difluoro-4-nitrobenzene (22.0 mmol, 3.50 g).

[0732] C 17 H 11 FN2O3; molecular weight 310.28g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.88 (s, 1H), 8.64 (d, J = 5.0Hz, 1H), 8.13 (dd, J = 10.2, 2.7Hz, 1H), 8.09-7. 98(m,2H),7.69-7.61(m,2H),7.55-7.48(m,1H),7.23-7.17(m,2H),7.11(dd,J=9.0,7.8Hz,1H).

[0733] Example 6: 4-([1,1'-biphenyl]-4-yloxy)-3-fluoro-N-methylaniline

[0734]

[0735] Following General Procedure C, 4-([1,1′-biphenyl]-4-yloxy)-3-fluoro-N-methylaniline (3.2 mmol, 0.93 g) was obtained in 77% yield from 4-([1,1′-biphenyl]-4-yloxy)-3-fluoroaniline (4.1 mmol, 1.15 g). 19 H 16 FNO; molecular weight 293.34 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.57-7.52(m,2H),7.52-7.47(m,2H),7.41(t,J=7.6Hz,2H),7.31(t,J=7.4Hz,1H) ,7.03-6.95(m,3H),6.46(dd,J=12.7,2.7Hz,1H),6.39(dd,J=8.7,1.7Hz,1H),4.04(s,1H),2.85(s,3H).

[0736] The starting material was prepared as follows:

[0737] Step 1: 1-(4-Bromophenoxy)-2-fluoro-4-nitrobenzene

[0738]

[0739] Following general procedure A, 1-(4-bromophenoxy)-2-fluoro-4-nitrobenzene (12.0 mmol, 3.73 g) was obtained in 96% yield from 4-bromophenol (12.8 mmol, 2.21 g) and 1,2-difluoro-4-nitrobenzene (12.5 mmol, 1.99 g).

[0740] C 12 H7BrFNO3; molecular weight 312.09g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.10 (dd, J=10.2, 2.7Hz, 1H), 8.01 (ddd, J=9.1, 2.7, 1.6Hz, 1H), 7.57-7.51 (m, 2H), 7.05-7.00 (m, 1H), 7.00-6.94 (m, 2H).

[0741] Step 2: 4-(2-Fluoro-4-nitrophenoxy)-1,1'-biphenyl

[0742]

[0743] Following General Procedure E, a mixture of phenylboronic acid (12.1 mmol, 1.48 g), 1-(4-bromophenoxy)-2-fluoro-4-nitrobenzene (9.9 mmol, 3.10 g), K2CO3 (21.5 mmol, 2.97 g) and Pd(PPh3)4 (10 mol%) in dioxane / H2O 4:1 (0.05-0.1 M) was converted to 4-(2-fluoro-4-nitrophenoxy)-1,1'-biphenyl (5.6 mmol, 1.72 g) in 56% yield.

[0744] C 18 H 12 FNO3; molecular weight is 309.30 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.11 (dd, J=10.2, 2.6Hz, 1H), 8.01 (ddd, J=9.1, 2.6, 1.5Hz, 1H), 7.67-7.62 (m, 2H), 7.6 1-7.56(m,2H),7.46(t,J=7.5Hz,2H),7.37(t,J=7.3Hz,1H),7.19-7.14(m,2H),7.06(dd,J=9.0,8.0Hz,1H).

[0745] Step 3: 4-([1,1'-biphenyl]-4-yloxy)-3-fluoroaniline

[0746]

[0747] Following general procedure B, 4-([1,1′-biphenyl]-4-yloxy)-3-fluoroaniline (4.7 mmol, 1.31 g) was obtained in 85% yield from 4-(2-fluoro-4-nitrophenoxy)biphenyl (5.5 mmol, 1.70 g).

[0748] C 18 H 14 FNO; molecular weight 279.31 g mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.58-7.52(m,2H),7.52-7.48(m,2H),7.41(t,J=7.6Hz,2H),7.31(t, J=7.4Hz,1H),7.01-6.93(m,3H),6.53(dd,J=12.0,2.7Hz,1H),6.48-6.42(m,1H),3.70(br s,2H).

[0749] Example 7: 4-([1,1'-biphenyl]-4-yloxy)aniline

[0750]

[0751] Following general procedure B, 4-([1,1'-biphenyl]-4-yloxy)aniline (2.4 mmol, 0.62 g) was obtained in 33% yield from 4-(4-nitrophenoxy)-1,1'-biphenyl (7.1 mmol, 2.08 g).

[0752] C 18 H 15 NO; molecular weight is 261.32 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.57-7.53(m,2H),7.53-7.47(m,2H),7.45-7.39(m,2H),7. 34-7.28(m,1H),7.03-6.97(m,2H),6.95-6.89(m,2H),6.74-6.66(m,2H),3.61(br s,2H).

[0753] The starting material was prepared as follows:

[0754] Step 1: 4-(4-nitrophenoxy)-1,1'-biphenyl

[0755]

[0756] Following General Procedure A, 4-(4-nitrophenoxy)-1,1'-biphenyl (7.1 mmol, 2.08 g) was obtained in 61% yield from [1,1'-biphenyl]-4-ol (11.8 mmol, 2.00 g) and 4-fluoro-nitrobenzene (11.5 mmol, 1.63 g). 18 H 13 NO3; molecular weight is 291.31 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.26-8.20(m,2H),7.69-7.63(m,2H),7.62-7.57(m,2H) ,7.50-7.43(m,2H),7.41-7.34(m,1H),7.19-7.14(m,2H),7.11-7.05(m,2H).

[0757] Example 8: 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine

[0758]

[0759] Following general procedure B, 6-([1,1′-biphenyl]-4-yloxy)-2-methylpyridin-3-amine (4.7 mmol, 1.31 g) was obtained in 90% yield from 6-([1,1′-biphenyl]-4-yloxy)-2-methyl-3-nitropyridine (5.3 mmol, 1.61 g).

[0760] C 18 H 16 N2O; molecular weight is 276.34 g.mol -1 ; 1 HNMR (400MHz, CDCl3) δ7.59-7.52(m,4H),7.42(t,J=7.6Hz,2H),7.32(ddd,J=7.4,3.9,1.2Hz,1H ), 7.10 (d, J = 8.7Hz, 2H), 7.02 (d, J = 8.4Hz, 1H), 6.63 (d, J = 8.4Hz, 1H), 3.49 (s, 2H), 2.37 (s, 3H).

[0761] The starting material was prepared as follows:

[0762] Step 1: 6-([1,1'-biphenyl]-4-yloxy)-2-methyl-3-nitropyridine

[0763]

[0764] Following general procedure A, 6-([1,1′-biphenyl]-4-yloxy)-2-methyl-3-nitropyridine (5.3 mmol, 1.63 g) was obtained in 89% yield from [1,1′-biphenyl]-4-ol (5.9 mmol, 1.00 g) and 6-chloro-2-methyl-3-nitropyridine (5.8 mmol, 1.00 g).

[0765] C 18 H 14 N2O3; molecular weight is 306.32g.mol -1 ; 1 HNMR(400MHz, CDCl3) δ8.38(d,J=8.9Hz,1H),7.63(dd,J=16.5,7.9Hz,4H),7.46(t,J=7.6Hz ,2H),7.37(dd,J=8.3,6.4Hz,1H),7.24(d,J=8.7Hz,2H),6.84(d,J=8.9Hz,1H),2.78(s,3H).

[0766] Example 9: 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin-3-amine

[0767]

[0768] Following General Procedure B, 6-([1,1′-biphenyl]-4-yloxy)-4-methylpyridin-3-amine (1.5 mmol, 410 mg) was obtained in 74% yield from 6-([1,1′-biphenyl]-4-yloxy)-4-methyl-3-nitropyridine (2.0 mmol, 600 mg).

[0769] C 18 H 16 N2O; molecular weight is 276.34 g.mol -1 ; 1 HNMR (400MHz, CDCl3) δ7.69 (s, 1H), 7.61-7.52 (m, 4H), 7.42 (t, J = 7.6Hz, 2H), 7.33 (dt, J =9.2, 4.3Hz, 1H), 7.12 (d, J = 8.7Hz, 2H), 6.72 (s, 1H), 3.03 (s, 2H), 2.21 (d, J = 0.5Hz, 3H).

[0770] The starting material was prepared as follows:

[0771] Step 1: 6-([1,1'-biphenyl]-4-yloxy)-4-methyl-3-nitropyridine

[0772]

[0773] Following general procedure A, 6-([1,1′-biphenyl]-4-yloxy)-4-methyl-3-nitropyridine (2.3 mmol, 0.71 g) was obtained in 38% yield from [1,1′-biphenyl]-4-ol (5.9 mmol, 1.00 g) and 6-chloro-4-methyl-3-nitropyridine (5.8 mmol, 1.00 g).

[0774] C 18 H 14 N2O3; molecular weight is 306.32g.mol -1 ; 1 H NMR(400MHz, CDCl3)δ8.92(s,1H),7.69-7.63(m,2H),7.63-7.57(m,2H),7.49-7.42(m, 2H),7.40-7.34(m,1H),7.25-7.20(m,2H),6.88(d,J=0.9Hz,1H),2.69(d,J=0.8Hz,3H).

[0775] Example 10: 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy]pyridinyl)-3-amine

[0776]

[0777] Following General Procedure B, 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine (3.9 mmol, 1.10 g) was obtained in 58% yield from 2-((4'-fluoro-[[1,1'-biphenyl]-4-yl)oxy]-5-nitropyridine (6.8 mmol, 2.10 g).

[0778] C 17 H 13 FN2O; molecular weight 280.30 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.75 (d, J = 3.0Hz, 1H), 7.51 (m, 4H), 7.16-7.07 (m, 5H), 6.82 (d, J = 8.6Hz, 1H). 19 F NMR (376 MHz, chloroform-d) δ 116.54.

[0779] The starting material was prepared as follows:

[0780] Step 1: 2-(4-bromophenoxy)-5-nitropyridine

[0781]

[0782] Following general procedure A, 2-(4-bromophenoxy)-5-nitropyridine (37.2 mmol, 10.97 g) was obtained in 89% yield from 4-bromophenol (42.8 mmol, 7.40 g) and 2-chloro-5-nitropyridine (41.6 mmol, 6.60 g).

[0783] C 11 H7BrN2O3; molecular weight 295.09g.mol -1 ; 1 H NMR (400 MHz, CDCl3) δ 9.03 (d, J = 2.6 Hz, 1H), 8.49 (dd, J = 9.0, 2.8 Hz, 1H), 7.57 (d, J = 8.8 Hz, 2H), 7.06 (m, 3H). Step 2: 2-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-5-nitropyridine

[0784]

[0785] Following General Procedure E, a mixture of 4-fluorophenylboronic acid (8.9 mmol, 1.25 g), 2-(4-bromophenoxy)-5-nitropyridine (7.8 mmol, 2.30 g), K2CO3 (19.5 mmol, 2.70 g) and Pd(PPh3)4 (10 mol%) in dioxane / H2O 4:1 (0.05-0.1 M) was converted to 2-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-5-nitropyridine (6.8 mmol, 2.10 g) in 87% yield.

[0786] C 17 H 11 FN2O3; molecular weight 310.28g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ9.07 (d, J = 2.7Hz, 1H), 8.50 (dd, J = 9.0, 2.7Hz, 1H), 7.62 (d, J = 8.5Hz, 2H), 7.55 (dd, J = 8.5, 5.4 Hz, 2H), 7.23 (d, J = 8.6 Hz, 2H), 7.14 (t, J = 8.6 Hz, 2H), 7.09 (d, J = 9.0 Hz, 1H).

[0787] Example 11: 6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine

[0788]

[0789] Following general procedure B, 6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine (1.8 mmol, 0.48 g) was obtained in 46% yield from 5-(4-((5-nitropyridin-2-yloxy)phenyl)thiazole (3.8 mmol, 1.15 g).

[0790] C 14 H 11 N3OS; molecular weight is 269.32 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.67 (s, 1H), 7.95 (s, 1H), 7.67 (d, J = 3.0Hz, 1H), 7.49 (d, J = 8.7Hz, 2H), 7.05 (m, 3H), 6.76 (d, J = 8.6Hz, 1H).

[0791] The starting material was prepared as follows:

[0792] Step 1: 5-Nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridine

[0793]

[0794] To a suspension of 2-(4-bromophenoxy)-5-nitropyridine (20.6 mmol, 6.08 g), CHCOOK (61.1 mmol, 6.00 g), and bis(pinacolato)diboron (30.5 mmol, 7.75 g) in dioxane (0.1 M, 150 mL) was added Pd(dppf)Cl·CHCl (5 mol%) under an inert atmosphere. The red mixture was stirred at 105° C. for 16 hours. The reaction mixture was filtered through a pad of Celite. Water was added to the filtrate, and the mixture was extracted with EtOAc (2×). The organic layer was washed with saturated aqueous NaHCO, brine, dried over NaSO, filtered, and concentrated. The crude product was purified by flash combined column chromatography using EtOAc / cyclohexane (1% to 20%) as eluent to give 5-nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridine (15.6 mmol, 5.93 g, 76% yield).

[0795] C 17 H 19 BN2O5; molecular weight 342.16 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ9.04 (d, J = 2.5 Hz, 1H), 8.47 (dd, J = 9.1, 2.8 Hz, 1H), 7.94-7.88 (m, 2H), 7.20-7.13 (m, 2H), 7.06-7.01 (m, 1H), 1.35 (s, 12H).

[0796] Step 2: 5-(4-((5-nitropyridin-2-yl)oxy)phenyl)thiazole

[0797]

[0798] Following General Procedure D, a mixture of 5-nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridine (9.2 mmol, 3.50 g), 5-bromothiazole (7.4 mmol, 1.25 g), Cs2CO3 (15.0 mmol, 4.90 g), and PdCl2(PPh3)2 (10 mol%) in dioxane / H2O 4:1 (0.05-0.1 M) was converted to 5-(4-((5-nitropyridin-2-yl)oxy)phenyl)thiazole (3.8 mmol, 1.15 g) in 52% yield. 14H9N3O3S; molecular weight is 299.30 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ9.05 (d, J=2.6Hz, 1H), 8.78 (s, 1H), 8.51 (dd, J=9.1, 2.8Hz, 1H ), 8.08 (s, 1H), 7.67 (d, J = 8.2Hz, 2H), 7.23 (d, J = 8.4Hz, 2H), 7.10 (d, J = 9.0Hz, 1H).

[0799] Example 12: 4-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)aniline

[0800]

[0801] Following General Procedure B, 4-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)aniline (21.9 mmol, 6.33 g) was obtained in 88% yield from 2,2'-dimethyl-4-(4-nitrophenoxy)-1,1'-biphenyl (24.9 mmol, 7.96 g).

[0802] C 20 H 19 NO; molecular weight is 289.38 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.26-7.24(m,2H),7.23-7.18(m,1H),7.10(d,J=6.8Hz,1H),7.00(d,J=8.3Hz,1H),6.96 -6.91(m,2H),6.84(d,J=2.5Hz,1H),6.77(dd,J=8.4,2.6Hz,1H),6.75-6.71(m,2H),2.07(s,3H),2.00(s,3H).

[0803] The starting material was prepared as follows:

[0804] Step 1: 1-Bromo-2-methyl-4-(4-nitrophenoxy)benzene

[0805]

[0806] Following general procedure A, 1-bromo-2-methyl-4-(4-nitrophenoxy)benzene (27.1 mmol, 8.34 g) was obtained in 91% yield from 4-bromo-3-methyl-phenol (31.5 mmol, 6.01 g) and 4-fluoro-nitrobenzene (29.9 mmol, 4.22 g).

[0807] C 13 H 10 BrNO3; molecular weight is 308.13 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.24-8.18(m,2H),7.57(d,J=8.6Hz,1H),7.05-6.96(m,3H),6.80(dd,J=8.6,2.9Hz,1H),2.41(s,3H).

[0808] Step 2: 2,2'-dimethyl-4-(4-nitrophenoxy)-1,1'-biphenyl

[0809]

[0810] Following General Procedure E, a mixture of o-tolylboronic acid (30.9 mmol, 4.20 g), 1-bromo-2-methyl-4-(4-nitrophenoxy)benzene (27.1 mmol, 8.34 g), K2CO3 (55.0 mmol, 7.60 g) and Pd(PPh3)4 (10 mol%) in dioxane / H2O4:1 (0.05-0.1 M) was converted to 2,2'-dimethyl-4-(4-nitrophenoxy)-1,1'-biphenyl (24.9 mmol, 7.96 g) in 92% yield.

[0811] C 20 H 17 NO3; molecular weight is 319.36 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.26-8.21(m,2H),7.31-7.27(m,2H),7.24(d,J=4.8Hz,1H),7.14(dd,J=14.2,7.6 Hz,2H),7.11-7.04(m,2H),7.00(d,J=2.5Hz,1H),6.95(dd,J=8.2,2.2Hz,1H),2.09(s,3H),2.07(s,3H).

[0812] Example 13: 4-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-N-methylaniline

[0813]

[0814] Following General Procedure C, 4-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-N-methylaniline (8.9 mmol, 2.70 g) was obtained in 86% yield from 4-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)aniline (10.4 mmol, 3.00 g).

[0815] C 21 H 21 NO; molecular weight is 303.41 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.26-7.23(m,2H),7.20(ddd,J=9.0,5.8,3.7Hz,1H),7.10(d,J=6.8Hz,1H),7.04-6.95(m,3H), 6.84(s,1H),6.77(dd,J=8.2,2.1Hz,1H),6.64(d,J=7.9Hz,2H),3.78(s,1H),2.86(s,3H),2.07(s,3H),2.00(s,3H).

[0816] Example 14: 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy])-N-methylpyridin-3-amine

[0817]

[0818] Following General Procedure C, 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy]-N-methylpyridin-3-amine (0.2 mmol, 53 mg) was obtained in 78% yield from 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine (0.2 mmol, 65 mg).

[0819] C 20 H 20 N2O; molecular weight is 304.39 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.72(d,J=3.0Hz,1H),7.26-7.24(m,2H),7.21(m,1H),7.11(d,J=6.8Hz,1H),7.08-7.02(m,2H ), 6.95 (d, J = 2.5Hz, 1H), 6.89 (dd, J = 8.2, 2.6Hz, 1H), 6.86 (d, J = 8.7Hz, 1H), 2.87 (s, 3H), 2.08 (s, 3H), 2.02 (s, 3H).

[0820] The starting material was prepared as follows:

[0821] Step 1: 2-(4-bromo-3-methylphenoxy)-5-nitropyridine

[0822]

[0823] Following general procedure A, 2-(4-bromo-3-methylphenoxy)-5-nitropyridine (6.2 mmol, 1.93 g) was obtained in 98% yield from 4-bromo-3-methylphenol (6.8 mmol, 1.28 g) and 2-chloro-5-nitropyridine (6.4 mmol, 1.01 g).

[0824] C 12 H9BrN2O3; molecular weight 309.12g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ9.04 (d, J=2.7Hz, 1H), 8.49 (dd, J=9.0, 2.9Hz, 1H), 7.59 (d, J=8.6Hz, 1H), 7.10-7.01 (m, 2H), 6.88 (dd, J=8.6, 2.8Hz, 1H), 2.42 (s, 3H).

[0825] Step 2: 2-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-5-nitropyridine

[0826]

[0827] Following General Procedure E, a mixture of o-toluic acid (1.9 mmol, 264 mg), 2-(4-bromo-3-methylphenoxy)-5-nitropyridine (1.3 mmol, 400 mg), K2CO3 (2.6 mmol, 358 mg) and Pd(PPh3)4 (10 % mol) in dioxane / H2O 4:1 (0.05-0.1 M) was converted into 2-((2,2'-dimethyl-[1,1'-biphenyl]-4(-yl)oxy)-5-nitropyridine (1.2 mmol, 392 mg) in 95% yield.

[0828] C 19 H 16 N2O3; molecular weight 320.35g.mol -1 ; 1H NMR(400MHz, CDCl3)δ9.11(d,J=2.8Hz,1H),8.49(dd,J=9.1,2.8Hz,1H),7.35-7.31(m,1H),7.29(m,1H),7.25 -7.22(m,1H),7.18(d,J=8.2Hz,1H),7.15(dt,J=7.0,1.2Hz,1H),7.09-7.00(m,3H),2.10(s,3H),2.09(s,3H).

[0829] Step 3: 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine

[0830]

[0831] Following General Procedure B, 6-(((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy]pyridin-3-amine (0.5 mmol, 132 mg) was obtained in 37% yield from 2-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-5-nitropyridine (1.2 mmol, 392 mg).

[0832] C 19 H 18 N2O; molecular weight is 290.37 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.79(d,J=2.8Hz,1H),7.25(s,2H),7.23-7.18(m,1H),7.12(t,J=6.2Hz,2H),7.06(d,J=8.2Hz, 1H), 6.96 (d, J = 1.9Hz, 1H), 6.90 (dd, J = 8.3, 2.3Hz, 1H), 6.82 (d, J = 8.6Hz, 1H), 2.85 (s, 2H), 2.08 (s, 3H), 2.02 (s, 3H).

[0833] Example 15: 3-Fluoro-4-(4-(pyridin-4-yl)phenoxy)aniline

[0834]

[0835] Following general procedure B, 3-fluoro-4-(4-(pyridin-4-yl)phenoxy)aniline (211 mg, 0.752 mmol) was obtained in 71% yield from 4-(4-(2-fluoro-4-nitrophenoxy)phenyl)pyridine (330 mg, 1.06 mmol).

[0836] C 17 H13 FN2O; molecular weight 280.30 g.mol -1 ; 1 H NMR (400MHz, DMSO-d6) δ8.59(dd,J=4.5,1.6Hz,2H),7.80-7.74(m,2H),7.65(dd,J=4.5,1. 6Hz, 2H), 7.01-6.93 (m, 3H), 6.51 (dd, J = 13.3, 2.5Hz, 1H), 6.44-6.39 (m, 1H), 5.39 (s, 2H).

[0837] The starting material was prepared as follows:

[0838] Step 1: 4-(4-(2-fluoro-4-nitrophenoxy)phenyl)pyridine

[0839]

[0840] Following General Procedure E, 4-(4-(2-fluoro-4-nitrophenoxy)phenyl)pyridine (300 mg, 0.967 mmol) was obtained in 75% yield from 1-(4-bromophenoxy)-2-fluoro-4-nitrobenzene (400 mg, 1.28 mmol; Example 6: Step 1).

[0841] C 17 H 11 FN2O3; molecular weight 310.28g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.68(d,J=6.1Hz,2H),8.13(dd,J=10.2,2.7Hz,1H),8.04(ddd,J=9.0,2.6,1.5Hz ,1H),7.70(d,J=8.8Hz,2H),7.49(d,J=6.2Hz,2H),7.19(d,J=8.8Hz,2H),7.10(dd,J=9.0,7.9Hz,1H).

[0842] Example 16: 6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine

[0843]

[0844] Following general procedure B, 6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine (15 mg, 0.057 mmol) was obtained in 21% yield from 2-(4-((5-nitropyridin-2-yloxy)phenyl)thiazole (100 mg, 0.300 mmol).

[0845] C14 H 11 N3OS; molecular weight is 269.32 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ 8.00-7.95 (m, 2H), 7.85 (d, J = 3.3Hz, 1H), 7.77 (d, J = 3.0Hz, 1H), 7.31 (d, J = 3.3Hz, 1H), 7.16-7.11 (m, 3H), 6.84 (d, J = 8.5Hz, 1H).

[0846] The starting material was prepared as follows:

[0847] Step 1: 2-(4-((5-nitropyridin-2-yl)oxy)phenyl)thiazole

[0848]

[0849] Following the general procedure A, 2-(4-((5-nitropyridin-2-yloxy)phenyl)thiazole (206 mg, 0.688 mmol) was obtained in 61% yield from 4-(thiazol-2-yl)phenol (0.23 g, 1.30 mmol) and 2-chloro-5-nitropyridine (0.18 g, 1.10 mmol).

[0850] C 14 H9N3SO3; molecular weight is 299.30 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ9.06 (d, J=2.8Hz, 1H), 8.51 (dd, J=9.0, 2.8Hz, 1H), 8.10-8.04 (m, 2H ), 7.88 (d, J = 3.3Hz, 1H), 7.36 (d, J = 3.3Hz, 1H), 7.29-7.23 (m, 2H), 7.10 (d, J = 9.0Hz, 1H).

[0851] Example 17: (4'-((5-aminopyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methanol

[0852]

[0853] Following General Procedure B, (4'-((5-aminopyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methanol (20 mg, 0.044 mmol) was obtained in 44% yield from (4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methanol (50 mg, 0.16 mmol).

[0854] C 18 H 16 N2O2; molecular weight is 292.34g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.75(d,J=2.9Hz,1H),7.57(dd,J=6.5,2.1Hz,3H),7.50(d,J=7.7Hz,1H),7.42(t, J=7.6Hz,1H),7.33(d,J=7.6Hz,1H),7.18-7.06(m,3H),6.82(d,J=8.6Hz,1H),4.76(s,2H),3.49(s,2H).

[0855] The starting material was prepared as follows:

[0856] Step 1: (4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methanol

[0857]

[0858] Following General Procedure E, (4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methanol (281 mg, 0.872 mmol) was obtained in 65% yield from 2-(4-bromophenoxy)-5-nitropyridine (400 mg, 1.36 mmol; Example 10: Step 1) and (3-(hydroxymethyl)phenyl)boronic acid (240 mg, 1.60 mmol).

[0859] C 18 H 14 N2O4; molecular weight is 322.32g.mol -1 ; 1 H NMR (400MHz, DMSO-d6) δ9.07(dd,J=2.8,0.6Hz,1H),8.50(dd,J=9.1,2.8Hz,1H),7.71-7.65(m,2H),7.62(td,J=1.8,0.7Hz,1H),7.54(dt,J=7.6,1.6H z,1H),7.46(t,J=7.5Hz,1H),7.37(dt,J=7.6,1.4Hz,1H),7.26-7.22(m,2H ), 7.08 (dd, J = 9.1, 0.6 Hz, 1H), 4.79 (d, J = 5.9 Hz, 2H), 1.72 (t, J = 5.9 Hz, 1H).

[0860] Example 18: 6-((3'-(Aminomethyl))-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine

[0861]

[0862] Under nitrogen, 2-((4'-((5-aminopyridinyl-2-yl)oxy)-[1,1'-biphenyl-3-yl)methyl)isoindoline-1,3-dione (51 mg, 0.121 mmol) was suspended in methanol (1 mL, 0.1 M) (poor solubility at room temperature). Hydrazine hydrate (15 mg, 0.30 mmol) was added. The yellow solution was refluxed overnight. Upon leaving it at room temperature, a white solid precipitated. The reaction mixture was filtered and the filtrate was concentrated. The crude residue was purified on a Biotage Isolera Four (KP-sil 25 g column, DCM / MeOH, MeOH 1-15%; 28 CV) to give 6-((3'-(aminomethyl)-[1,1'-biphenyl]-4-yl)oxy]pyridin-3-amine (20 mg, 0.07 mmol, 57% yield) as a light yellow solid.

[0863] C 18 H 17 N3O; molecular weight is 291.35g.mol-1; 1 H NMR (400MHz, DMSO-d6) δ7.66(d,J=1.8Hz,1H),7.65-7.61(m,2H),7.57(d,J=2.9Hz,1H),7.52(dt,J=7.7,1.5Hz,1H),7.41(t,J=7 .6Hz,1H),7.33(d,J=7.7Hz,1H),7.10(dd,J=8.6,3.0Hz,1H),7.06-7.02(m,2H),6.81(d,J=8.6Hz,1H),5.13(s,2H),3.88(s,2H).

[0864] The starting material was prepared as follows:

[0865] Step 1: 2-((4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methyl)isoindoline-1,3-dione

[0866]

[0867] Under nitrogen, (4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methanol (0.117 g, 0.363 mmol), triphenylphosphine (0.115 g, 0.438 mmol), and phthalimide (0.068 g, 0.46 mmol) were placed in a 25 mL round-bottom flask, followed by tetrahydrofuran (THF) (2 mL). Diisopropyl azodicarboxylate (0.075 mL, 0.39 mmol) was added dropwise at 0°C. The yellow solution was stirred at room temperature for 2 days. The mixture was concentrated and the crude extract was purified on a Biotage Isolera Four (KP-sil 25 g column, cyclohexane / EtOAc, EtOAc 0-40%, 15 CV) to give 2-((4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methyl)isoindoline-1,3-dione (158 mg, 0.350 mmol, 96% yield) as a yellow foam.

[0868] C 26 H 17 N3O5; molecular weight 451.44g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ9.07 (dd, J=2.8, 0.6Hz, 1H), 8.49 (dd, J=9.0, 2.8Hz, 1H), 7.87-7.84(m,2H),7.72(dd,J=5.5,3.0Hz,2H),7.66(d,J=1.8Hz,1H),7.66-7. 62(m,2H),7.50(dt,J=7.3,1.7Hz,1H),7.47-7.43(m,1H),7.40(t,J=7.5Hz,1H ),7.24-7.20(m,2H),7.07(dd,J=9.0,0.6Hz,1H),4.92(s,2H).TLC(cyclohexane / EtOAc 7:3)R f =0.42.

[0869] Step 2: 2-((4'-((5-aminopyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methyl)isoindoline-1,3-dione

[0870]

[0871] 2-((4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl-3-yl)methyl)isoindoline-1,3-dione (158 mg, 0.350 mmol) was suspended in EtOAc (3 mL) under nitrogen. Pd / C (10%, 16 mg) was added to give a black suspension, which was stirred under a hydrogen atmosphere (1 atm) overnight. The reaction mixture was filtered through celite, and the filtrate was concentrated to give 170 mg of the crude product as a yellow oil. The crude product was purified on a Biotage Isolera Four (KP-sil 25 g column, cyclohexane / EtOAc, EtOAc 12-100%, 18 CV) to afford 2-((4'-((5-aminopyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)methyl)isoindoline-1,3-dione (100 mg, 0.200 mmol, 67% yield) as a yellow gum.

[0872] C 26 H 19 N3O3; molecular weight 421.46g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.85(dd,J=5.4,3.1Hz,2H),7.75(dd,J=3.0,0.7Hz,1H),7.71(dd,J=5.5,3.0Hz,2H),7.63(s,1H),7.5 6-7.52(m,2H),7.47(dt,J=7.0,1.8Hz,1H),7.43-7.34(m,2H),7.14-7.09(m,3H),6.81(dd,J=8.7,0.6Hz,1H),4.90(s,2H).

[0873] Example 19: 2-(4'-((5-aminopyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)acetamide

[0874]

[0875] Following General Procedure B, 2-(4'-((5-aminopyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)acetamide (17 mg, 0.053 mmol) was obtained in 89% yield from 2-(4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)acetamide (21 mg, 0.060 mmol).

[0876] C 19 H 17 N3O2; molecular weight 319.36g.mol -1 ;1 H NMR (400MHz, CDCl3) δ7.74(d,J=2.9Hz,1H),7.56(d,J=8.6Hz,2H),7.53-7.46(m,2H),7.42(t,J=7.6 Hz, 1H), 7.24 (s, 1H), 7.17-7.06 (m, 3H), 6.82 (d, J = 8.6Hz, 1H), 5.37 (d, J = 24.0Hz, 2H), 3.66 (s, 2H).

[0877] The starting material was prepared as follows:

[0878] Step 1: 2-(4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)acetonitrile

[0879]

[0880] Following General Procedure E, 2-(4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)acetonitrile (432 mg, 1.7 mmol) was obtained in 99% yield from 2-(4-bromophenoxy)-5-nitropyridine (500 mg, 1.69 mmol; Example 10: Step 1) and 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2)-yl)phenyl)acetonitrile (536 mg, 2.20 mmol).

[0881] C 19 H 13 N3O3; molecular weight 331.33g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ9.07(d,J=2.7Hz,1H),8.51(dd,J=9.1,2.8Hz,1H),7.69-7.63(m,2H),7.57(d,J=6.7H z, 2H), 7.47 (t, J = 8.0Hz, 1H), 7.33 (d, J = 7.9Hz, 1H), 7.28-7.24 (d, 2H), 7.10 (d, J = 9.0Hz, 1H), 3.84 (s, 2H).

[0882] Step 2: 2-(4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)acetamide

[0883]

[0884] H2SO4 (500ul; 9.0mmol) was slowly added to 2-(4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)acetonitrile (50mg, 0.18mmol) at 0°C. The mixture was stirred at room temperature overnight. The solution was poured into ice water and neutralized with 2M aqueous NaOH. A 2M aqueous HCl solution was then used to obtain a solution with pH=6. The aqueous layer was washed three times with EtOAc. The crude product was purified using a Biotage Isolera Four (KP-sil 25g column, cyclohexane / EtOAc, EtOAc 0 to 100%, 18CV) to give 2-(4'-((5-nitropyridin-2-yl)oxy)-[1,1'-biphenyl]-3-yl)acetamide (30mg, 0.100mmol, 57% yield) as a yellow gum.

[0885] C 19 H 15 N3O4; molecular weight 349.35g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ9.07(d,J=2.8Hz,1H),8.51(dd,J=9.1,2.8Hz,1H),7.66(d,J=8.6Hz,2H),7.57-7.51(m ,2H),7.46(t,J=7.7Hz,1H),7.30(d,1H),7.24(d,2H),7.09(d,J=9.0Hz,1H),5.43-5.32(m,2H),3.67(s,2H).

[0886] Example 20: 6-((2-(4-aminophenoxy)-[1,1′-biphenyl]-4-yl)oxy)pyridin-3-amine

[0887]

[0888] Following General Procedure B, 6-((2-(4-nitrophenoxy)-[1,1′-biphenyl]-4-yl)oxy)pyridin-3-amine (50 mg, 0.13 mmol) was obtained in 32% yield from 5-nitro-2-((2-(4-nitrophenoxy)-[1,1′-biphenyl]-4-yl)oxy)pyridin-3-amine (50 mg, 0.130 mmol) was then suspended in MeOH (1.5 mL, 0.08 M). Pd / C (10%, 6.7 mg) was added to give a black suspension. The mixture was stirred under a hydrogen atmosphere (1 atm) overnight. The reaction mixture was filtered through a pad of celite. The filtrate was concentrated. The crude product was purified with Biotage Isolera Four (KP-sil10g column, cyclohexane / EtOAc, EtOAc 50-100%, 22CV) to give 6-((2-(4-aminophenoxy)-[1,1′-biphenyl]-4-yl)oxy)pyridin-3-amine (40 mg, 0.110 mmol, 86%) as an orange solid. 23 H 19 N3O2; molecular weight 369.42g.mol -1 ; 1 H NMR(400MHz, CDCl3)δ7.72(d,J=2.9Hz,1H),7.57(d,J=7.1Hz,2H),7.40-7.34(m,4H),7 .07(dd,J=8.6,3.0Hz,1H),6.84(d,J=8.8Hz,2H),6.80-6.74(m,2H),6.64-6.60(m,3H).

[0889] The starting material was prepared as follows:

[0890] Step 1: 4-Methoxy-[1,1'-biphenyl]-2-ol

[0891]

[0892] Under nitrogen, phenylboronic acid (310 mg, 2.50 mmol), 2-bromo-5-methoxyphenol (0.41 g, 2.00 mmol), potassium carbonate (0.66 g, 4.70 mmol), water (4 mL) and 2-propanol (16 mL) were added to a 500 mL round-bottom flask. Bis(triphenylphosphine)palladium(II) chloride (140 mg, 0.20 mmol) was then added and the yellow suspension was stirred at room temperature for 20 minutes and then heated to reflux (16 hours). The mixture was filtered through a pad of celite and the filtrate was concentrated under vacuum. Water and EtOAc were added to the residue. The layers were separated and the aqueous layer was washed with EtOAc (twice). All organic layers were combined, dried (Na2SO4), filtered and concentrated under vacuum. The crude product was purified with Biotage Isolera Fourion (KP-sil 50 g column, hexane / EtOAc, EtOAc 2-20%, 16 CV) to give 4-methoxy-[1,1′-biphenyl]-2-ol (0.87 g, 84% yield) as a brown oil.

[0893] C 13 H 12 O2; molecular weight is 200.24g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.51-7.41(m,4H),7.38(d,J=7.1Hz,1H),7.19-7.12(m,1H),6.57(d,J=7.1Hz,2H),5.25(s,1H),3.83(s,3H).

[0894] Step 2: 4-Methoxy-2-(4-nitrophenoxy)-1,1'-biphenyl

[0895]

[0896] Following general procedure A, 4-methoxy-2-(4-nitrophenoxy)-1,1'-biphenyl (0.255 g, 0.794 mmol) was obtained in 66% yield from 4-methoxy-[1,1'-biphenyl]-2-ol (0.244 g, 1.20 mmol) and 1-fluoro-4-nitrobenzene (0.200 g, 1.40 mmol).

[0897] C 19 H 15 NO4; molecular weight is 321.33 g.mol -1 ; 1H NMR (400 MHz, CDCl3) δ 8.11-8.05 (m, 2H), 7.43 (d, J = 8.6 Hz, 1H), 7.41-7.37 (m, 2H), 7.29 (t, J = 7.4 Hz, 2H), 7.24-7.20 (m, 1H), 6.92 (dd, J = 8.6, 2.6 Hz, 1H), 6.90-6.85 (m, 2H), 6.68 (d, J = 2.6 Hz, 1H), 3.84 (s, 3H). TLC (cyclohexane / EtOAc 9:1) R f =0.39.

[0898] Step 3: 2-(4-nitrophenoxy)-[1,1'-biphenyl]-4-ol

[0899]

[0900] Under nitrogen, 4-methoxy-2-(4-nitrophenoxy)-1,1'-biphenyl (255 mg, 0.794 mmol) was dissolved in CHCl (10 mL, 0.06 M) in a 100 mL round-bottom flask. The brown solution was cooled to 0°C. A solution of BBr in CHCl (0.5 M, 2.38 mL, 1.19 mmol) was added dropwise over 1 hour using a syringe pump. The solution was allowed to reach room temperature and then stirred for 4 hours. The mixture was quenched with water at 0°C and then neutralized with 6 M aqueous NaOH. The layers were separated, and the aqueous layer was washed twice with CHCl. ​​The combined organic layers were washed with brine, dried (NaSO), filtered, and concentrated. The crude product was purified on a Biotage Isolera Fourion (KP-sil 25 g column, cyclohexane / EtOAc, EtOAc 0-15%, 22 CV) to afford 139 mg of 2-(4-nitrophenoxy)-[1,1′-biphenyl]-4-ol as a yellow solid (51% yield).

[0901] C 18 H 13 NO4; molecular weight is 307.31 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.12-8.06(m,2H),7.41-7.35(m,3H),7.29(t,J=7.5Hz,2H),7.25-7.2 2(m,1H),6.91-6.86(m,2H),6.84(dd,J=8.4,2.5Hz,1H),6.64(d,J=2.5Hz,1H),4.94(s,1H).

[0902] Step 4: 5-nitro-2-((2-(4-nitrophenoxy)-[1,1'-biphenyl]-4-yl)oxy]pyridine

[0903]

[0904] Following the general procedure A, 5-nitro-2-((2-(4-nitrophenoxy)-[1,1′-biphenyl]-4-yl)oxy]pyridine (166 mg, 0.387 mmol) was obtained in 86% yield from 2-(4-nitrophenoxy)-[1,1′-biphenyl]-4-ol (139 mg, 0.452 mmol) and 2-chloro-5-nitropyridine (72 mg, 0.452 mmol).

[0905] C 23 H 15 N3O6; molecular weight 429.39 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ9.07 (d, J=2.8Hz, 1H), 8.52 (dd, J=9.0, 2.8Hz, 1H), 8.14-8.09 (m, 2H), 7.58 (d, J=8.5Hz, 1H), 7.49-7. 44(m,2H),7.38-7.28(m,3H),7.19(dd,J=8.5,2.4Hz,1H),7.11(d,J=9.0Hz,1H),7.00(d,J=2.4Hz,1H),6.97-6.93(m,2H).

[0906] Example 21: 6,6'-([1,1'-biphenyl]-2,4-diylbis(oxy))bis(pyridin-3-amine)

[0907]

[0908] Following General Procedure B, 6,6'-([1,1'-biphenyl]-2,4-diylbis(oxy))bis(pyridin-3-amine) was obtained in 13% yield from 6,6'-([1,1'-biphenyl]-2,4-diylbis(oxy))bis(3-nitropyridine) (90 mg, 0.31 mmol).

[0909] C 22 H 18 N4O2; molecular weight 370.41g.mol -1 ; 1H NMR (400MHz, CDCl3) δ7.75(d,J=2.9Hz,1H),7.66(d,J=2.9Hz,1H),7.53-7.48(m,2H),7.38(d,J=8.5Hz,1H),7.32(t,J=7.4H z,3H),7.09(dd,J=8.7,2.9Hz,1H),7.01-6.96(m,1H),6.92(dd,J=8.4,2.3Hz,1H),6.82-6.78(m,2H),6.62(d,J=8.7Hz,1H).

[0910] The starting material was prepared as follows:

[0911] Step 1: 6,6'-((4-bromo-1,3-phenylene)bis(oxy))bis(3-nitropyridine)

[0912]

[0913] Following general procedure A, 6,6′-((4-bromo-1,3-phenylene)bis(oxy))bis(3-nitropyridine) (320 mg, 0.74 mmol) was obtained in 97% yield from 4-bromoresorcinol (150 mg, 0.78 mmol) and 2-chloro-5-nitropyridine (260 mg, 1.60 mmol).

[0914] C 16 H9BrN4O6; molecular weight 433.17g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ9.05 (dd, J=2.8, 0.6Hz, 1H), 9.02 (dd, J=2.8, 0.6Hz, 1H), 8.52 (ddd, J=9.0, 8.3, 2.8Hz, 2H), 7.73 (d, J=8.7Hz, 1H), 7.18-7.05 (m, 4H).

[0915] Step 2: 6,6'-([1,1'-biphenyl]-2,4-diylbis(oxy))bis(3-nitropyridine)

[0916]

[0917] Under nitrogen, phenylboronic acid (120 mg, 0.96 mmol), 6,6'-((4-bromo-1,3-phenylene)bis(oxy))bis(3-nitropyridine) (320 mg, 0.74 mmol), potassium carbonate (210 mg, 1.50 mmol), water (1 mL), and 2-propanol (6 mL) were added to a 250 mL round-bottom flask. Bis(triphenylphosphine)palladium(II) chloride (51 mg, 0.071 mmol) was then added, and the yellow suspension was stirred at room temperature for 5 minutes and then heated to reflux (16 hours). The mixture was filtered through a pad of celite, and the filtrate was concentrated under vacuum. Water and EtOAc were added to the residue. The layers were separated, and the aqueous layer was washed twice with EtOAc. All organic layers were combined, dried (Na2SO4), filtered, and concentrated under vacuum. The crude product was purified with Biotage Isolera Four (KP-sil 50 g column, cyclohexane / EtOAc, EtOAc 0-25%, 22 CV) to give 6,6'-([1,1'-biphenyl]-2,4-diylbis(oxy)bis(3-nitropyridine) (90 mg, 28% yield) as a colorless oil.

[0918] C 22 H 14 N4O6; molecular weight 430.38g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ9.09(dd,J=2.8,0.6Hz,1H),8.92(dd,J=2.8,0.6Hz,1H),8.52(dd,J=9.0,2.8Hz,1H),8.34(dd,J=9.0,2.8Hz,1H), 7.56(d,J=8.4Hz,1H),7.45-7.40(m,2H),7.35-7.27(m,3H),7.23(dd,J=8.5,2.4Hz,1H),7.16-7.10(m,2H),6.90(dd,J=9.0,0.6Hz,1H).

[0919] Example 22: 6-((2-(2-(4-aminophenoxy)ethyl)-[1,1′-biphenyl]-4-yl)oxy)pyridin-3-amine

[0920]

[0921] Following General Procedure B, 6-((2-(2-(4-(4-aminophenoxy)ethyl)-[1,1′-biphenyl]-4-yl)oxy)pyridin-3-amine (5 mg, 0.012 mmol) was obtained in 12% yield from 5-nitro-2-((2-(2-(4-nitrophenoxy)ethyl))-[1,1′-biphenyl]-4-yl)oxy)pyridine (48 mg, 0.10 mmol).

[0922] C 25 H 23 N3O2; molecular weight is 397.48g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.75(d,J=3.0Hz,1H),7.42-7.38(m,2H),7.37-7.31(m,3H),7.20(d,J=8.3Hz,1H),7.13-7.07(m, 2H), 6.96 (dd, J = 8.3, 2.5Hz, 1H), 6.82 (d, J = 8.6Hz, 1H), 6.59-6.51 (m, 4H), 3.92 (t, J = 7.4Hz, 2H), 3.01 (t, J = 7.4Hz, 2H).

[0923] The starting material was prepared as follows:

[0924] Step 1: 2-(2-Bromo-5-methoxyphenyl)acetic acid

[0925]

[0926] In a 250 mL round-bottom flask, 2-(3-methoxyphenyl)acetic acid (1.50 g, 9.00 mmol) was dissolved in CHCl (25 mL, 0.36 M). N-bromosuccinimide (1.80 g, 9.90 mmol) was added portionwise at 0°C under nitrogen. The colorless solution was stirred at room temperature for 3 hours. Water was added to the mixture and the layers were separated. The aqueous layer was washed with CHCl. ​​All organic layers were combined and washed with brine, dried (NaSO), filtered and concentrated to give 2-(2-bromo-5-methoxyphenyl)acetic acid (2.22 g, 100% yield) as an orange solid. CHBrO; molecular weight 245.07 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.46 (d, J = 8.8 Hz, 1H), 6.86 (d, J = 3.0 Hz, 1H), 6.73 (dd, J = 8.8, 3.0 Hz, 1H), 3.81 (s, 2H), 3.79 (s, 3H).

[0927] Step 2: 2-(2-Bromo-5-methoxyphenyl)ethan-1-ol

[0928]

[0929] In a 250mL round-bottom flask, 2-(2-bromo-5-methoxyphenyl)acetic acid (2.22g, 9.06mmol) was dissolved in anhydrous THF (16mL, 0.55M). The yellow solution was cooled to 0°C and a 2.4M THF solution of LiAlH4 (2.30ml, 5.5mmol) was added dropwise. The yellow solution was stirred at room temperature (2 hours). The reaction mixture was quenched with 1M NaOH (10mL) at 0°C. THF was evaporated, and CH2Cl2 and water were added. The turbid mixture was stirred for 1 hour. The layers were separated and the aqueous layer was washed with CH2Cl2. All organic layers were combined and washed with 1M HCl, brine, dried (Na2SO4), filtered and concentrated to give 2-(2-bromo-5-methoxyphenyl)ethan-1-ol (1.35g, 65% yield) as a light yellow oil.

[0930] C9H 11 BrO2; molecular weight is 231.09 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.43 (d, J = 8.8 Hz, 1H), 6.83 (d, J = 3.0 Hz, 1H), 6.67 (dd, J = 8.8, 3.1 Hz, 1H), 3.88 (t, J = 6.6 Hz, 2H), 3.78 (s, 3H), 2.99 (t, J = 6.6 Hz, 2H).

[0931] Step 3: 1-Bromo-4-methoxy-2-(2-(4-nitrophenoxy)ethyl)benzene

[0932]

[0933] In a 25 mL round-bottom flask, 2-(2-bromo-5-methoxyphenyl)ethan-1-ol (190 mg, 0.82 mmol) was dissolved in dry DMF (3 mL, 0.3 M). NaH (60%, 42 mg, 1.00 mmol) was added portionwise to give a dark yellow suspension. The solution was stirred at room temperature (15 minutes) and then 1-fluoro-4-nitrobenzene (110 mg, 0.78 mmol) was added. The dark green suspension was stirred at room temperature overnight. Water was added to quench the mixture and then EtOAc was added. The layers were separated. The aqueous layer was washed with EtOAc. All organic layers were combined, washed with brine, dried (Na2SO4), filtered and concentrated. The crude product was purified on Biotage IsoleraFour (KP-sil 25 g column, cyclohexane / EtOAc, EtOAc 0-20%, 16 CV) to give 1-bromo-4-methoxy-2-(2-(4-nitrophenoxy)ethyl)benzene (150 mg, 60% yield) as a yellow solid.

[0934] C 15 H 14 BrNO4; molecular weight is 352.18 g.mol -1 ; 1 H NMR (400 MHz, CDCl3) δ 8.22-8.16 (m, 2H), 7.45 (d, J = 8.8 Hz, 1H), 6.98-6.93 (m, 2H), 6.88 (d, J = 3.0 Hz, 1H), 6.70 (dd, J = 8.8, 3.0 Hz, 1H), 4.28 (t, J = 7.0 Hz, 2H), 3.79 (s, 3H), 3.23 (t, J = 7.0 Hz, 2H). TLC (cyclohexane / EtOAc 9:1) R f =0.28.

[0935] Step 4: 4-Methoxy-2-(2-(4-nitrophenoxy)ethyl)-1,1'-biphenyl

[0936]

[0937] Phenylboronic acid (63 mg, 0.51 mmol), 1-bromo-4-methoxy-2-(2-(4-nitrophenoxy)ethyl)benzene (150 mg, 0.43 mmol), potassium carbonate (154 mg, 1.11 mmol), water (1 mL), and 2-propanol (4 mL) were added to a 250 mL round-bottom flask under nitrogen. Bis(triphenylphosphine)palladium(II) chloride (39 mg, 0.054 mmol) was then added, and the yellow suspension was stirred at room temperature for 5 minutes and then heated to reflux (16 hours). The mixture was filtered through a pad of celite, and the filtrate was concentrated under vacuum. Water and EtOAc were added to the residue. The layers were separated, and the aqueous layer was washed with EtOAc (twice). All organic layers were combined, dried (Na2SO4), filtered, and concentrated under vacuum. The crude product was purified with Biotage Isolera Four (KP-sil 50 g column, cyclohexane / EtOAc, EtOAc 0-30%, 13 CV) to give 4-methoxy-2-(2-(4-nitrophenoxy)ethyl)-1,1′-biphenyl (120 mg, 81% yield) as a colorless oil.

[0938] C 21 H 19 NO4; molecular weight is 349.39 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.12-8.06(m,2H),7.47-7.38(m,3H),7.34-7.30(m,2H),7.19(d,J=8.4Hz,1H),6.92(d,J=2. 6Hz, 1H), 6.86 (dd, J = 8.4, 2.7Hz, 1H), 6.70-6.64 (m, 2H), 4.06 (t, J = 7.4Hz, 2H), 3.85 (s, 3H), 3.09 (t, J = 7.4Hz, 2H).

[0939] Step 5: 2-(2-(4-nitrophenoxy)ethyl)-[1,1'-biphenyl]-4-ol

[0940]

[0941] Under nitrogen, 4-methoxy-2-(2-(4-nitrophenoxy)ethyl)-1,1'-biphenyl (115 mg, 0.329 mmol) was dissolved in CHCl (4 mL, 0.9 M) in a 100 mL round-bottom flask. The brown solution was cooled to 0°C. A solution of BBr in CHCl (0.5 M, 1.0 mL, 0.50 mmol) was added dropwise over 30 minutes using a syringe pump. The solution was allowed to reach room temperature and then stirred for 2.3 hours. The mixture was quenched with water at 0°C and then neutralized with 6 M aqueous NaOH. The layers were separated, and the aqueous layer was extracted again with CHCl (twice). The combined organic layers were washed with brine, dried (NaSO), filtered, and concentrated. The crude product was purified with Biotage Isolera Four (KP-sil 25 g column, cyclohexane / EtOAc, EtOAc 5-40%, 13 CV) to give 2-(2-(4-nitrophenoxy)ethyl)-[1,1′-biphenyl]-4-ol (47 mg, 41% yield) as a yellow oil.

[0942] C 20 H 17 NO4; molecular weight is 349.39 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.13-8.07(m,2H),7.47-7.38(m,3H),7.33-7.28(m,2H),7.13(d,J=8.2Hz,1H),6.86(d,J=2. 7Hz, 1H), 6.78 (dd, J = 8.3, 2.7Hz, 1H), 6.70-6.65 (m, 2H), 4.76 (s, 1H), 4.05 (t, J = 7.4Hz, 2H), 3.07 (t, J = 7.4Hz, 2H).

[0943] Step 6: 5-nitro-2-((2-(2-(4-nitrophenoxy)ethyl)-[1,1'-biphenyl]-4-yl)oxy)pyridine

[0944]

[0945] Following General Procedure A, 5-nitro-2-((2-(2-(4-(4-nitrophenoxy)ethyl))-[1,1′-biphenyl]-4-yl)oxy)pyridine (48 mg, 0.10 mmol) was obtained in 75% yield from 2-(2-(4-nitrophenoxy)ethyl)-[1,1′-biphenyl]-4-ol (47 mg, 0.14 mmol) and 2-chloro-5-nitropyridine (27 mg, 0.17 mmol). 25 H 19N3O6; molecular weight 457.44g.mol -1 ; 1 H NMR(400MHz, CDCl3)δ9.08(dd,J=2.8,0.6Hz,1H),8.51(dd,J=9.0,2.8Hz,1H),8.13-8.07(m,2H),7.49-7.43(m,3H),7.4 0-7.32(m,3H),7.20(d,J=2.4Hz,1H),7.15-7.08(m,2H),6.72-6.66(m,2H),4.08(t,J=7.2Hz,2H),3.14(t,J=7.2Hz,2H).

[0946] Example 23: N-methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine

[0947]

[0948] To a freshly prepared solution of MeONa (4.4 eq, 2.609 mmol) in MeOH (0.15 M) was added 6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine (1.0 eq, 0.588 mmol, 155 mg added; Example 3) under an inert atmosphere. The suspension thus obtained was stirred for 0.5 h and became a solution. A suspension of paraformaldehyde (1.4 eq, 0.824 mmol, 27 mg) in MeOH (1 ml) was then poured into the previous solution, and the mixture was stirred for 14 h. NaBH4 (2.0 eq, 1.165 mmol, 45 mg) was added to the reaction, and the mixture was stirred for 3 h (completion monitored by TLC). The mixture was finally diluted with water at 0°C. The aqueous layer was extracted three times with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated. The crude product was purified by flash column chromatography using EtOAc / cyclohexane (15% to 70%) as eluent to afford N-methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine (0.436 mmol, 121 mg, 74% yield). 17 H 15 N3O; molecular weight is 277.33 g.mol -1 ;solid; 1H NMR (400MHz, CDCl3) δ8.52(d,J=2.7Hz,1H),7.95(d,J=7.5Hz,2H),7.71(d,J=8.6Hz,1H),7.63(d,J=3.0Hz,1 H),7.51-7.42(m,3H),7.38(t,J=7.3Hz,1H),7.05(dd,J=8.7,3.0Hz,1H),6.89(d,J=8.7Hz,1H),2.86(s,3H).

[0949] Example 24: 6-(4-(pyridin-2-yl)phenoxy)pyridin-3-amine

[0950]

[0951] Following general procedure B, 6-(4-(pyridin-2-yl)phenoxy)pyridin-3-amine (0.23 mmol, 60 mg) was obtained in 67% yield from 5-nitro-2-(4-pyridin-2-yl)phenoxy)pyridine (100 mg, 0.341 mmol).

[0952] C 16 H 13 N3O; molecular weight is 263.30 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.67 (dd, J=4.8, 0.8Hz, 1H), 7.98 (d, J=8.7Hz, 2H), 7.76-7.66 (m, 3H), 7. 23-7.17(m,1H),7.15(d,J=8.8Hz,2H),7.12-7.06(m,1H),6.81(d,J=8.6Hz,1H),3.24(s,2H).

[0953] The starting material was prepared as follows:

[0954] Step 1: 5-Nitro-2-(4-(pyridin-2-yl)phenoxy)pyridine

[0955]

[0956] Following the general procedure A, 5-nitro-2-(4-(pyridin-2-yl)phenoxy)pyridine (500 mg, 1.70 mmol) was obtained in 97% yield from 4-(pyridin-2-yl)phenol (1.75 mmol, 0.300 g) and 2-chloro-5-nitropyridine (1.75 mmol, 0.278 g).

[0957] C 16 H 11N3O3; molecular weight is 293.28g.mol -1 ; 1 H NMR (300MHz, CDCl3) δ9.11-9.05(m,1H),8.91-8.85(m,1H),8.62(d,J=4.8Hz,1H),8.52(dd,J=9.1,2.8Hz,1H ),7.94-7.85(m,1H),7.67(d,J=8.6Hz,2H),7.42-7.36(m,1H),7.29(d,J=8.6Hz,2H),7.11(d,J=9.0Hz,1H).

[0958] Example 25: 6-(4-(pyridin-3-yl)phenoxy)pyridin-3-amine

[0959]

[0960] Following general procedure B, 6-(4-(pyridin-3-yl)phenoxy)pyridin-3-amine (1.25 mmol, 330 mg) was obtained in 52% yield from 5-nitro-2-(4-(pyridin-3-yl)phenoxy)pyridine (710 mg, 2.42 mmol).

[0961] C 16 H 13 N3O; molecular weight is 263.30 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.85-8.81(m,1H),8.56(dd,J=4.8,1.6Hz,1H),7.84(ddd,J=7.9,2.4,1.6Hz,1H),7.74(dd,J=3.0,0.6Hz,1H),7.55(d, J=8.7Hz,2H),7.34(ddd,J=7.9,4.8,0.9Hz,1H),7.17(d,J=8.7Hz,2H),7.11(dd,J=8.6,3.0Hz,1H),6.83(dd,J=8.6,0.7Hz,1H),3.48(s,2H).

[0962] The starting material was prepared as follows:

[0963] Step 1: 5-Nitro-2-(4-(pyridin-3-yl)phenoxy)pyridine

[0964]

[0965] Following general procedure A, 5-nitro-2-(4-(pyridin-3-yl)phenoxy)pyridine (270 mg, 0.92 mmol) was obtained in 40% yield from 4-(pyridin-3-yl)phenol (2.34 mmol, 0.400 g) and 2-chloro-5-nitropyridine (2.34 mmol, 0.370 g).

[0966] C 16 H 11 N3O3; molecular weight is 293.28g.mol -1 ; 1 H NMR(300MHz, CDCl3) δ9.07(dd,J=2.8,0.6Hz,1H),8.70(ddd,J=4.8,1.7,1.1Hz,1H),8.50(dd,J=9.1,2 .8Hz,1H),8.10(d,J=8.9Hz,2H),7.79-7.74(m,2H),7.28(d,J=9.0Hz,3H),7.08(dd,J=9.1,0.6Hz,1H).

[0967] Example 26: 6-(4-(pyridin-4-yl)phenoxy)pyridin-3-amine

[0968]

[0969] Following general procedure B, 6-(4-(pyridin-4-yl)phenoxy)pyridin-3-amine (0.40 mmol, 100 mg) was obtained in 57% yield from 5-nitro-2-(4-(pyridin-4-yl)phenoxy)pyridine (19 mg, 0.672 mmol).

[0970] C 16 H 13 N3O; molecular weight is 263.30 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.64 (dd, J=4.6, 1.6Hz, 2H), 7.75 (d, J=3.0Hz, 1H), 7.66-7. 60(m,2H),7.50(dd,J=4.6,1.6Hz,2H),7.20-7.10(m,3H),6.85(d,J=8.6Hz,1H).

[0971] The starting material was prepared as follows:

[0972] Step 1: 5-Nitro-2-(4-(pyridin-4-yl)phenoxy)pyridine

[0973]

[0974] Following General Procedure E, 5-nitro-2-(4-(pyridin-4-yl)phenoxy)pyridine (33 mg, 0.11 mmol) was obtained in 95% yield from 2-(4-bromophenoxy)-5-nitropyridine (50 mg, 0.17 mmol; Example 10: Step 1) and pyridin-4-ylboronic acid (25 mg, 0.20 mmol).

[0975] C 16 H 11 N3O3; molecular weight is 293.28g.mol -1 ; 1 H NMR (300MHz, CDCl3) δ9.06(d,J=2.7Hz,1H),8.69(d,J=6.2Hz,2H),8.62(dd,J=9.1,2.7Hz,1H ), 7.70 (d, J = 8.7Hz, 2H), 7.52 (d, J = 6.2Hz, 2H), 7.30 (d, J = 8.7Hz, 2H), 7.11 (d, J = 9.1Hz, 1H).

[0976] Example 27: 6-((4'-fluoro-[1,1'-biphenyl]-4-yl]oxy)-N-methylpyridin-3-amine

[0977]

[0978] Following General Procedure C, 6-((4'-fluoro-[1,1'-biphenyl]-4-yl]oxy)-N-methylpyridin-3-amine (0.221 mmol, 85 mg) was obtained in 73% yield from 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine (0.303 mmol, 65 mg; Example 10).

[0979] C 18 H 15 FN2O; molecular weight is 294.33 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.68 (d, J = 3.0 Hz, 1H), 7.53-7.47 (m, 4H), 7.14-7.08 (m, 4H), 7.05 (dd, J = 8.7, 3.0 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 2.86 (s, 3H).

[0980] Example 28: 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-2-methylpyridin-3-amine

[0981]

[0982] Following General Procedure B, 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-2-methylpyridin-3-amine (1.11 mmol, 330 mg) was obtained in 72% yield from 6-((4'-fluoro-[1,1'-biphenyl]-4-yl]oxy)-2-methyl-3-nitropyridine (1.54 mmol, 500 mg).

[0983] C 18 H 15 FN2O; molecular weight is 294.33 g.mol -1 ; 1 H NMR(400MHz,DMSO-d6)δ7.71-7.63(m,2H),7.63-7.56(m,2H),7.32-7.22(m,2H),7.08 (d,J=8.3Hz,1H),7.02-6.96(m,2H),6.67(d,J=8.3Hz,1H),4.90(s,2H),2.18(s,3H).

[0984] The starting material was prepared as follows:

[0985] Step 1: 6-(4-bromophenoxy)-2-methyl-3-nitropyridine

[0986]

[0987] Following general procedure A, 6-(4-bromophenoxy)-2-methyl-3-nitropyridine (26.9 mmol, 8.31 g) was obtained in 93% yield from 6-chloro-2-methyl-3-nitropyridine (29 mmol, 5.00 g) and 4-bromophenol (32 mmol, 5.50 g).

[0988] C 12 H9BrN2O3; molecular weight 309.12 g mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.38 (d, J = 8.9 Hz, 1H), 7.72-7.42 (m, 2H), 7.15-6.99 (m, 2H), 6.84 (d, J = 8.9 Hz, 1H), 2.73 (s, 3H).

[0989] Step 2: 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy]-2-methyl-3-nitropyridine

[0990]

[0991] Following General Procedure E, a mixture of (4-fluorophenyl)boronic acid (4.85 mmol, 679 mg), 6-(4-bromophenoxy)-2-methyl-3-nitropyridine (3.23 mmol, 1.00 g), K2CO3 (8.09 mmol, 1.12 g), and Pd(PPh3)4 (0.162 mmol, 187 mg, 5 mol%) in dioxane / H2O (0.1 M) was converted to 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-2-methyl-3-nitropyridine (2.94 mmol, 900 mg) in 90% yield. 18 H 13 FN2O3; molecular weight 324.31 g.mol -1 ; 1 H NMR(400MHz, CDCl3)δ8.38(d,J=8.9Hz,1H),7.62-7.58(m,2H),7.58-7.53(m,2H) ,7.25-7.21(m,2H),7.19-7.11(m,2H),6.84(dd,J=8.9,0.7Hz,1H),2.77(s,3H).

[0992] Example 29: 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-4-methylpyridin-3-amine

[0993]

[0994] Following General Procedure B, 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-4-methylpyridin-3-amine (476 mmol, 0.140 g) was obtained in 86% yield from 2-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-4-methyl-5-nitropyridine (555 mmol, 0.180 g).

[0995] C 18 H 15 FN2O; molecular weight is 294.33 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.69(s,1H),7.54-7.46(m,4H),7.14-7.06(m,4H),6.72(s,1H),2.20(s,3H),2.07(s,2H).

[0996] The starting material was prepared as follows:

[0997] Step 1: 2-(4-bromophenoxy)-4-methyl-5-nitropyridine

[0998]

[0999] Following general procedure A, 2-(4-bromophenoxy)-4-methyl-5-nitropyridine (11 mmol, 3.50 g) was obtained in 40% yield from 4-bromophenol (31.9 mmol, 5.51 g) and 2-chloro-4-methyl-5-nitropyridine (29 mmol, 5.00 g).

[1000] C 12 H9BrN2O3; molecular weight 309.12g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ 8.86 (s, 1H), 7.55 (d, J = 8.9Hz, 2H), 7.04 (d, J = 8.9Hz, 2H), 6.86 (d, J = 1.0Hz, 1H), 2.68 (app d, J = 1.0Hz, 3H).

[1001] Step 2: 2-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-4-methyl-5-nitropyridine

[1002]

[1003] Following General Procedure E, 2-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-4-methyl-5-nitropyridine (1.13 mmol, 0.30 g) was obtained in 82% yield from 2-(4-bromophenoxy)-4-methyl-5-nitropyridine (1.13 mmol, 0.350 mg) and (4-fluorophenyl)boronic acid (1.70 mmol, 0.238 mg).

[1004] C 18 H 13 FN2O3; molecular weight 324.31 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.91 (s, 1H), 7.63-7.58 (m, 2H), 7.57-7.52 (m, 2H), 7.23-7.19 (m, 2H), 7.17-7.11 (m, 2H), 6.89 (d, J = 0.9Hz, 1H), 2.69 (s, 3H).

[1005] Example 30: 2-Methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine

[1006]

[1007] Following general procedure B, 2-methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine (1.08 mmol, 300 mg) was obtained in 89% yield from 2-methyl-3-nitro-6-((6-phenylpyridin-3-yl)oxy)pyridine (1.22 mmol, 374 mg).

[1008] C 17 H 15 N3O; molecular weight is 277.33 g.mol -1 ; 1 H NMR(400MHz, DMSO-d6)δ8.40(d,J=2.5Hz,1H),8.15-7.98(m,2H),7.94(d,J=8.7Hz,1H),7.55-7.45 (m,3H),7.44-7.37(m,1H),7.10(d,J=8.4Hz,1H),6.75(d,J=8.4Hz,1H),4.93(s,2H),2.17(s,3H).

[1009] The starting material was prepared as follows:

[1010] Step 1: 6-phenylpyridin-3-ol

[1011]

[1012] Following General Procedure D, a mixture of phenylboronic acid (11.49 mmol, 1.40 g), 6-bromopyridin-3-ol (5.75 mmol, 1.00 g), Na2CO3 (11.49 mmol, 1.22 g) and Pd(PPh3)4 (0.287 mmol, 332 mg) in 3:1 mixture of DME / H2O (0.32 M) was converted to 6-phenylpyridin-3-ol (3.50 mmol, 600 mg) in 61% yield.

[1013] C 11 H9NO; molecular weight is 171.20 g mol -1 ; 1 H NMR(400MHz,DMSO-d6)δ9.19(s,1H),7.40-7.34(m,1H),7.15-7.09(m,2H),6.95(dd, J=8.6,0.7Hz,1H),6.65-6.57(m,2H),6.54-6.49(m,1H),6.40(dd,J=8.6,2.9Hz,1H).

[1014] Step 2: 2-Methyl-3-nitro-6-((6-phenylpyridin-3-yl)oxy)pyridine

[1015]

[1016] Following general procedure A, 2-methyl-3-nitro-6-((6-phenylpyridin-3-yl)oxy]pyridine (1.22 mmol, 374 mg) was obtained in 95% yield from 6-chloro-2-methyl-3-nitropyridine (1.27 mmol, 220 mg).

[1017] C 17 H 13 N3O3; molecular weight 307.31g.mol -1 ; 1 H NMR(400MHz, CDCl3)δ8.60(dd,J=2.8,0.7Hz,1H),8.42(d,J=8.9Hz,1H),8.09-7.93(m,2H),7.82(dd, J=8.7,0.7Hz,1H),7.62(dd,J=8.7,2.8Hz,1H),7.56-7.40(m,3H),6.96(d,J=8.9Hz,1H),2.73(s,3H).

[1018] Example 31: 4-Methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine

[1019]

[1020] Following general procedure B, 4-methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine (0.30 mmol, 84 mg) was obtained in 78% yield from 4-methyl-5-nitro-2-((6-phenylpyridin-3-yl)oxy)pyridine (0.39 mmol, 120 mg).

[1021] C 17 H 15 N3O; molecular weight is 277.33 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.51 (dd, J=2.8, 0.7Hz, 1H), 7.98-7.90 (m, 2H), 7.71 (dd, J=8.6, 0.7Hz, 1 H),7.64(s,1H),7.50-7.42(m,3H),7.41-7.35(m,1H),6.77(s,1H),3.49(s,2H),2.22(s,3H).

[1022] The starting material was prepared as follows:

[1023] Step 1: 4-Methyl-5-nitro-2-((6-phenylpyridin-3-yl)oxy)pyridine

[1024]

[1025] Following general procedure A, 4-methyl-5-nitro-2-((6-phenylpyridin-3-yl)oxy)pyridine (0.664 mmol, 204 mg) was obtained in 76% yield from 6-phenylpyridin-3-ol (0.956 mmol, 164 mg) and 2-chloro-4-methyl-5-nitropyridine (0.869 mmol, 150 mg).

[1026] C 17 H 13 N3O3; molecular weight 307.31g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.87(s,1H),8.57(d,J=2.7Hz,1H),8.02-7.97(m,2H),7.82(d,J =8.6Hz,1H),7.60(dd,J=8.6,2.7Hz,1H),7.52-7.39(m,3H),6.97(s,1H),2.71(s,3H).

[1027] Example 32: 2-Methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine

[1028]

[1029] Following general procedure B, 2-methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine (0.42 mmol, 120 mg) was obtained in 64% yield from 5-(4-((6-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole (0.66 mmol, 206 mg).

[1030] C 15 H 13 N3OS; molecular weight is 283.35 g.mol -1 ; 1 H NMR (400MHz, DMSO-d6) δ9.04(d,J=0.7Hz,1H),8.22(d,J=0.7Hz,1H),7.63(d,J=8.8Hz,2H),7 .08(d,J=8.3Hz,1H),6.99(d,J=8.7Hz,2H),6.68(d,J=8.4Hz,1H),4.92(s,2H),2.17(s,3H).

[1031] The starting material was prepared as follows:

[1032] Step 1: 5-(4-((6-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole

[1033]

[1034] Following General Procedure D, a mixture of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole (4.89 mmol, 1.03 g), 6-(4-bromophenoxy)-2-methyl-3-nitropyridine (3.26 mmol, 1.01 g; Example 28, Step 1), Na2CO3 (8.15 mmol, 864 mg) and Pd(PPh3)4 (0.163 mmol, 188 mg, 5 mol%) in 4:1 dioxane / H2O (0.06 M) was converted to 5-(4-((6-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole (0.67 mmol, 209 mg) in 20% yield.

[1035] C 15 H 11 N3O3S; molecular weight is 313.33 g.mol -1 ; 1 H NMR(400MHz,DMSO-d6)δ9.10(app d,J=0.7Hz,1H),8.52(d,J=8.9Hz,1H),8.33(s,1H),7.91-7.71(m,2H),7.40-7.21(m,2H),7.11(d,J=8.9Hz,1H),2.60(s,3H).

[1036] Example 33: 4-Methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine

[1037]

[1038] Following general procedure B, 4-methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine (0.424 mmol, 0.120 g) was obtained in 33% yield from 5-(4-((4-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole (1.02 mmol, 0.320 g).

[1039] C 15 H 13 N3OS; molecular weight is 283.35 g.mol -1 ; 1H NMR (400MHz, CDCl3) δ 8.72 (s, 1H), 8.00 (s, 1H), 7.67 (s, 1H), 7.54 (d, J = 8.7Hz, 2H), 7.09 (d, J = 8.7Hz, 2H), 6.73 (s, 1H), 2.21 (s, 3H), 2.04 (s, 2H).

[1040] The starting material was prepared as follows:

[1041] Step 1: 5-(4-((4-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole

[1042]

[1043] Following General Procedure E, 5-(4-((4-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole (1.02 mmol, 0.320 g) was obtained in 40% yield from 5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)thiazole (3.78 mmol, 0.799 mg) and 2-(4-bromophenoxy)-4-methyl-5-nitropyridine (2.52 mmol, 0.780 g; Example 29, Step 1).

[1044] C 15 H 11 N3O3S; molecular weight is 313.33 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ 8.89 (s, 1H), 8.78 (s, 1H), 8.07 (s, 1H), 7.65 (d, J = 8.7Hz, 2H), 7.21 (d, J = 8.7Hz, 2H), 6.90 (s, 1H), 2.69 (s, 3H).

[1045] Example 34: N-methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine

[1046]

[1047] Following General Procedure C, N-methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine (0.18 mmol, 50 mg) was obtained in 59% yield from 6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine (0.30 mmol, 80 mg; Example 11).

[1048] C 15 H 13 N3OS; molecular weight is 283.35 g.mol -1 ; 1H NMR (400MHz, CDCl3) δ8.72 (s, 1H), 8.00 (s, 1H), 7.67 (d, J = 3.0Hz, 1H), 7.57-7.51 (m, 2 H),7.13-7.07(m,2H),7.05(dd,J=8.7,3.1Hz,1H),6.86(d,J=8.7Hz,1H),2.86(s,3H).

[1049] Example 35: 2-Methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine

[1050]

[1051] Following general procedure B, 2-methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine (0.434 mmol, 123 mg) was obtained in 68% yield from 2-(4-((6-methyl-5-nitropyridin-2-yloxy)phenyl)thiazole (0.638 mmol, 200 mg).

[1052] C 15 H 13 N3OS; molecular weight is 283.35 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.85(d,J=8.8Hz,2H),7.76(d,J=3.3Hz,1H),7.22(d,J=3.3Hz, 1H), 7.01 (d, J=8.8Hz, 2H), 6.97 (d, J=8.4Hz, 1H), 6.59 (d, J=8.4Hz, 1H), 2.30 (s, 3H).

[1053] The starting material was prepared as follows:

[1054] Step 1: 2-(4-((6-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole

[1055]

[1056] Following the general procedure A, 2-(4-((6-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole (1.44 mmol, 0.450 g) was obtained in 51% yield from 4-(2-thiazolyl)phenol (2.82 mmol, 500 mg) and 6-chloro-2-methyl-3-nitropyridine (3.10 mmol, 536 mg).

[1057] C 15 H 11 N3O3S; molecular weight is 313.33 g.mol-1 ; 1 H NMR (400MHz, CDCl3) δ8.39(d,J=8.9Hz,1H),8.04(d,J=8.5Hz,2H),7.88(s,1H),7.36(s,1H),7.25(d,J=8.2Hz,2H),6.87(d,J=8.9Hz,1H),2.74(s,3H).

[1058] Example 36: 4-Methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine

[1059]

[1060] Following General Procedure F, 4-methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine (1.16 mmol, 330 mg) was obtained in 94% yield from 2-(4-((4-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole (1.24 mmol, 390 mg).

[1061] C 15 H 13 N3OS; molecular weight is 283.35 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.95-7.90(m,2H),7.83(d,J=3.3Hz,1H),7.69(s,1H),7.28(d,J=3.3Hz,1H),7.12-7.07(m,2H),6.73(s,1H),2.21(s,3H).

[1062] The starting material was prepared as follows:

[1063] Step 1: 2-(4-((4-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole

[1064]

[1065] Following the general procedure A, 2-(4-((4-methyl-5-nitropyridin-2-yl)oxy)phenyl)thiazole (1.24 mmol, 390 mg) was obtained in 72% yield from 4-(thiazol-2-yl)phenol (1.91 mmol, 339 mg) and 2-chloro-4-methyl-5-nitropyridine (1.74 mmol, 300 mg).

[1066] C 15 H 11 N3O3S; molecular weight is 313.33 g.mol -1 ; 1H NMR (400MHz, CDCl3) δ8.89(s,1H),8.09-7.99(m,2H),7.87(d,J=3.3Hz,1H),7.34(d,J=3.3Hz,1H),7.25-7.20(m,2H),6.90-6.87(m,1H),2.68(s 3H).

[1067] Example 37: 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-2-methylpyridin-3-amine

[1068]

[1069] Following General Procedure B, 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl]oxy)-2-methylpyridin-3-amine (0.60 mmol, 183 mg) was obtained in 80% yield from 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-2-methyl-3-nitropyridine (0.75 mmol, 250 mg).

[1070] C 20 H 20 N2O; molecular weight is 304.39 g.mol -1 ; 1 H NMR(400MHz, methanol-d4)δ7.29-7.16(m,4H),7.06-7.03(m,1H),7.01(d,J=8.3Hz,1H),6.88(d,J=2.6 Hz, 1H), 6.80 (dd, J=8.3, 2.6Hz, 1H), 6.63 (dd, J=8.5, 0.7Hz, 1H), 2.33 (s, 3H), 2.05 (s, 3H), 1.99 (s, 3H).

[1071] The starting material was prepared as follows:

[1072] Step 1: 6-(4-bromo-3-methylphenoxy)-2-methyl-3-nitropyridine

[1073]

[1074] Following general procedure A, 6-(4-bromo-3-methylphenoxy)-2-methyl-3-nitropyridine (5.46 mmol, 1.76 g) was obtained in 94% yield from 6-chloro-2-methyl-3-nitropyridine (5.79 mmol, 1.00 g) and 4-bromo-3-methylphenol (6.37 mmol, 1.19 g).

[1075] C 13 H11 BrN2O3; molecular weight 323.15 g mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.36(d,J=8.9Hz,1H),7.56(d,J=8.6Hz,1H),7.05(d,J=2.6Hz ,1H),6.88(dd,J=8.6,2.6Hz,1H),6.80(d,J=8.9Hz,1H),2.74(s,3H),2.42(s,3H).

[1076] Step 2: 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-2-methyl-3-nitropyridine

[1077]

[1078] Following General Procedure D, a mixture of o-tolueneboronic acid (3.71 mmol, 505 mg), 6-(4-bromo-3-methylphenoxy)-2-methyl-3-nitropyridine (2.48 mmol, 800 mg), Na2CO3 (4.95 mmol, 525 mg) and Pd(PPh3)4 (0.124 mmol, 143 mg, 5 mol%) in a 3:1 mixture of DME / H2O (0.43 M) was converted to 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-2-methyl-3-nitropyridine (2.24 mmol, 750 mg) in 90% yield.

[1079] C 20 H 18 N2O3; molecular weight 334.38g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.38(d,J=8.9Hz,1H),7.33-7.21(m,3H),7.19-7.09(m,2H),7.07(d,J=2.5H z, 1H), 7.02 (dd, J = 8.2, 2.5Hz, 1H), 6.81 (d, J = 8.9Hz, 1H), 2.81 (s, 3H), 2.10 (s, 3H), 2.08 (s, 3H).

[1080] Example 38: N-methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine

[1081]

[1082] Following General Procedure C, N-methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine (0.32 mmol, 90 mg) was obtained in 86% yield from 6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine (0.371 mmol, 100 mg; Example 16).

[1083] C 15 H 13 N3OS; molecular weight is 283.35 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.96-7.90(m,2H),7.83(d,J=3.3Hz,1H),7.68(dd,J=3.1,0.6Hz,1H),7.28(d,J =3.3Hz,1H),7.13-7.07(m,2H),7.03(dd,J=8.7,3.1Hz,1H),6.86(dd,J=8.7,0.6Hz,1H),2.87(s,3H).

[1084] Example 39: 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-N,4-dimethylpyridin-3-amine

[1085]

[1086] Following General Procedure C, 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-N,4-dimethylpyridin-3-amine (0.15 mmol, 0.047 g) was obtained in 45% yield from 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-4-methylpyridin-3-amine (0.34 mmol, 100 mg; Example 29).

[1087] C 19 H 17 FN2O; molecular weight 308.35 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.55 (s, 1H), 7.45-7.35 (m, 4H), 7.10 (t, J = 8.3Hz, 4H), 6.73 (s, 1H), 3.36 (s, 1H), 2.91 (s, 3H), 2.17 (s, 3H).

[1088] Example 40: 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-N,2-dimethylpyridin-3-amine

[1089]

[1090] Following General Procedure C, 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-N,2-dimethylpyridin-3-amine (0.19 mmol, 0.060 g) was obtained in 72% yield from 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)-2-methylpyridin-3-amine (0.27 mmol, 80 mg; Example 28).

[1091] C 19 H 17 FN2O; molecular weight 308.35 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.55-7.45(m,4H),7.19-7.00(m,5H),6.74(d,J=8.6Hz,1H),2.92(s,3H),2.42(s,3H),1.65-1.48(bs,1H).

[1092] Example 41: N,4-dimethyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine

[1093]

[1094] Following General Procedure C, N,4-dimethyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine (0.091 mmol, 0.027 g) was obtained in 51% yield from 4-methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine (0.18 mmol, 0.050 g; Example 33).

[1095] C 16 H 15 N3OS; molecular weight is 297.38 g.mol -1 ; 1 H NMR (400MHz, DMSO-d6) δ9.03(d,J=0.7Hz,1H),8.22(d,J=0.7Hz,1H),7.63(d,J=8.7Hz,2H),7.0 0-6.95(m,3H),6.79(d,J=8.5Hz,1H),5.20(q,J=5.0Hz,1H),2.73(d,J=4.9Hz,3H),2.21(s,3H).

[1096] Example 42: N,2-dimethyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine

[1097]

[1098] Following General Procedure C, N,2-dimethyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine (0.098 mmol, 29 mg) was obtained in 55% yield from 2-methyl-6-(4-(thiazol-5-yl)phenoxy)pyridin-3-amine (0.18 mmol, 50 mg; Example 32).

[1099] C 16 H 15 N3OS; molecular weight 297.38 g mol -1 ; 1 H NMR(400MHz,DMSO-d6)δ9.03(d,J=0.7Hz,1H),8.22(d,J=0.7Hz,1H),7.78-7.50(m,2H),7.05- 6.90 (m, 3H), 6.79 (d, J = 8.5Hz, 1H), 5.20 (q, J = 5.0Hz, 1H), 2.73 (d, J = 4.9Hz, 3H), 2.21 (s, 3H).

[1100] Example 43: 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-N,2-dimethylpyridin-3-amine

[1101]

[1102] Following General Procedure C, 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-N,2-dimethylpyridin-3-amine (0.22 mmol, 69 mg) was obtained in 82% yield from 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-2-methylpyridin-3-amine (0.26 mmol, 80 mg; Example 37).

[1103] C 21 H 22 N2O; molecular weight 318.42 g mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.26-7.18(m,3H),7.10(d,J=6.8Hz,1H),7.03(dd,J=8.4,3.3Hz,2H),6.92(d,J=2.5Hz,1H),6.85 (dd,J=8.3,2.5Hz,1H),6.74(d,J=8.5Hz,1H),2.91(s,3H),2.40(s,3H),2.07(s,3H),2.01(s,3H),1.70-1.48(bs,1H).

[1104] Example 44: N,2-dimethyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine

[1105]

[1106] Following General Procedure C, N,2-dimethyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine (0.404 mmol, 0.120 g) was obtained in 93% yield from 2-methyl-6-(4-(thiazol-2-yl)phenoxy)pyridin-3-amine (0.434 mmol, 0.123 g; Example 35).

[1107] C 16 H 15 N3OS; molecular weight is 297.38 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.89(d,J=8.9Hz,2H),7.80(d,J=8.9Hz,2H),7.25(d,J=3.3Hz,1H),7. 04(d,J=8.9Hz,2H),6.94(d,J=8.5Hz,1H),6.74(d,J=8.5Hz,1H),2.88(s,3H),2.32(s,3H).

[1108] Example 45: N,2-dimethyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine

[1109]

[1110] Following General Procedure C, N,2-dimethyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine (0.23 mmol, 67 mg) was obtained in 80% yield from 2-methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine (0.29 mmol, 80 mg; Example 30).

[1111] C 18 H 17 N3O; molecular weight 291.35 g mol -1 ; 1H NMR(400MHz,DMSO-d6)δ8.40(d,J=2.8Hz,1H),8.03(app d,J=8.2,2H),7.93(d,J=8.7Hz,1H),7.51-7.44(m,3H),7.43-7.37(m,1H),6.98(d,J=8.2 Hz, 1H), 6.86 (d, J = 8.4Hz, 1H), 5.21 (q, J = 5.0Hz, 1H), 2.73 (d, J = 4.9Hz, 3H), 2.20 (s, 3H).

[1112] Example 46: 6-(4-(6-methoxypyridin-3-yl)phenoxy)-4-methylpyridin-3-amine

[1113]

[1114] Following general procedure B, 6-(4-(6-methoxypyridin-3-yl)phenoxy)-4-methylpyridin-3-amine (0.490 mmol, 165 mg) was obtained in 55% yield from 2-(4-(6-methoxypyridin-3-yl)phenoxy)-4-methyl-5-nitropyridine (0.892 mmol, 0.300 g).

[1115] C 18 H 17 N3O2; molecular weight is 307.35g.mol -1 ; δ 1 H NMR (400MHz, CDCl3) δ8.21(d,J=5.4Hz,1H),7.71(s,1H),7.62(d,J=8.8Hz,2H),7.16(d,J=8.8 Hz, 2H), 7.12 (dd, J = 5.4, 1.5Hz, 1H), 6.97-6.94 (m, 3H), 6.77 (s, 1H), 4.01 (s, 3H), 2.24 (s, 3H).

[1116] The starting material was prepared as follows:

[1117] Step 1: 2-(4-(6-methoxypyridin-3-yl)phenoxy)-4-methyl-5-nitropyridine

[1118]

[1119] Following General Procedure E, 2-(4-(6-methoxypyridin-3-yl)phenoxy)-4-methyl-5-nitropyridine (0.892 mmol, 0.300 g) was obtained in 55% yield from 2-(4-bromophenoxy)-4-methyl-5-nitropyridine (1.62 mmol, 0.500 g; Step 1 of Example 29) and (6-methoxypyridin-3-yl)boronic acid (1.95 mmol, 0.298 g). 18 H 15 N3O4; molecular weight is 337.33g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.91(s,1H),8.40(d,J=2.1Hz,1H),7.79(dd,J=8.6,2.6Hz,1H),7.59(d, J=8.7Hz,2H),7.23(d,J=8.6Hz,2H),6.90(s,1H),6.86-6.81(m,1H),3.99(s,3H),2.69(s,3H).

[1120] Example 47: 6-(4-(2-methoxypyridin-4-yl)phenoxy)-4-methylpyridin-3-amine

[1121]

[1122] Following general procedure B, 6-(4-(2-methoxypyridin-4-yl)phenoxy)-4-methylpyridin-3-amine (0.091 mmol, 28 mg) was obtained in 20% yield from 2-(4-(2-methoxypyridin-4-yl)phenoxy)-4-methyl-5-nitropyridine (0.446 mmol, 0.150 g).

[1123] C 18 H 17 N3O2; molecular weight is 307.35g.mol -1 ; δ 1 H NMR(400MHz, CDCl3)δ8.38(d,J=2.0Hz,1H),7.78(dd,J=8.6,2.6Hz,1H),7.70(s,1H),7.53-7.48( m,2H),7.17-7.12(m,2H),6.85-6.80(m,1H),6.75(s,1H),4.00(s,3H),2.23(m,3H),1.61(s,2H).

[1124] The starting material was prepared as follows:

[1125] Step 1: 2-(4-(2-methoxypyridin-4-yl)phenoxy)-4-methyl-5-nitropyridine

[1126]

[1127] Following General Procedure E, 2-(4-(2-methoxypyridin-4-yl)phenoxy)-4-methyl-5-nitropyridine (0.446 mmol, 0.150 g) was obtained in 28% yield from 2-(4-bromophenoxy)-4-methyl-5-nitropyridine (1.62 mmol, 0.500 g; Step 1 of Example 29) and (2-methoxypyridin-4-yl)boronic acid (1.95 mmol, 0.298 g). 18 H 15 N3O4; molecular weight is 337.33g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.91(s,1H),8.40(dd,J=2.6,0.7Hz,1H),7.79(dd,J=8.6,2.6Hz,1H),7.61-7.55(m,2H ),7.25-7.20(m,2H),6.90(d,J=1.0Hz,1H),6.83(dd,J=8.6,0.7Hz,1H),3.99(s,3H),2.69(d,J=0.8Hz,3H).

[1128] Example 48: 6-(4-(1H-imidazol-4-yl)phenoxy)-4-methylpyridin-3-amine

[1129]

[1130] Following general procedure B, 6-(4-(1H-imidazol-4-yl)phenoxy)-4-methylpyridin-3-amine (86 μmol, 23 mg) was obtained in 61% yield from 2-(4-(1H-imidazol-4-yl)phenoxy)-4-methyl-5-nitropyridine (0.10 mmol, 0.040 g).

[1131] C 15 H 14 N4O;Mw 266.30; 1 H NMR(400MHz, methanol-d4)δ7.72(d,J=1.2Hz,1H),7.71-7.64(m,2H),7.62(s,1H),7 .37(d,J=1.2Hz,1H),7.02-6.92(m,2H),6.77-6.64(m,1H),3.35(s,1H),2.20(s,3H).

[1132] The starting material was prepared as follows:

[1133] Step 1: 4-Bromo-1-trityl-1H-imidazole

[1134]

[1135] To a solution of 4-bromo-1H-imidazole (10.00 mmol, 2.00 g) in CHCl₃ (20 mL) was added TEA (40.00 mmol, 4.00 g, 6.0 mL), and the mixture was cooled to 0°C. A solution of trityl-Cl (10.00 mol, 4.00 g) in 20 mL of CHCl₃ was added, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with 1 M HCl and extracted with CHCl₃ (3x). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to give 4-bromo-1-trityl-1H-imidazole (4.40 g). This was used without further purification.

[1136] C 22 H 17 BrN2; molecular weight 389.30 g mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.39-7.30 (m, 10H), 7.16-7.08 (m, 6H), 6.80 (d, J = 1.6Hz, 1H).

[1137] Step 2: 4-Methyl-5-nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridine

[1138]

[1139] Following General Procedure E, 4-methyl-5-nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridine (3.09 mmol, 1.10 g) was obtained in 95% yield from 2-(4-bromophenoxy)-4-methyl-5-nitropyridine (3.23 mmol, 1.0 g; expl. 29, step 1) and bis(pinacolato)diborane (4.79 mmol, 1.22 g).

[1140] C 18 H 21 BN2O5; molecular weight 356.19 g.mol -1 ; 1H NMR (400MHz, CDCl3) δ 8.88 (s, 1H), 7.90 (d, J = 8.5Hz, 2H), 7.14 (d, J = 8.5Hz, 2H), 6.82 (s, 1H), 2.66 (s, 3H), 1.35 (s, 12H).

[1141] Step 3: 4-Methyl-5-nitro-2-(4-(1-trityl-1H-imidazol-4-yl)phenoxy)pyridine

[1142]

[1143] Following General Procedure E, 4-methyl-5-nitro-2-(4-(1-trityl-1H-imidazol-4-yl)phenoxy)pyridine (0.15 mmol, 81 mg) was obtained in 51% yield from 4-methyl-5-nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridine (0.3 mmol, 0.1 g) and 4-bromo-1-trityl-1H-imidazole (0.4 mmol, 0.2 g).

[1144] C 34 H 26 N4O3; molecular weight is 538.61; 1 H NMR(400MHz, CDCl3)δ8.89(s,1H),7.82-7.76(m,2H),7.53-7.48(m,1H),7.45-7.27(m, 9H),7.24-7.18(m,6H),7.13-7.07(m,3H),6.80(d,J=1.0Hz,1H),2.65(d,J=0.8Hz,3H).

[1145] Step 4: 2-(4-(1H-imidazol-4-yl)phenoxy)-4-methyl-5-nitropyridine

[1146]

[1147] To a solution of 4-methyl-5-nitro-2-(4-(1-trityl-1H-imidazol-4-yl)phenoxy)pyridine (0.15 mmol, 0.081 g) in DCM (10 mL) was added HCl in dioxane (0.19 mL, 4 moles, 0.75 mmol) and stirred at room temperature overnight. The reaction mixture was concentrated to dryness, and the residue was suspended in a saturated solution of NaHCO₃ and extracted with CHCl₃ (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under reduced pressure to give the crude product. This was purified using a Biotage, 25 g silica gel column with DCM and MeOH as eluents to give 2-(4-(1H-imidazol-4-yl)phenoxy)-4-methyl-5-nitropyridine (0.1 mmol, 0.04 g).

[1148] C 15 H 12 N4O3; molecular weight is 296.29; 1 H NMR (400MHz, CDCl3) δ8.91 (s, 1H), 7.82 (d, J = 8.4Hz, 2H), 7.73 (s, 1H), 7.34 ( d,J=1.1Hz,1H),7.23-7.09(m,2H),6.90-6.79(m,1H),2.67(d,J=0.8Hz,3H).

[1149] Example 49: 6-(4-(2H-tetrazol-5-yl)phenoxy)-4-methylpyridin-3-amine

[1150]

[1151] In a flask, 2-(4-(2H-tetrazol-5-yl)phenoxy)-4-methyl-5-nitropyridine (0.14 mmol, 42 mg) was dissolved in EtOH (1.4 mL, 0.10 mol) and flushed with nitrogen. Pd / C (0.014 mmol, 15 mg) was added, a hydrogen balloon was connected, and the mixture was evacuated / backfilled (3x). The mixture was then stirred for 5 hours. After complete conversion, the mixture was evacuated / backfilled with nitrogen (3x), filtered through a syringe filter, and concentrated under reduced pressure. The crude material was purified on a Biotage C18 column (25 g, 5-95% MeOH / HO + 0.1% HCOOH) to give 6-(4-(2H-tetrazol-5-yl)phenoxy)-4-methylpyridin-3-amine (0.097 mmol, 26 mg) as a light yellow solid in 69% yield.

[1152] C 13 H 12 N6O; molecular weight 268.28 g mol -1; 1 H NMR (400MHz, DMSO-d6) δ7.99 (d, J = 8.8 Hz, 2H), 7.58 (s, 1H), 7.12 (d, J = 8.7 Hz, 2H), 6.79 (s, 1H), 2.12 (s, 3H).

[1153] The starting material was prepared as follows:

[1154] Step 1: 4-(2H-tetrazol-5-yl)phenol

[1155]

[1156] A magnetic stir bar with Teflon coating and a Findenser TM A 100mL round-bottom flask of a cooler was charged with 4-hydroxybenzonitrile (8.39mmol, 1.00g), sodium azide (25.2mmol, 1.64g) and triethylamine hydrochloride (25.2mmol, 3.47g) and toluene (42.0mL, 0.20M). The reaction mixture was heated overnight at 100°C under vigorous stirring. It was then cooled to ambient temperature, poured into a separating funnel, and extracted with H2O (3x). The combined aqueous phase was dropwise treated with HCl (concentrated) to precipitate the product. The precipitate was collected by vacuum filtration and vacuum dried to obtain 4-(2H-tetrazol-5-yl)phenol (7.40mmol, 1.19g) as an off-white solid in an 88% yield.

[1157] C7H6N4O; molecular weight is 162.15 g mol -1 ; 1 H NMR (400MHz, DMSO-d6) δ 10.16 (s, 1H), 7.86 (d, J = 8.7Hz, 2H), 6.95 (d, J = 8.7Hz, 2H).

[1158] Step 2: 2-(4-(2H-tetrazol-5-yl)phenoxy)-4-methyl-5-nitropyridine

[1159]

[1160] In a 100 mL round-bottom flask were added 4-(2H-tetrazol-5-yl)phenol (0.62 mmol, 100 mg), 2-chloro-4-methyl-5-nitropyridine (1.85 mmol, 319 mg), and anhydrous KCO (1.85 mmol, 256 mg). DMF (2.1 mL, 0.30 mol) was added, and the resulting brown suspension was heated to 60° C. overnight. After complete conversion by TLC, the reaction mixture was cooled to room temperature, concentrated to a minimum of solvent, and loaded directly onto a Biotage C18 column (30 g column, 5-95% MeOH / HO + 0.1% HCOOH) to afford 2-(4-(2H-tetrazol-5-yl)phenoxy)-4-methyl-5-nitropyridine (0.15 mmol, 45 mg) in 24% yield.

[1161] C 13 H 10 N6O3; molecular weight 298.26 g mol -1 ; 1 H NMR (400MHz, DMSO-d6) δ8.87(s,1H),8.22-7.99(m,2H),7.52-7.36(m,2H),7.30(s,1H),2.63(s,3H).

[1162] Example 50: 6-(4-(1H-pyrazol-4-yl)phenoxy)-4-methylpyridin-3-amine

[1163]

[1164] To a solution of 4-methyl-6-(4-(1-trityl-1H-pyrazol-4-yl)phenoxy)pyridin-3-amine (0.08 mmol, 0.04 g) in DCM (0.4 mL) was added a 4 M solution of HCl (0.2 mL, 0.8 mmol) in dioxane. The mixture was stirred at room temperature overnight. The mixture was diluted in water, and the two layers were separated. The aqueous layer was washed with DCM. The aqueous layer was basified to pH = 8 with saturated aqueous NaHCO 3 solution. The aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over MgSO 4 , filtered and concentrated under reduced pressure. 6-(4-(1H-pyrazol-4-yl)phenoxy)-4-methylpyridin-3-amine (0.072 mmol, 19 mg) was obtained as a light green solid in 90% yield.

[1165] C 15 H 14 N4O; molecular weight 266.30 g mol -1 ; 1H NMR (400MHz, methanol-d4) δ7.91 (s, 2H), 7.61 (s, 1H), 7.58-7.52 (m, 2H), 7.00-6.92 (m, 2H), 6.72-6.67 (m, 1H), 2.20 (app d, J = 0.8Hz, 3H).

[1166] The starting material was prepared as follows:

[1167] Step 1: 4-Bromo-1-trityl-1H-pyrazole

[1168]

[1169] 4-Bromo-1H-pyrazole (3.40 mmol, 500 mg) was dissolved in DMF (4.00 mL, 0.85 mol), placed under nitrogen, and cooled to 0°C. To this solution were added tBuOK (4.08 mmol, 458 mg, 1.20 equiv) and trityl-Cl (3.74 mmol, 1.04 g, 1.10 equiv), and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with H2O, and the aqueous layer was extracted with EtOAc (3×). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude material was purified by column chromatography using cyclohexane:EtOAc as eluent to give 4-bromo-1-trityl-1H-pyrazole (2.638 mmol, 1.027 g) as a white solid in 77% yield.

[1170] C 22 H 17 BrN2; molecular weight 389.30 g mol -1 ; 1 H NMR (400MHz, DMSO-d6) δ7.76 (d, J = 0.7Hz, 1H), 7.51 (d, J = 0.7Hz, 1H), 7.43-7.31 (m, 9H), 7.11-6.99 (m, 6H).

[1171] Step 2: 4-Methyl-5-nitro-2-(4-(1-trityl-1H-pyrazol-4-yl)phenoxy)pyridine

[1172]

[1173] Following General Procedure D, a mixture of 4-methyl-5-nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridine (0.85 mmol, 302 mg; Example 48, Step 2), 4-bromo-1-trityl-1H-pyrazole (0.77 mmol, 300 mg), K2CO3 (1.54 mmol, 213 mg) and Pd(PPh3)4 (0.08 mmol, 89 mg, 10 mol%) in 3:1 DME / H2O (0.13 M) was converted to 4-methyl-5-nitro-2-(4-(1-trityl-1H-pyrazol-4-yl)phenoxy)pyridine (0.41 mmol, 223 mg) in 54% yield.

[1174] C 34 H 26 N4O3; molecular weight 538.61 g mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.87(s,1H),7.93(d,J=0.8Hz,1H),7.60(d,J=0.9Hz,1H),7.52-7.46(m,2 H),7.40-7.27(m,9H),7.22-7.16(m,6H),7.13-7.07(m,2H),6.82(d,J=1.0Hz,1H),2.66(s,3H).

[1175] Step 3: 4-Methyl-6-(4-(1-(trityl-1H-pyrazol-4-yl)phenoxy)pyridin-3-amine

[1176]

[1177] Following General Procedure B, 4-methyl-6-(4-(1-trityl-1H-pyrazol-4-yl)phenoxy)pyridin-3-amine (0.08 mmol, 0.04 g) was obtained in 42% yield from 4-methyl-5-nitro-2-(4-(1-(trityl-1H-pyrazol-4-yl)phenoxy)phenoxy)pyridine (0.20 mmol, 0.10 g).

[1178] C 34 H 28 N4O; molecular weight 508.61 g mol -1 ; 1H NMR (400MHz, CDCl3) δ7.89(d,J=0.8Hz,1H),7.64(s,1H),7.55(d,J=0.8Hz,1H),7.41-7.37(m,2H),7.4 0-7.27(m,9H),7.22-7.17(m,6H),7.01(d,J=8.7Hz,2H),6.65(t,J=0.7Hz,1H),3.42(s,2H),2.18(app d,J=0.8Hz,3H).

[1179] Example 51: 6,6'-((4'-fluoro-[1,1'-biphenyl]-2,4-diyl)bis(oxy))bis(pyridin-3-amine)

[1180]

[1181] Following General Procedure B, 6,6'-((4'-fluoro-[1,1'-biphenyl]-2,4-diyl)bis(oxy))bis(pyridin-3-amine) (0.05 mmol, 0.02 g) was obtained from 6,6'-((4'-fluoro-[1,1'-biphenyl]-2,4-diyl)bis(oxy))bis(3-nitropyridine) (0.156 mmol, 0.070 g) in 32% yield after purification.

[1182] C 22 H 17 FN4O2; molecular weight 388.39 g mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.73(dd,J=3.1,0.7Hz,1H),7.64(dd,J=3.0,0.7Hz,1H),7.49-7.44(m,2H),7.34(d,J=8.5Hz,1H),7.08(dd ,J=8.6,3.0Hz,1H),7.03-6.95(m,3H),6.91(dd,J=8.6,2.4Hz,1H),6.81-6.77(m,2H),6.61(dd,J=8.6,0.7Hz,1H),3.53(s,4H). 19 F NMR (377MHz, CDCl3) δ-115.99.

[1183] The starting material was prepared as follows:

[1184] Step 1: 4'-Fluoro-2-methoxy-[1,1'-biphenyl]-4-ol

[1185]

[1186] Following General Procedure D, a mixture of 4-bromo-3-methoxyphenol (9.9 mmol, 2.0 g), (4-fluorophenyl)boronic acid (11 mmol, 1.5 g), K2CO3 (20 mmol, 2.7 g) and Pd(PPh3)2Cl2 (0.985 mmol, 0.691 g) in a 3:1 mixture of 2-propanol / H2O (0.1 M) was converted to 4'-fluoro-2-methoxy-[1,1'-biphenyl]-4-ol (5.45 mmol, 1.19 g) in 55% yield.

[1187] C 13 H 11 FO2; molecular weight is 218.22 g.mol -1 ;1H NMR (400MHz, CDCl3) δ7.48-7.40(m,2H),7.14(d,J=8.2Hz,1H),7.10-7.01(m,2H),6.51(d,J=2.4Hz,1H),6.47(dd,J=8.2,2.4Hz,1H),3.79(s,3H).

[1188] Step 2: 4'-Fluoro-[1,1'-biphenyl]-2,4-diol

[1189]

[1190] Under nitrogen, 4'-fluoro-2-methoxy-[1,1'-biphenyl]-4-ol (916 μmol, 200 mg) was dissolved in DCM (9.16 mL, 0.1 M) and cooled to -78 ° C. BBr 3 (1.83 mmol, 1.83 mL, 1 M in DCM solution) was added dropwise. After 30 minutes at this temperature, the mixture was slowly allowed to reach room temperature overnight. A small amount of starting material was still observed, but the reaction mixture was quenched by slowly adding water. The aqueous layer was neutralized / basified with 15% NaOH and extracted with DCM (3×). The combined organic layers were dried over Na 2 SO 4, filtered, and concentrated under reduced pressure. The crude material was purified by flash column chromatography using EtOAc:cyclohexane to give 4'-fluoro-[1,1'-biphenyl]-2,4-diol (0.74 mmol, 152 mg) as a white solid in 81% yield.

[1191] C 12 H9FO2; molecular weight is 204.20 g mol -1 ; 1H NMR (400MHz, CDCl3) δ7.48-7.33(m,2H),7.18-7.07(m,2H),7.09-7.05(m,1H),6.65-6.35(m,2H),5.07(s,1H),4.81(s,1H).

[1192] Step 3: 6,6'-((4'-fluoro-[1,1'-biphenyl]-2,4-diyl)bis(oxy))bis(3-nitropyridine)

[1193]

[1194] Following general procedure A, 6,6'-((4'-fluoro-[1,1'-biphenyl]-2,4-diyl)bis(oxy))bis(3-nitropyridine) (0.44 mmol, 195 mg) was obtained in 63% yield from 4'-fluoro-[1,1'-biphenyl]-2,4-diol (0.69 mmol, 140 mg) and 2-chloro-5-nitropyridine (1.51 mmol, 239 mg).

[1195] C 22 H 13 FN4O6; molecular weight 448.37 g mol -1 ; 1 H NMR (400MHz, CDCl3) δ9.09(dd,J=2.8,0.6Hz,1H),8.93(dd,J=2.8,0.6Hz,1H),8.52(dd,J=9.0,2.8Hz,1H),8.37(dd,J=9.0,2.8Hz,1H),7.53(d,J=8.5Hz ,1H),7.44-7.36(m,2H),7.23(dd,J=8.4,2.4Hz,1H),7.13(dd,J=9.1,0.6Hz ,1H),7.10(d,J=2.3Hz,1H),7.04-6.98(m,2H),6.91(dd,J=9.0,0.6Hz,1H).

[1196] Example 52: 6-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-4-methylpyridin-3-amine

[1197]

[1198] Following General Procedure B, 6-(((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy]-4-methylpyridin-3-amine (0.31 mmol, 94 mg) was obtained in 61% yield from 2-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-4-methyl-5-nitropyridine (0.508 mmol, 170 mg).

[1199] C 20 H 20 N2O; molecular weight is 304.39 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.71(s,1H),7.25-7.23(m,2H),7.23-7.18(m,1H),7.13-7.09(m,1H),7.05(d,J=8.3Hz,1H ), 6.94 (d, J = 2.6Hz, 1H), 6.88 (dd, J = 8.3, 2.5Hz, 1H), 6.73-6.71 (m, 1H), 2.21 (s, 3H), 2.08 (s, 3H), 2.02 (s, 3H).

[1200] The starting material was prepared as follows:

[1201] Step 1: 2,2'-dimethyl-[1,1'-biphenyl]-4-ol

[1202]

[1203] Following General Procedure D, 2,2'-dimethyl-[1,1'-biphenyl]-4-ol (4.54 mmol, 0.900 g) was obtained in 85% yield from 4-bromo-3-methylphenol (5.3 mmol, 1.0 g) and o-tolueneboronic acid (6.95 mmol, 0.944 g).

[1204] C 14 H 14 O; molecular weight is 198.26 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.28-7.18(m,3H),7.11-7.07(m,1H),6.97(d,J=8.2Hz,1H),6.77(d,J=2.4Hz,1H),6.71(dd,J=8.2,2.6Hz,1H),5.21(app d,1H),2.06(s,3H),2.01(s,3H).

[1205] Step 2: 2-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-4-methyl-5-nitropyridine

[1206]

[1207] Following general procedure A, 2-((2,2'-dimethyl-[1,1'-biphenyl]-4-yl)oxy)-4-methyl-5-nitropyridine (0.526 mmol, 176 mg) was obtained in 61% yield from 2-chloro-4-methyl-5-nitropyridine (0.869 mmol, 150 mg) and 2,2'-dimethyl-[1,1'-biphenyl]-4-ol (0.956 mmol, 190 mg).

[1208] C 20 H 18 N2O3; molecular weight 334.37 g mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.30-7.27(m,3H),7.25-7.21(m,1H),7.19-7.13(m,2H),7.05(d,J=2 .5Hz,1H),7.00(dd,J=8.2,2.4Hz,1H),6.86(s,1H),2.69(s,3H),2.10(s,3H),2.08(s,3H).

[1209] Example 53: 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-2-methylpyridin-3-amine

[1210]

[1211] Following general procedure B, 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-2-methylpyridin-3-amine (2.80 mmol, 732 mg) was obtained in 89% yield from 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-2-methyl-3-nitropyridine (2.80 mmol, 910 mg).

[1212] C 17 H 14 FN3O; molecular weight 295.31 g mol -1 ; 1H NMR (400MHz, CDCl3) δ8.49 (dd, J=2.8, 0.7Hz, 1H), 7.98-7.88 (m, 2H), 7.64 (dd, J=8.4, 0.7Hz, 1H), 7.45 (dd, J=8 .7, 2.8Hz, 1H), 7.19-7.08 (m, 2H), 7.04 (d, J = 8.4Hz, 1H), 6.68 (dd, J = 8.4, 0.7Hz, 1H), 3.50 (s, 2H), 2.33 (s, 3H).

[1213] The starting material was prepared as follows:

[1214] Step 1: 2-Bromo-5-(methoxymethoxy)pyridine

[1215]

[1216] To a solution of 6-bromopyridin-3-ol (29 mmol, 5.0 g) in dry DMF (29 mL) was added NaH (29 mmol, 1.1 g, 60% weight percent) in portions under nitrogen at 0°C. The mixture was stirred at 0°C for 1 hour. Methyl chloromethyl ether (29 mmol, 2.3 g, 2.2 mL) was then slowly added. The mixture was stirred at 0°C for 1 hour and then allowed to warm to room temperature over the weekend. The reaction mixture was cooled to 0°C and a saturated NaHCO solution was added. The mixture was warmed to room temperature and diluted with water. The mixture was extracted with AcOEt (3x). The combined organic layers were washed with H2O (3x) and brine. The mixture was dried over MgSO4, filtered and concentrated under reduced pressure. The 2-bromo-5-(methoxymethoxy)pyridine product (29 mmol, 6.3 g) was isolated as a colorless oil in a quantitative yield.

[1217] C7H8BrNO2; molecular weight is 218.05 g mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.15 (dd, J=3.1, 0.6Hz, 1H), 7.35 (dd, J=8.7, 0.6Hz, 1H), 7.27-7.20 (m, 1H), 5.15 (s, 2H), 3.46 (s, 3H).

[1218] Step 2: 2-(4-Fluorophenyl)-5-(methoxymethoxy)pyridine

[1219]

[1220] Following General Procedure D, a mixture of (4-fluorophenyl)boronic acid (32.0 mmol, 4.4 g), 2-bromo-5-(methoxymethoxy)pyridine (29.0 mmol, 6.3 g), K2CO3 (58.0 mmol, 8.0 g) and Pd(PPh3)2Cl2 (2.9 mmol, 2.0 g) in a 4:1 mixture of 2-propanol / H2O (0.1 M) was converted to 2-(4-fluorophenyl)-5-(methoxymethoxy)pyridine (16.20 mmol, 3.79 g) in 56% yield.

[1221] C 13 H 12 FNO2; molecular weight is 233.24 g mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.46 (dd, J=2.9, 0.7Hz, 1H), 7.97-7.83 (m, 2H), 7.60 (dd, J=8.7, 0.7H z, 1H), 7.43 (dd, J = 8.7, 2.9Hz, 1H), 7.13 (dd, J = 8.9, 8.5Hz, 2H), 5.23 (s, 2H), 3.51 (s, 3H).

[1222] Step 3: 6-(4-Fluorophenyl)pyridin-3-ol

[1223]

[1224] To a solution of 2-(4-fluorophenyl)-5-(methoxymethoxy)pyridine (16.20 mmol, 3.79 g) in dioxane (20 mL) was added 4 M HCl (146 mmol, 36.6 mL) in dioxane at room temperature. The mixture was heated at 80 ° C overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in water and extracted with DCM (3x). The aqueous layer was neutralized to pH = 6-7 with solid Na2CO3. The precipitated white solid was filtered, washed with hexane, and dried under vacuum for 2 hours to give 6-(4-fluorophenyl)pyridin-3-ol (15.0 mmol, 2.83 g) in 92% yield.

[1225] C 11 H8FNO; molecular weight 189.19 g mol -1 ; 1 H NMR (400MHz, DMSO-d6) δ10.04(s,1H),8.20(dd,J=2.9,0.7Hz,1H),8.09-7.93(m,2H),7.78(dd,J=8.7,0.7Hz,1H),7.33-7.15(m,3H).

[1226] Step 4: 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-2-methyl-3-nitropyridine

[1227]

[1228] Following the general procedure A, 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-2-methyl-3-nitropyridine (3.00 mmol, 900 mg) was obtained in 100% yield from 6-(4-fluorophenyl)pyridin-3-ol (3.00 mmol, 600 mg) and 6-chloro-2-methyl-3-nitropyridine (3.00 mmol, 500 mg).

[1229] C 17 H 12 FN3O3; molecular weight 325.29 g mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.58(dd,J=2.7,0.7Hz,1H),8.42(d,J=8.9Hz,1H),8.03-7.96(m,2H),7.76(dd,J=8 .7, 0.7Hz, 1H), 7.60 (dd, J=8.7, 2.7Hz, 1H), 7.20-7.14 (m, 2H), 6.96 (dd, J=8.9, 0.7Hz, 1H), 2.72 (s, 3H).

[1230] Example 54: 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-N,2-dimethylpyridin-3-amine

[1231]

[1232] Following General Procedure C, 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-N,2-dimethylpyridin-3-amine (0.810 mmol, 0.250 g) was obtained from 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-2-methylpyridin-3-amine (1.155 mmol, 0.341 g) and paraformaldehyde (1.617 mmol, 1.40 equiv) in 70% yield after purification.

[1233] C 18 H 16 FN3O;MW=309.34g mol-1; 1H NMR (400MHz, DMSO-d6) δ8.38(d,J=2.7Hz,1H),8.08(dd,J=8.9,5.6Hz,2H),7.93(d,J=8.7Hz,1H),7.46(dd,J=8.7,2.9Hz,1H), 7.30(t,J=8.9Hz,2H),6.98(d,J=8.5Hz,1H),6.86(d,J=8.5Hz,1H),5.21(q,J=5.0Hz,1H),2.73(d,J=5.0Hz,3H),2.20(s,3H).

[1234] Example 55: 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-4-methylpyridin-3-amine

[1235]

[1236] Following general procedure B, 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-4-methylpyridin-3-amine (2.58 mmol, 763 mg) was obtained in 96% yield from 2-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-4-methyl-5-nitropyridine (2.70 mmol, 900 mg).

[1237] C 17 H 14 FN3O; molecular weight 295.31 g mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.48(dd,J=2.8,0.6Hz,1H),7.95-7.89(m,2H),7.66(dd,J=8.1,0.6Hz,1H),7.64(s,1H),7.47(dd,J=8.7,2.8Hz,1H),7.19(app t,J=8.7Hz,2H),6.77(s,1H),3.48(s,2H),2.22(s,3H).

[1238] The starting material was prepared as follows:

[1239] Step 1: 2-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-4-methyl-5-nitropyridine

[1240]

[1241] Following General Procedure A, 2-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-4-methyl-5-nitropyridine (2.70 mmol, 900 mg) was obtained in 90% yield from 6-(4-fluorophenyl)pyridin-3-ol (3.00 mmol, 600 mg; Example 53, Step 3) and 2-chloro-4-methyl-5-nitropyridine (5.00 mmol, 800 mg).

[1242] C 17 H 12 FN3O3; molecular weight 325.29 g mol -1 ; H NMR (400MHz, CDCl3) δ8.86 (s, 1H), 8.55 (dd, J = 2.8, 0.6Hz, 1H), 8.01-7.95 (m, 2H), 7.76 (dd, J = 8.7, 0.6Hz, 1H), 7.60 (dd, J = 8.6, 2.8Hz, 1H), 7.17 (app t,J=8.8Hz,2H),6.97(s,1H),2.72(s,3H).

[1243] Example 56: 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-N,4-dimethylpyridin-3-amine

[1244]

[1245] Following General Procedure C, 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-N,4-dimethylpyridin-3-amine (0.786 mmol, 0.243 g) was obtained from 6-((6-(4-fluorophenyl)pyridin-3-yl)oxy)-4-methylpyridin-3-amine (1.14 mmol, 0.337 g) and paraformaldehyde (1.60 mmol, 1.40 equiv) in 69% yield after purification.

[1246] C 18 H 16 FN3O;MW=309.34g mol-1; 1 H NMR (400MHz, DMSO-d6) δ8.41(d,J=2.8Hz,1H),8.11-8.03(m,2H),7.94(d,J=8.7Hz,1H),7.52(dd,J=8.7 ,2.8Hz,1H),7.36-7.24(m,3H),6.87(s,1H),5.14(q,J=4.9Hz,1H),2.74(d,J=4.9Hz,3H),2.15(s,3H).

[1247] Example 57: (4-aminophenyl)(4'-fluoro-[1,1'-biphenyl]-4-yl)methanol

[1248]

[1249] Following General Procedure F, (4-aminophenyl)(4'-fluoro-[1,1'-biphenyl]-4-yl)methanol (1.55 mmol, 0.445 g) was obtained in 98% yield from (4'-fluoro-[1,1'-biphenyl]-4-yl)(4-nitrophenyl)methanol (1.52 mmol, 0.500 g).

[1250] C 19 H 16 FNO; molecular weight 293.33 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.56-7.48(m,4H),7.47-7.41(m,2H),7.22-7.15(m,2H),7.13-7.07(m,2H),6.71-6.60(m,2H),5.80(s,1H).

[1251] The starting material was prepared as follows:

[1252] Step 1: (4'-Fluoro-[1,1'-biphenyl]-4-yl)boronic acid

[1253]

[1254] To a solution of 4-bromo-4'-fluoro-1,1'-biphenyl (1.99 mmol, 0.500 g) in anhydrous THF (19.9 ml) at -78°C under an inert atmosphere was added tert-butyl lithium (2.390 mmol, 1.4 ml) dropwise. The reaction mixture was stirred at -78°C for 20 minutes, followed by the dropwise addition of trimethyl borate (1.99 mmol, 0.222 ml). After stirring for 1 hour, the reaction mixture was allowed to reach room temperature and quenched with 1N HCl and stirred for 30 minutes. The reaction mixture was concentrated under vacuum, and the observed precipitate was filtered and air-dried to afford (4'-fluoro-[1,1'-biphenyl]-4-yl)boronic acid (1.852 mmol, 0.400 g) as a white powder in 93% yield.

[1255] The NMR spectrum was identical to that reported previously (Neya et al., WO 2003 022842).

[1256] Step 2: (4'-Fluoro-[1,1'-biphenyl]-4-yl)(4-nitrophenyl)methanol

[1257]

[1258] To a solution of chloro(1,5-cyclooctadiene)rhodium(I) dimer (0.093 mmol, 0.046 g) in anhydrous dioxane (12.3 ml) at room temperature under an inert atmosphere was added potassium hydroxide (1.852 mmol, 1.234 ml), and the mixture was stirred for 3 minutes. To this solution was added (4'-fluoro-[1,1'-biphenyl]-4-yl)boronic acid (1.852 mmol, 0.400 g), followed by 4-nitrobenzaldehyde (3.760 mmol, 0.560 g). The mixture was stirred at room temperature for 14 hours and then quenched by the addition of brine. The mixture was extracted with EtOAc (3x). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography (Biotage KP-Sil 50 g, hexanes / EtOAc, 0-20%) to give (4′-fluoro-[1,1′-biphenyl]-4-yl)(4-nitrophenyl)methanol (1.46 mmol, 0.473 g) as a white solid in 79% yield.

[1259] C 19 H 14 FNO3; molecular weight is 323.32g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.25-8.16(m,2H),7.65-7.59(m,2H),7.56-7.48(m,4H),7.44-7.39(m,2H),7.17-7.06(m,2H),5.97(s,1H),2.41(s,1H). 19 F NMR (377MHz, CDCl3) δ-115.19.

[1260] Example 58: 4-((4'-fluoro-[1,1'-biphenyl]-4-yl)(methoxy)methyl)aniline

[1261]

[1262] Following General Procedure F, 4-((4'-fluoro-[1,1'-biphenyl]-4-yl)(methoxy)methyl)aniline (1.30 mmol, 0.400 g) was obtained in 78% yield from 4-fluoro-4'-(methoxy(4-nitrophenyl)methyl)-1,1'-biphenyl (1.78 mmol, 0.600 g).

[1263] C 20 H 18 FNO; molecular weight 307.37 g.mol -1; 1 H NMR (300 MHz, CHLOROFORM-d) δ 7.59-7.44 (m, 4H), 7.45-7.33 (m, 2H), 7.22-7.00 (m, 4H), 6.76-6.55 (m, 2H), 5.19 (s, 1H), 3.38 (s, 3H).

[1264] The starting material was prepared as follows:

[1265] Step 1: 4-Fluoro-4'-(methoxy(4-nitrophenyl)methyl)-1,1'-biphenyl

[1266]

[1267] To a solution of (4'-fluoro-[1,1'-biphenyl]-4-yl)(4-nitrophenyl)methanol (0.464 mmol, 0.15 g; Example 57, Step 2) in acetone (4.64 ml) was added CsCO (1.392 mmol, 0.453 g) followed by iodomethane (0.696 mmol, 0.044 ml). The reaction mixture was refluxed in a sealed tube at 60° C. for 4 hours. The cooled reaction mixture was directly loaded onto silica, and the residue was purified by flash chromatography (Biotage KP-Sil 25 g, hexane / EtOAc, 0-20%) to give 4-fluoro-4'-(methoxy(4-nitrophenyl)methyl)-1,1'-biphenyl (0.406 mmol, 0.137 g) in 88% yield.

[1268] C 20 H 16 FNO3; molecular weight is 337.34 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.22-8.17(m,2H),7.61-7.48(m,6H),7.41-7.36(m,2H),7.15-7.07(m,2H),5.36(s,1H),3.43(s,3H).

[1269] Example 59: 4-((4'-Fluoro-[1,1'-biphenyl]-4-yl)methyl)aniline

[1270]

[1271] Following General Procedure F, 4-((4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)aniline (1.30 mmol, 0.154 g) was obtained in 60% yield from 4-fluoro-4'-(fluoro(4-nitrophenyl)methyl)-1,1'-biphenyl (0.92 mmol, 0.300 g).

[1272] C 19 H 16 FN; molecular weight is 277.34 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.56-7.50(m,2H),7.49-7.44(m,2H),7.27-7.24(m, 2H),7.16-7.09(m,2H),7.06-7.01(m,2H),6.71-6.66(m,2H),3.94(s,2H).

[1273] The starting material was prepared as follows:

[1274] Step 1: 4-Fluoro-4'-(fluoro(4-nitrophenyl)methyl)-1,1'-biphenyl

[1275]

[1276] To a solution of (4'-fluoro-[1,1'-biphenyl]-4-yl)(4-nitrophenyl)methanol (1.54mmol, 0.500g; Example 57, Step 2) in anhydrous DCM (7.73ml) was added diethylamino-sulfur trifluoride (1.85mmol, 0.245ml) dropwise at -78°C under an inert atmosphere. The reaction mixture was stirred at the same temperature for 2 hours and then allowed to reach room temperature. The reaction was then quenched with saturated NaHCO3 solution. The two layers were separated, and the aqueous layer was extracted with DCM (3x). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give 4-fluoro-4'-(fluoro(4-nitrophenyl)methyl)-1,1'-biphenyl (1.38mmol, 0.450g) as a yellow solid in 89% yield. 19 H 13 F2NO2; molecular weight is 325.31g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ8.29-8.22(m,2H),7.59-7.49(m,6H),7.42-7.36(m,2H),7.17-7.09(m,2H),6.58(d,J=47.0Hz,1H).

[1277] Example 60: (4-Aminophenyl)(4'-fluoro-[1,1'-biphenyl]-4-yl)methanone hydrochloride

[1278]

[1279] To a solution of tert-butyl (4-(4'-fluoro-[1,1'-biphenyl]-4-carbonyl)phenyl)carbamate (0.51 mmol, 0.200 g) in DCM (10 ml) was added a 4M solution of HCl in dioxane. The mixture was stirred at room temperature overnight. The reaction mixture was concentrated to dryness, and the residue was suspended in Et2O, sonicated for 10 minutes, and filtered. The residue was washed with Et2O and then air-dried to provide (4-aminophenyl)(4'-fluoro-[1,1'-biphenyl]-4-yl)methanone hydrochloride (0.29 mmol, 0.098 g) in a 58% yield.

[1280] C 19 H 14 FNO·HCl; molecular weight 291.33 g·mol -1 ; 1 H NMR (400MHz, DMSO-d6) δ9.33(s),7.90-7.74(m,8H),7.72-7.65(m,2H),7.41-7.30(m,2H).

[1281] The starting material was prepared as follows:

[1282] Step 1: tert-Butyl((4'-fluoro-[1,1'-biphenyl]-4-yl)(4-nitrophenyl)methoxy)dimethylsilane

[1283]

[1284] To a solution of (4'-fluoro-[1,1'-biphenyl]-4-yl)(4-nitrophenyl)methanol (3.09 mmol, 1.00 g; Example 57, Step 2) in DMF (31 ml) was added imidazole (6.09 mmol, 0.421 g) and tert-butyldimethylsilyl chloride (4.02 mmol, 0.606 g) at room temperature, and the reaction mixture was stirred overnight. The reaction was quenched by the addition of brine and extracted with Et2O (3x). The combined organic layers were washed with water (5x), and the separated organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure to provide the crude product. This was purified by flash chromatography (Biotage KP-Sil 50 g, hexanes / EtOAc, 0-20%) to give tert-butyl((4'-fluoro-[1,1'-biphenyl]-4-yl)(4-nitrophenyl)methoxy)dimethylsilane (1.37 mmol, 0.600 g) in 44% yield as a white solid.

[1285] C 25 H 28 FNO3Si; molecular weight 437.58g.mol -1 ;1 H NMR (400MHz, CDCl3) δ8.20-8.17(m,2H),7.61-7.46(m,6H),7.41-7.36(m,2H),7.15-7.06(m,2H),5.86(s,1H),0.94(app d,9H),0.04(bs,3H),0.01(bs,3H).

[1286] Step 2: 4-(((tert-Butyldimethylsilyl)oxy)(4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)aniline

[1287]

[1288] Following General Procedure F, 4-(((tert-butyldimethylsilyl)oxy)(4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)aniline (12.50 mmol, 5.10 g) was obtained in 99% yield from tert-butyl((4'-fluoro-[1,1'-biphenyl]-4-yl)(4-nitrophenyl)methoxy)dimethylsilane (12.57 mmol, 5.50 g).

[1289] C 25 H 30 FNOSi; molecular weight 407.60 g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.56-7.35(m,6H),7.17-7.03(m,4H),6.66-6.59(m,2H),5.70(s,1H),0.92(app d,9H),0.01(s,3H),-0.03(s,3H).

[1290] Step 3: tert-Butyl (4-(((tert-butyldimethylsilyl)oxy)(4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)phenyl)carbamate

[1291]

[1292] To a solution of 4-(((tert-butyldimethylsilyl)oxy)(4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)aniline (14.72 mmol, 6.00 g) in DCM (75 ml) was added DMAP (1.472 mmol, 0.18 g) and triethylamine (29.4 mmol, 4.1 ml) at room temperature. To this stirred solution was added a solution of Boc anhydride (10.83 mmol, 5.50 g) in DCM (20 ml). The reaction mixture was stirred at room temperature overnight. It was then washed with water and 1N HCl. The organic layer was dried over NaSO, filtered, and concentrated to afford tert-butyl (4-(((tert-butyldimethylsilyl)oxy)(4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)phenyl)carbamate (12.80 mmol, 6.5 g) in 87% yield.

[1293] C 30 H 38 FNO3Si; molecular weight 507.71g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.54-7.48(m,2H),7.48-7.27(m,8H),7.15-7.04(m,2H),5.75 (d,J=2.1Hz,1H),1.41(d,J=4.9Hz,9H),0.98-0.81(m,9H),0.09until-0.12(m,6H).

[1294] Step 4: tert-Butyl (4-((4'-fluoro-[1,1'-biphenyl]-4-yl)(hydroxy)methyl)phenyl)carbamate

[1295]

[1296] To a solution of tert-butyl (4-(((tert-butyldimethylsilyl)oxy)(4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)phenyl)carbamate (10.83 mmol, 5.50 g) in THF (110 mL) at room temperature under an inert atmosphere was added tetrabutylammonium fluoride (16.25 mmol, 8.12 ml). The reaction mixture was stirred at room temperature for 4 hours. It was then diluted with saturated NH4Cl solution and extracted with Et2O (2x). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography (Biotage KP-Sil 100 g, hexanes / EtOAc, 0-80%) to give tert-butyl (4-((4'-fluoro-[1,1'-biphenyl]-4-yl)(hydroxy)methyl)phenyl)carbamate (6.40 mmol, 2.52 g) as a foam in 59% yield.

[1297] C 24 H 24 FNO3; molecular weight 393.45g.mol -1 ; 1 H NMR (400MHz, CDCl3) δ7.54-7.46(m,4H),7.41-7.34(m,4H),7.23-7.18(m,2H),7.14-7.07(m,2H),5.87(s,1H),2.26(s,1H),1.44(s,9H).

[1298] Step 5: tert-Butyl (4-(4'-fluoro-[1,1'-biphenyl]-4-carbonyl)phenyl)carbamate

[1299]

[1300] To a solution of tert-butyl (4-((4'-fluoro-[1,1'-biphenyl]-4-yl)(hydroxy)methyl)phenyl)carbamate (0.762mmol, 0.300g) in DCM (80mL) was added MnO2 (4.57mmol, 0.40g), and the suspension was stirred at room temperature for 16 hours. The reaction mixture was filtered through a fritted funnel, and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (Biotage KP-Sil 25g, hexane / EtOAc, 0-40%) to give tert-butyl (4-(4'-fluoro-[1,1'-biphenyl]-4-carbonyl)phenyl)carbamate (0.588mmol, 0.230g) as a yellow solid in 77% yield.

[1301] C 24 H 22 FNO3; molecular weight 391.43g.mol-1 ; 1 H NMR (400MHz, CDCl3) δ7.94-7.80(m,4H),7.71-7.56(m,4H),7.46-7.41(m,2H),7.21-7.13(m,2H),1.48(s,9H).

[1302] Biological properties of the compounds

[1303] Identification of compounds with high potency against NOTCH-driven human cancers

[1304] To determine the anticancer efficacy of compounds, the positive / driving human T cell acute lymphoblastic leukemia cell line RPMI 8402 was treated with selected compounds and downregulation of NOTCH target genes was measured.

[1305] Materials and Methods

[1306] Cell culture

[1307] One million cells of the human NOTCH-positive T-ALL cell line RPMI8402 were treated with a NOTCH-targeting compound at a concentration of 1 μM for 24 hours. Following treatment, the cells were harvested and washed with 1x PBS. Total RNA and total protein lysates were extracted as described below.

[1308] RNA extraction

[1309] use Total RNA was extracted from cells using an extraction kit (Invitrogen). Briefly, 1×10 6 cells and 1 ml of The solution was lysed for 5 minutes to dissociate the nucleoprotein complex. The lysed cells were then treated with 200 μl of chloroform and shaken vigorously for 15-30 seconds, then incubated at room temperature for 2-3 minutes. The sample was centrifuged at 14,000 rpm for 10 minutes at 4°C using an Eppendorf tabletop centrifuge. After centrifugation, the upper aqueous phase was transferred to a new Eppendorf tube. To precipitate total RNA, 500 μl of isoamyl alcohol was added to the separated aqueous phase and incubated at room temperature for 10 minutes. RNA precipitation was obtained by centrifuging the sample at 4°C for 10 minutes. The obtained RNA precipitate was washed with 1 ml of ice-cold 75% ethanol and centrifuged at 14,000 rpm at 4°C. The RNA precipitate was dried with excess ethanol and then resuspended in 40 μl of DPEC water.

[1310] cDNA synthesis

[1311] Total RNA extracted from cells was used to synthesize cDNA by reverse transcription. Reverse transcription was performed according to one of the following two protocols.

[1312] In the first solution, SuperScript TM RT (Invitrogen) was used for reverse transcription reaction. RNA concentration was measured using an ND-1000 spectrophotometer (Witec AG). 500 ng of total RNA was mixed with 10 mM dNTPs mixture and 100 ng of random primers. The reaction mixture was incubated at 65°C for 5 minutes, followed by a quick incubation on ice for 1 minute. After incubation on ice, 5x first-strand buffer and 0.1 M DTT were added, and the mixture was incubated at 25°C for 2 minutes. To start the reverse transcription reaction, 200 U of SuperScript TM II RT was added to the reaction mixture and incubated at 42° C. for 50 minutes. The reaction was terminated by incubating the reaction mixture at 75° C. for 15 minutes.

[1313] In the second protocol, reverse transcription was performed using PrimeScript RT Master Mix (Takara). RNA concentration was measured using an ND-1000 spectrophotometer (Witec AG), and 1 μg of total RNA was mixed with 4 μL of 5X PrimeScript RT Master Mix in a total reaction volume of 20 μL. The reaction mixture was incubated at 37°C for 15 minutes and then heat-inactivated at 85°C for 5 seconds.

[1314] Quantitative real-time PCR analysis

[1315] QRT-PCR was performed using the 7900HT Fast Real-Time PCR System (Applied Biosystems) or the QuantStudio 3 System (ThermoFisher). Briefly, 12.5 ng of template cDNA, 0.5 μM primers, and 1X SYBR Green dye were used in a final volume of 10 μL in a 96- or 384-well plate format. Melting curves and ct values ​​were analyzed using SDS software (Applied Biosystems) or QuantStudio design and analysis software (ThermoFisher).

[1316] Western blot analysis

[1317] The cells were lysed in RIPA buffer (50 mM Tris.Cl, pH 7.5, 150 mM NaCl, 1% nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS) at 4°C for 30 minutes. The lysed cells were centrifuged at 14,000 rpm at 4°C to remove debris. The supernatant was transferred to a new Eppendorf tube. Protein concentration was determined by Bradford assay using a spectrophotometer (Ultrospec 3000 pro).

[1318] For Western blot analysis, initially 40 μg of protein were denatured in 1x SDS gel loading buffer (100mM Tris.Cl, pH 6.8, 200mM DTT, 4% SDS, 0.2% bromophenol, 20% glycerol) by heating at 99°C for 5 minutes. Denatured protein samples were stored on ice until loaded onto an acrylamide gel. Samples were electrophoresed on an 8% or 10% acrylamide gel in Tris-glycine running buffer (25mM Tris, 250mM glycine, 0.1% SDS). After separation on an acrylamide gel, protein samples were transferred to a PVDF membrane (PEQ lab company, model 39-3010) using transfer buffer (39mM glycine, 48mM Tris alkali, 0.037% SDS and 20% methanol).

[1319] For immunoblotting, the membrane was blocked with 5% milk and incubated with primary antibodies overnight at 4°C. The membrane was washed three times with 1x TBST (1x TBS + 0.5% tween 20) for 5 minutes and incubated with HRP-conjugated secondary antibodies for 1 hour at room temperature. Signals were detected using Super Signal West chemiluminescent substrate (Thermo Scientific, model 34077).

[1320] Western blot analysis was then performed using Jess (ProteinSimple, biotechne). Samples containing 0.8 μg of protein were denatured in loading buffer containing DTT by heating at 95°C for 5 minutes. Samples were run on a 12-230 kDa gel matrix with incubation times of 1 hour for the primary antibody and 30 minutes for the secondary antibody. Data were analyzed using Compass for SW (ProteinSimple, biotechne). Alamarblue / PrestoBlue proliferation assay

[1321] conduct and PrestoBlue proliferation assays to determine the growth kinetics of Notch inhibitor-treated cells. PrestoBlue is composed of a cell-permeable matrix called resazurin. In metabolically active and proliferating cells, resazurin is converted to resorufin due to the inherent reducing capacity of living cells, generating red fluorescence. Therefore, resorufin production can be used as an indicator of cell population viability.

[1322] Proliferation assays were performed by seeding 5000 cells / well in 96-well plates. Cells were treated with DMSO or compound at concentrations ranging from 0.01 to 10 μM for 72 hours. Each concentration was tested in triplicate. To determine growth kinetics, 10 μl of Alamar or PrestoBlue (Invitrogen) were added to each well and incubated for 4 hours. The plates were read using a Tecan F500 (Tecan) multiplate reader or a Varioskan LUX (ThermoFisher) multiplate reader.

[1323] Example 27: Compounds showing high potency against NOTCH-driven human cancers

[1324] To determine the anticancer activity of the compounds compared to 6-(4-tert-butylphenoxy)pyridin-3-amine (described in WO2013 / 093885), NOTCH-positive / driven human T-cell acute lymphoblastic leukemia cell line RPMI 8402 was treated with the selected compounds. Figure 1 As shown in Table 1, compared with 6-(4-tert-butylphenoxy)pyridin-3-amine, 4-([1,1'-biphenyl]-4-yloxy)aniline, 6-([1,1'-biphenyl]-4-yloxy)-N-methylpyridin-3-amine, 4-([1,1'-biphenyl]-4-yloxy)-3-fluoro-N-methylaniline, 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine, 6-([1,1 '-biphenyl]-4-yloxy)-4-methylpyridin-3-amine), 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine, N-methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine and 6-((2-(2-(4-(4-aminophenoxy)ethyl)-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine showed an anti-proliferative ability increased by 1.05-9 times.

[1325]

[1326] *Comparative compounds described in WO2013 / 093885

[1327] Table 1: Antiproliferative effects of compounds on NOTCH-positive human leukemia cells. Cells were treated with compounds (concentration range 0.01-10 μM) for 72 hours. Antiproliferative effects were measured using the Alamar Blue assay (see Materials and Methods for details). IC was calculated using Graph Prism software. 50 value.

[1328] Example 28: Downregulation of mRNA transcripts of NOTCH target genes

[1329] To further determine the anti-NOTCH activity and efficacy of the compound (compared to 6-(4-tert-butylphenoxy)pyridin-3-amine), NOTCH-positive human leukemia cell lines were treated with the compound at a concentration of 1 μM for 24 hours. The effect on NOTCH signaling was studied by quantifying the mRNA transcription level of NOTCH target genes by quantitative PCR. The potency of the newly synthesized compound was calculated as a percentage of the increased activity of 6-(4-tert-butylphenoxy)pyridin-3-amine. As shown in Table 2, the compound showed enhanced efficacy in downregulating NOTCH target genes such as HES1, cMYC, and DTX1.

[1330]

[1331] *Comparative compounds described in WO2013 / 093885

[1332] Table 2: Human leukemia RPMI8402 cells were treated with 1 mM compound concentration for 24 hours at 37°C. Total RNA was extracted, cDNA was synthesized, and RNA expression of each gene was quantified using quantitative PCR (qPCR). The activity of 6-(4-tert-butylphenoxy)pyridin-3-amine downregulating the NOTCH target gene was set to 100%, and the corresponding increased activity of each compound was calculated using the activity of 6-(4-tert-butylphenoxy)pyridin-3-amine as a reference point. ND: Not determined.

[1333] Example 29: Downregulation of NOTCH target genes at the protein level

[1334] To further confirm the anti-NOTCH activity and efficacy of the compounds, NOTCH-positive leukemia cell lines were treated with selected compounds at a concentration of 1 μM for 24 hours. Total protein lysates were analyzed by Western blot analysis using N1-ICD (cleaved and activated NOTCH1 intracellular domain), cMYC and ACTIN specific antibodies. Figure 2 and Figure 3As shown, compared with 6-(4-tert-butylphenoxy)pyridin-3-amine (described in WO2013 / 093885), 6-([1,1'-biphenyl]-4-yloxy)-N-methylpyridin-3-amine, 6-((4'-fluoro-[1,1'-biphenyl]-4-yl)oxy)pyridin-3-amine, 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin-3-amine, 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine and N-methyl-6-((6-phenylpyridin-3-yl)oxy)pyridin-3-amine showed stronger downregulation of cMYC and N1-ICD (both are direct target genes of NOTCH signaling in human leukemia cells).

[1335] Example 30: Compounds showing high potency against NOTCH-driven human cancers

[1336] To determine the anticancer ability of the compounds compared to 6-(4-tert-butylphenoxy)pyridin-3-amine (described in WO2013 / 093885), NOTCH-positive / driven human T-cell acute lymphoblastic leukemia cell line RPMI 8402 was treated with the selected compounds. Figure 1 The antiproliferative activity of the compounds shown in Table 3 was enhanced by 1.5 to 24 times.

[1337]

[1338] *Comparative compounds described in WO2013 / 093885

[1339] Table 3: Antiproliferative effects of compounds on NOTCH-positive human leukemia cells. Cells were treated with compounds (at concentrations ranging from 0.03 to 100 μM) for 72 hours. Antiproliferative effects were determined using the PrestoBlue assay (see Materials and Methods for details). IC values ​​were calculated using Graph Prism software. 50 value.

[1340] Example 31: Downregulation of NOTCH target genes at the protein level

[1341] To further confirm the anti-NOTCH activity and efficacy of the compounds, NOTCH-positive leukemia cell lines were treated with selected compounds at a concentration of 1 μM for 24 hours. Total protein lysates were analyzed by Jess Western blot analysis using antibodies specific for N1-ICD (cleaved and activated NOTCH1 intracellular domain), cMYC, and GAPDH. Compared to 6-(4-tert-butylphenoxy)pyridin-3-amine (described in WO2013 / 093885), the compounds shown in Table 4 demonstrated a stronger downregulation of cMYC and N1-ICD (both direct target genes of NOTCH signaling in human leukemia cells).

[1342]

[1343] *Comparative compounds described in WO2013 / 093885

[1344] Table 4: Human leukemia cells RPMI8402 were treated with compounds at a concentration of 1 μM for 24 hours at 37° C. Total protein lysates were analyzed by Jess Western blot analysis.

[1345] Example 32: Downregulation of mRNA transcripts of NOTCH target genes

[1346] To further determine the anti-NOTCH activity and potency of the compounds compared to 6-(4-tert-butylphenoxy)pyridin-3-amine, NOTCH-positive human leukemia cell lines were treated with compounds at a 1 μM concentration for 24 hours. The effects on NOTCH signaling were investigated by quantitative PCR quantification of mRNA transcript levels of NOTCH target genes. As shown in Table 5, the listed compounds demonstrated enhanced potency in downregulating NOTCH target genes such as cMYC, DTX1, and HES1 compared to 6-(4-tert-butylphenoxy)pyridin-3-amine.

[1347]

[1348] *Comparative compounds described in WO2013 / 093885

[1349] Table 5: Human leukemia cells RPMI8402 were treated with compounds at a concentration of 1 mM for 24 hours at 37° C. Total RNA was extracted, cDNA was synthesized, and RNA expression of each gene was quantified using quantitative PCR (qPCR).

Claims

1. A compound of formula (I), a pharmaceutically acceptable salt or stereoisomer thereof, wherein X is selected from CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O; where Y 1 N and R 7 Does not exist, Y 2 is selected from N and C, and Y 3 is C; Where Z is NR 10 R 11 , where R 10 With R 11 Each independently selected from H and C1-C6 alkyl; Where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted with aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substitution; Where R 2 is selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace; Where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl; Where R 4 , R5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl; Where R 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl; When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and Where R 12 is selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl, The condition is that the compound of formula (I) is not 6-([1,1'-biphenyl]-4-yloxy)-pyridin-3-amine, 4-([1,1'-biphenyl]-4-yloxy)-aniline, 6-([1,1'-biphenyl]-4-yloxy)-2-methylpyridin-3-amine and 6-([1,1'-biphenyl]-4-yloxy)-4-methylpyridin-3-amine.

2. A compound of formula (I), a pharmaceutically acceptable salt or stereoisomer thereof, for use in a method for preventing or treating cancer, wherein X is selected from CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O; where Y 1 N and R 7 Does not exist, Y 2 is selected from N and C, and Y 3 is C; Where Z is NR 10 R 11 , where R 10 With R 11 Each independently selected from H and C1-C6 alkyl; Where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12Heterocyclic group substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted with aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substitution; Where R 2 is selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace; Where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl; Where R 4 , R 5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl; Where R 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl; When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and Where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

3. A pharmaceutical composition comprising a compound of formula (I), a pharmaceutically acceptable salt or stereoisomer thereof and a pharmaceutically acceptable carrier, wherein X is selected from CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O; where Y 1 N and R 7 Does not exist, Y 2 is selected from N and C, and Y3 is C; Where Z is NR 10 R 11 , where R 10 With R 11 Each independently selected from H and C1-C6 alkyl; Where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted with aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substitution; Where R 2 is selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace; Where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl; Where R 4 , R 5 and R6 are each independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl; Where R 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl; When Y 2 When N is R 9 does not exist, or when Y 2 When R is C9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and Where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

4. A compound of formula (I) according to claim 1, a compound of formula (I) for use according to claim 2, or a pharmaceutical composition comprising a compound of formula (I) according to claim 3, wherein X is selected from CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O; where Y 1 N and R 7 Does not exist, Y 2 Selected from N, C and Y 3 is C; Where Z is NR 10 R 11 , where R 10 With R 11 Each independently selected from H and C1-C6 alkyl; Where R 1 Selected from H, C1-C6 alkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted with NH2; C0-C3 alkylOC0-C3 alkylheteroaryl, wherein the heteroaryl is optionally substituted with NH2; Where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C(O)R 12 replace; Where R 3 is H; Where R 4 is selected from H and halogen; Where R 5 and R 6 Each independently selected from H and C1-C6 alkyl; Where R 8 is H; When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is H; and Where R 12 is NH2.

5. A compound of formula (I) according to claim 1, a compound of formula (I) for use according to claim 2, or a pharmaceutical composition comprising a compound of formula (I) according to claim 3, wherein X is selected from CH2, NH and O; where Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C; Where Z is NR 10 R 11 , where R 10 With R 11 Each independently selected from H and C1-C6 alkyl; Where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 heterocyclyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group substituted; C0-C3 alkyl OC0-C3 alkyl heteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C1-C6 alkyl substituted with aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substitution; Where R 2 is selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace; Where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl; Where R 4 , R 5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl; Where R 8Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl; When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and Where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

6. A compound of formula (I) according to claim 1, a compound of formula (I) for use according to claim 2, or a pharmaceutical composition comprising a compound of formula (I) according to claim 3, wherein X is selected from CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O; where Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C; Where Z is NR 10 R 11 , where R 10 With R 11 Each independently selected from H and C1-C6 alkyl; Where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl; Where R 2 is selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace; Where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl; Where R 4 , R 5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl; Where R 8Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl; When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and Where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

7. A compound of formula (I) according to claim 1, a compound of formula (I) for use according to claim 2, or a pharmaceutical composition comprising a compound of formula (I) according to claim 3, wherein X is selected from CH2, NH and O; where Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C; Where Z is NR 10 R 11 , where R 10 With R 11 Each independently selected from H and C1-C6 alkyl; Where R 1 Selected from H, halogen, C1-C6 alkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl, C1-C6 alkoxy and C1-C6 heteroalkyl; Where R 2 is selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclic group, C(O)R 12 、C1-C6 alkyl C(O)R 12 replace; Where R 3 Selected from H, halogen, C1-C6 alkyl and C3-C 12 Cycloalkyl; Where R 4 , R 5 and R 6 Each is independently selected from H, halogen, CN, C1-C6 alkyl and C1-C6 heteroalkyl; Where R 8 Selected from H, halogen, C1-C6 alkyl and C3-C 12Cycloalkyl; When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen, C1-C6 alkyl and C3-C 12 cycloalkyl; and Where R 12 Selected from NH2, NHC1-C6 alkyl, C1-C6 alkyl and C1-C6 heteroalkyl.

8. A compound of formula (I) according to claim 1, a compound of formula (I) for use according to claim 2, or a pharmaceutical composition comprising a compound of formula (I) according to claim 3, wherein X is selected from CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O; where Y 1 N and R 7 Does not exist, Y 2 Selected from N, C and Y 3 is C; Where Z is NR 10 R 11 , where R 10 With R 11 Each independently selected from H and C1-C6 alkyl; Where R 1 Selected from H and C1-C6 alkyl; Where R 2 Selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, C1-C6 alkyl C(O)R 12 replace; Where R 3 is H; Where R 4 is selected from H and halogen; Where R 5 and R 6 Each independently selected from H and C1-C6 alkyl; Where R 8 is H; When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 is H; and Where R 12 is NH2.

9. A compound of formula (I) according to claim 1, a compound of formula (I) for use according to claim 2, or a pharmaceutical composition comprising a compound of formula (I) according to claim 3, wherein X is selected from CH2, CO, CHOH, CHO(C1-C3)alkyl, NH and O; where Y 1 N and R 7 Does not exist, Y 2 Selected from N and C and Y 3 is C; Where Z is NR 10 R 11 , where R 10 With R 11 Each independently selected from H and C1-C6 alkyl; Where R 1 is selected from C0-C3 alkyl, OC0-C3 alkylaryl, wherein the aryl is optionally substituted with NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 and C0-C3 alkylOC0-C3 alkylheteroaryl, wherein the heteroaryl is optionally NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclyl substitution; Where R 2 is selected from aryl and heteroaryl, wherein the aryl and the heteroaryl are optionally substituted by NH2, halogen, C1-C6 alkyl, CN; Where R 3 is selected from H, halogen and C1-C4 alkyl; Where R 4 , R 5 and R 6 Each independently selected from H, halogen and C1-C4 alkyl; Where R 8 is selected from H, halogen and C1-C4 alkyl; and When Y 2 When N is R 9 does not exist, or when Y 2 When R is C 9 Selected from H, halogen and C1-C4 alkyl.

10. A compound of formula (I) according to any one of claims 1 to 3 and 5, a compound of formula (I) for use and a pharmaceutical composition comprising a compound of formula (I), wherein R 1is selected from H, halogen, C1-C6 alkyl, C1-C6 heteroalkyl, C0-C3 alkylOC0-C3 alkylaryl, wherein the aryl is optionally substituted with NH2, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, preferably optionally substituted with NH2; and C0-C3 alkylOC0-C3 alkylheteroaryl, wherein the heteroaryl is optionally substituted with NH2, OC1-C6 alkyl, C1-C6 alkyl, C1-C6 heteroalkyl, halogen, CN, C3-C 12 Cycloalkyl, C3-C 12 The heterocyclyl is substituted, preferably optionally substituted by NH2.

11. A compound of formula (I) according to any one of claims 1 to 10, a compound of formula (I) for use and a pharmaceutical composition comprising a compound of formula (I), wherein R 2 is selected from aryl and heteroaryl, wherein the aryl is optionally substituted phenyl, wherein the optional substitution of the phenyl is in the meta or para position, preferably in the para position.

12. A compound of formula (I) according to any one of claims 1 to 11, a compound of formula (I) for use and / or a pharmaceutical composition comprising a compound of formula (I), wherein R 2 is selected from aryl and heteroaryl, wherein the heteroaryl is an optionally substituted aromatic 5- or 6-membered monocyclic group.

13. A compound of formula (I) according to claim 1, a compound of formula (I) for use according to claim 2, and / or a pharmaceutical composition comprising a compound of formula (I) according to claim 3, selected from the group consisting of:

14. The compound of formula (I) used according to claim 2 is selected from the group consisting of:

15. A compound of formula (I) according to claim 1, a compound of formula (I) for use according to claim 2, and / or a pharmaceutical composition comprising a compound of formula (I) according to claim 3, selected from the group consisting of:

16. A compound of formula (I) for use according to any one of claims 2 to 15, wherein the cancer is a Notch-dependent cancer.